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Abstract
In an attempt to establish an in vivo animal model to study Hodgkin's
disease (HD) and the histogenesis of the neoplastic cell of the disease - the
Reed-Sternberg (RS) cell, and to study non-Hodgkin's lymphomas (NHL),
severe combined immunodeficient (SCID) mice were transplanted with fresh
biopsy material from 17 cases of HD and 25 cases of NHL. Five of the
Hodgkin's (3 lymphocyte predominant, 1 nodular sclerosing and 1 mixed
cellularity) and 7 of the non-Hodgkin's lymphomas (3 centroblastic, 1
immunoblastic, 1 follicular lymphoma and 2 biopsies from a case of B cell
large cell anaplastic lymphoma) produced human high grade B cell
lymphomas in the mice. All of the Hodgkin's disease derived SCID tumours
expressed the Epstein-Barr virus (EBV) gene products EBER, EBNA-2 and
LMP-1, even though only 1 of the original biopsies showed EBV positive RS
cells. However, EBV clonality analysis showed that the EBV positive clone
present in the original biopsy was not present in the SCID tumour.
Morphologically, these tumours resembled polymorphous immunoblastic
lymphomas, although in each case there were a few RS-like cells. The HD-
derived SCID tumours did not retain the phenotype of the original biopsies,
instead exhibiting an activated B cell phenotype with high expression of the
CD23 and CD43 antigens. All HD-derived SCID tumours showed clonal Ig
gene rearrangements. Further characterisation demonstrated that all of the
HD-derived SCID tumours showed Ig secretion and contained the normal
diploid DNA content. One SCID tumour derived from a follicular lymphoma
showed similar morphology, phenotype, identical EBV gene expression and
properties of Ig secretion and diploid DNA content as the HD-derived SCID
tumours. Three centroblastic and 1 immunoblastic lymphoma were EBV
negative. They all showed near identical morphology and B cell phenotype,
and identical Ig gene rearrangements to that of the original biopsies. In
addition, no Ig secretion was seen and DNA aneuploidy was exhibited.
SCID tumours derived from the large cell anaplastic lymphoma showed 2
types of lymphoproliferation; firstly immunoblastic tumours showing EBER,
EBNA-2 and LMP-1 expression, an activated B cell phenotype with Ig gene
rearrangements different to those of the original biopsy, Ig secretion and
diploid DNA content; secondly large cell anaplastic tumours retaining the
EBV (EBER only) and restricted antigenic phenotype of the original biopsy,
and showing identical Ig gene rearrangements to those of the original
biopsy, no Ig secretion and DNA aneuploidy.
Chapter One
Introduction
This introduction describes both Hodgkin's disease and the non-Hodgkin's
lymphomas in some detail, including a general introduction to clinical
features and pathology of the diseases.
The Hodgkin's disease section includes a description of the previous
phenotypic and genotypic studies carried out in an attempt to define the
histogenesis of the neoplastic cell of Hodgkin's disease - the Reed-
Stemberg cell - and the problems encountered in these studies.
In the non-Hodgkin's lymphomas section, the various sub-types
encountered in this thesis are described in detail.
The aetiology of Hodgkin's disease and non-Hodgkin's lymphoma is
then discussed with special reference to the Epstein-Barr virus, described in
more detail because of its involvement in the SCID tumours grown in this
thesis.
The alternative models used to investigate Hodgkin's disease and
non-Hodgkin's lymphoma, such as cell lines and nude mice, and the
associated difficulties are discussed and finally the model that is used in this
thesis to investigate Hodgkin's disease and non-Hodgkin's lymphoma - the
SCID mouse - is described in some detail.
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Malignant lymphomas are primary tumours of the lymphoreticular system,
most if not all arising from lymphocytes. They all exhibit the ability to
disseminate or metastasise and most, if untreated, will be fatal although they
do vary greatly, some being capable of a fatal out-come in a few weeks or
months (high grade) while others may take many years to do so (low grade).
Malignant lymphomas can arise in almost any organ due to the wide¬
spread nature of the lymphoreticular system, but most originate in the
primary or secondary lymphoid organs especially the lymph nodes.
Lymphomas also tend to spread to other parts of the lymphoreticular system
- wide-spread lymphadenopathy and splenomegaly are thus common
features (Lee & Bird 1992).
Lymphomas are divided into 2 main groups - Hodgkin's Lymphoma or
Disease (HD) and the Non-Hodgkin's lymphomas (NHL).
1.1 Hodgkin's Disease
1.1.1 Clinical Features
This was first described by Thomas Hodgkin (1832), being pathologically
characterised following descriptions of the histological marker cell by
Sternberg (1898) and Reed (1902) and which now bears their names - the
Reed-Sternberg cell.
Hodgkin's disease is one of the most common types of lymphoma,
accounting for about 40% of all malignant lymphoma cases in Western
Europe and the USA (Smithers 1973). It has a biphasic age incidence,
peaking in early adult life and again in late middle age (MacMohen 1966).
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Lymph node enlargement, involving the neck and mediastinal nodes,
and less commonly the axillary, inguinal and intra-abdominal nodes is by far
the most common presenting feature (Colby et al 1981, Mauch et al 1993).
Only rarely does the disease arise extra-nodally. In some cases systemic
symptoms such as low grade intermittent pyrexia, sweating, pruritus and
weight loss are seen. There can be anaemia sometimes accompanied by
neutrophilia or eosinophilia. In the majority of cases the disease soon
spreads via the lymphatics to adjacent nodal groups and subsequently to
distant nodes - the spleen may also be involved at an early stage. Only later
are extra-nodal sites involved. This pattern of spread forms the basis of the
Ann Arbor clinical staging system - this is the important factor in selecting
treatment for HD (Carbone et al 1971).
Approximately 75% of all patients who present with Hodgkin's disease
should be cured of their disease. Radiotherapy alone may be used to treat
Stage I or II disease. Some cases of Stage I and II and most patients with
advanced Hodgkin's disease (Stage III or IV) are treated with one of the
standard programmes of combination chemotherapy (reviewed by Urba &
Longo 1992, Devita & Hubbard 1993).
1.1.2 Histology
The diagnosis of HD is carried out on a histological basis, and the
histopathological criteria for the diagnosis and classification of HD is well
established (Lukes & Butler 1966, Lukes et al 1966, Lukes 1971, Colby et al
1981, Bennett etal 1991).
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Diagnosis of Hodgkin's disease depends on the presence of the Reed-
Sternberg (RS) cell - usually regarded as the neoplastic component of the
disease (Lukes 1971). The classical Reed-Sternberg cell measures
between 20-30pm in diameter and contains either a bi-lobed nucleus or 2
nuclei. Each lobe or nucleus has a large, prominent nucleolus (3-5pm)
which is usually eosinophilic. There is often a clear zone around the
nucleolus with a rim of chromatin condensation around the nuclear
membrane. The cells show abundant, usually eosinophilic cytoplasm. The
mononuclear version of the RS cell is called the Hodgkin cell - this is
morphologically similar to the RS cell, but because it is also similar to other
lymphoid cells, it is not so important in the primary diagnosis of the disease
(Lukes & Butler 1966).
The RS cells (and Hodgkin cells) (RS/H) must be accompanied by an
appropriate stromal response before a specific diagnosis of Hodgkin's
disease can be made (Lukes 1971). A typical lymph node affected by the
disease will have distorted architecture. In most cases, the paracortical
areas (the T cell areas) are primarily affected, although sometimes it is the
cortical B cell areas. There is a polymorphic cellular infiltrate consisting of
lymphocytes, neutrophils, eosinophils, histiocytes or macrophages, plasma
cells and fibre forming cells. The patterns of this cellular response are very
varied depending on the sub-type and the prognosis of the disease. The
RS/H cells may only be present in small numbers, even in extensive disease.
The lymphocytes present are believed to be the host immune response to
the RS/H cells - they are mostly T cells (Hsu et al 1985) (except in the
nodular Lymphocyte Predominance sub-type of Hodgkin's, where the back¬
ground lymphocytes are mostly polyclonal B cells (Abdulaziz et al 1984))
and were found to be predominantly mature helper T cells (CD3+, CD4+,
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CD45RO+)(Martin & Warnke 1984, Poppema 1989). Because they are
found in such close proximity to the perimeter of the RS/H cells, there has
been speculation that some kind of reaction is taking place between them
(Stuart et al 1977). T cells in Hodgkin's disease have been shown to be well
equipped for cell-cell interactions by the presence of high levels of LFA-1
and LFA-2. RS cells express high levels of LFA-3 - the ligand for LFA-2. It
has also been demonstrated that 'lymphocyte rosetting' of T cells with the
Hodgkin cell line L248 can be inhibited by antibodies against LFA-1, LFA-2
and LFA-3 (Sanders et al 1988).
The histological appearance of Hodgkin's disease (i.e. low numbers of
RS/H cells against a back-ground of reactive cells) and clinical features of
Hodgkin's disease could be explained by local cytokine release by either the
malignant RS/H cells or by the lymphoid population infiltrating the involved
tissues. Expression of several cytokines have been demonstrated in RS
cells in biopsy material including IL-1 (Hsu & Zhao 1986, Xerri et al 1992),
IL-3 (Merz et al 1991), IL-4 (Merz et al 1991), IL-5 (Samoszuk & Nansen
1990), IL-6 (Jucker et al 1991), IL-9 (Merz et al 1991), TGF-p (Hsu et al
1993) and TNF-a (Kretschmer et al 1990).
In addition to the above cytokines, HD-derived cell lines have also
been found to express IL-8 (Gruss et al 1992) and CSF(GM-CSF)(Burrichter
et al 1983). This cytokine expression could explain the infiltration of
eosinophils (IL-5), neutrophils, macrophages and lymphocytes (IL-1),
particularly CD4 T lymphocytes (IL-9), and the fever (IL-1, TNF-a) and
depressed cellular immunity (TGF-p) involved with the disease.
Expression of IL-6 and the IL-6 receptor have both been found on
RS/H cells and Jucker et al (1991) suggest that the IL-6, either by an
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autocrine or paracrine (produced by the back-ground CD4+ T cells) loop,
may stimulate the growth of the neoplastic RS/H cells.
1.1.3 Histological Sub-typing of Hodqkin's Disease
The nature of the cellular back-ground in which RS cells are found forms the
basis of the Rye classification which divides Hodgkin's disease into 4 main
sub-groups :- Lymphocyte Predominant (LP), Nodular Sclerosing (NS),
Mixed Cellularity (MC) and Lymphocyte Depleted (LD). Each sub-type
contains a specific sub-type of the RS cell as well as the classical RS cells
(Lukes & Butler 1966, Lukes et al 1966, Butler 1992) (Figures 1.1 & 1.2).
Lymphocyte Predominant Hodqkin's Disease
This sub-type is now widely regarded as distinct from the other sub¬
types as a B cell lymphoma. It represents about 7% of cases in most series.
It is only rarely encountered over the age of 40 and it shows a marked male
predominance. This sub-type most commonly presents in the neck nodes,
mediastinal involvement is rare (Mauch et al 1993).
There are 2 sub-types - Nodular and Diffuse (Lukes & Butler 1966,
Lukes et al 1966). The affected lymph node is characterised by proliferation
of mostly lymphocytes and some histiocytes (plasma cells and eosinophils
are rarely found), and by the presence of the Lymphocytic and Histiocytic (L
and H) variant of the RS cell. This cell, also known as the 'popcorn' cell,
tends to be slightly smaller than the other RS cell variants (Figure 1.1). The
nucleus shows lobation with multiple small nucleoli and the cytoplasm is pale
and seldom abundant. These L and H cells are more abundant in the
6
Nodular sub-type where they are confined to large, poorly defined nodules in
which they often form small aggregates (Colby et al 1981). Other enlarged
follicles showing features of a nodal lesion known as progressive
transformation of germinal centres with or without L and H cells may also be
present (Hansmann et al 1990). Classical RS cells are rarely found in this
LP sub-type (Butler 1992), indeed if they are too readily found the sub-typing
should be reconsidered as cellular phase NSHD or MCHD. However the
presence of the L and H cell is essential in diagnosis of LPHD and to
prevent mis-diagnosis as progressive transformation of germinal centres.
Nodular Sclerosis Hodgkin's Disease
This sub-type is the most common form of Hodgkin's disease (about
65%). It mainly affects young adults and is the predominant sub-type in
young females. This sub-type presents most commonly in the neck nodes
and mediastinum (Colby et al 1981, Mauch et al 1993).
In addition to classical RS cells, the lacunar variant is also found.
Lacunar cells show abundant, clear cytoplasm, a polylobated nucleus
showing fine chromatin and much less conspicuous nucleoli (Figure 1.1).
They may be found singly or in small aggregates, sometimes forming large,
syncytial sheets in which there are areas of necrosis.
The diagnosis of NS also requires the identification of nodule
formation and some evidence of banding sclerosis and intranodal bands of
sclerosis (Lukes et al 1971). The number and morphology of the classical
RS cells and lacunar cells can vary widely as can the cellular back-ground -
ranging from lymphocyte predominance to lymphocyte depleted with varying
numbers of plasma cells, histiocytes and eosinophils. The extent of
sclerosis present is also very variable.
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KEY FOR FIGURE 1.1
Arrow indicates an L and H cell.
RS - classical Reed-Sternberg cell
Lac - Lacunar cell
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NSHD can be sub-divided into 2 prognostic groups depending on
histological features. In NS1, the nodules show a predominance of
lymphocytes, and the prognosis is better than any other sub-type apart from
LPHD. In NS2, more than half the nodules show lymphocyte depletion and
marked pleomorphism of the RS cells with prognosis worse than MCHD and
only marginally better than LDHD. Type 2 NSHD makes up about 30% of
the NS cases and is the predominant sub-type over the age of 50 (Bennett et
al 1985).
Mixed Cellularitv Hodqkin's Disease
This is the second most common sub-type, making up between 20 -
40% of cases. It mostly occurs in young adults but it is the most common
sub-type encountered in later life. This sub-type is more commonly found in
males and usually presents in the neck nodes (Colby et al 1981, Mauch et al
1993).
There can be difficulties in defining the MC sub-type from the other
sub-types as it contains numerous classical RS cells but both Lacunar cells
and the Pleomorphic variant of the RS cell may also be present. The
Pleomorphic variant shows even more bizarre nuclear multilobation, some
also show gigantic nucleoli. The composition of the cellular infiltrate present
in the MC sub-type is very varied from areas of lymphocyte depletion to
areas of lymphocyte predominance, but usually also includes eosinophils,
neutrophils, plasma cells and histiocytes (Figure 1.2). The MC sub-type may
also show disorganised sclerosis unlike the banded , organised sclerosis
seen in the NS sub-type.
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Lymphocyte Depleted Hodqkin's Disease
This is the least common sub-type accounting for about 4% of cases
(Bennett et al 1985). It is mainly a disease of late adult life. There are 2
sub-types of LDHD - Reticular and Diffuse Sclerosis (Lukes & Butler 1966,
Lukes et al 1966). In the Reticular form, there is a stromal response similar
to that found in the MC sub-type, but there is a predominance of the
Pleomorphic RS cell variant. In the Diffuse Sclerosis sub-type, Pleomorphic
and Classical RS cells are set in a hypo-cellular back-ground of
disorganised sclerosis (Figure 1.2).
The Rye classification of Hodgkin's disease has remained stable for 25
years and is still considered to be clinically and pathologically relevant
(Bennett et al 1991). However, the accurate distinction of the 4 histological
sub-types can be difficult. Also, it is necessary to be aware that there is
considerable morphological over-lap between certain types of Non-Hodgkin
Lymphomas and Hodgkin's disease, i.e. MCHD and the peripheral T Cell
Lymphomas and LDHD and the Ki-1 positive Large Cell Anaplastic
Lymphomas, to avoid misdiagnosis as Hodgkin's disease (Agnarsson &
Kadin 1988, Harris 1992).
Another problem with the Rye classification is the concept that the 4
sub-types are inter-related with possible progression from good to poor
prognosis sub-types i.e. transition from LP to MC to LD. It is now clear that
LPHD is a biologically distinct entity that does not progress to other sub¬
types but may rarely transform to a high grade B cell lymphoma (Poppema
1992).
Recently, there has been a proposal for a new classification system
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KEY FOR FIGURE 1.2
RS - classical Reed-Sternberg cell
Arrow indicates a pleomorphic Reed-Sternberg cell
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(REAL) classification (Chan et al 1994). Under this classification system, an
extra HD sub-type has been entered called Lymphocyte-Rich Classical
Hodgkin's Disease. This sub-type shares the clinical features of NS or
MCHD and the immunophenotype of NSHD. Histologically, diffuse
effacement of architecture is seen, with infrequent classical RS cells (rather
than L and H cells) scattered in a lymphocyte-rich back-ground (Chan et al
1994). However this is a provisional entity which may be deleted or become
established as more information is collected.
1.1.4 Histogenesis of the Reed-Sternberq Cell
Although much progress has been made in the treatment of Hodgkin's
disease, and it has been the subject of many studies, the histogenesis of the
RS cell remains unclear.
Immunohistochemical staining of HD in general shows that RS cells
commonly express the CD30 activation marker (Schwab et al 1982), the
granulocyte-associated antigen CD15 (Hsu & Jaffe 1984), MHC Class II,
CD71 (the transferrin receptor) and the Tac antigen (IL-2 receptor - CD25)
demonstrating the activated state of the RS cells (Hugh & Poppema 1992),
and adhesion molecules such as CD54 (ICAM-1), CD58 (LFA-3) and CD44
(Paeitta 1992). They are usually negative or stain very weakly with the
leucocyte common antigen (LCA - CD45) and the epithelial membrane
antigen (EMA). The exception to this rule is the L and H variant of the RS
cell in the Lymphocyte Predominant sub-type which stains additionally for
CD45 and EMA. Variable results have been reported with antibodies
against CD30 (Ki-1, Ber-H2). Although most cases show CD30 (Ki-1)
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staining of L & H cells in frozen sections, Ber-H2 stains less than 50% of
cases in paraffin sections. CD15 staining of the L and H cells however is
unusual in NLPHD (Nicholas et al 1990).
Cell kinetic studies in HD are comparatively limited (Peckham &
Cooper 1969). However, with the use of specific markers for RS/H cells and
the monoclonal antibody Ki-67 which stains a cell cycle associated antigen
expressed in all phases except Go, both Gerdes et al (1987) and Falini et al
(1987) demonstrated a high percentage of RS/H cell proliferation (53-98%
Ki-67 positive RS/H cells). More recently, studies using anti-PCNA/cyclin (a
cell cycle regulated protein with increased expression in G1 and S phase,
correlating to DNA synthesis) (Otago et al 1987) antibodies have also
reported the high percentage of apparently cycling RS/H cells (Benjamin &
Gown 1991, Schmid et al 1992).
Conflicting evidence over the years has suggested a
monocyte/macrophage (Kadin et al 1978), dendritic reticulum cell (Curran &
Jones 1977) and interdigitating cell origin for the RS cell (Hsu at al 1985).
Kadin et al (1978) supported the view that the RS cell is derived from
the macrophage. They argue against a B cell origin as they found that
cytoplasmic immunoglobulin of individual RS cells was always polyclonal
(expresses both kappa and lambda light chains) making intracellular
synthesis of the immunoglobulin by the RS cells unlikely. Using in vitro
studies, they concluded that exogenous immunoglobulin is internalised
(probably via an Fc receptor) by the RS cells and favoured a macrophage
origin for the cell.
However, Hsu et al (1985) and Watanabe et al (1982) found that RS
cells failed to react with macrophage markers such as a1-antitrypsin or
lysozyme. Meiss et al (1986) found occasional positivity with a1-antitrypsin
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but this was also found in some B and T cell lymphomas. RS cells also
failed to react with monocyte markers such as OKM1, MO-2, Leu-3 etc (Hsu
etal 1985).
Curran & Jones (1977) suggested an origin from follicular dendritic
cells with the presence of immunoglobulin resulting from absorption.
However, Hsu et al (1985) found that the RS cells also failed to react with
the follicular dendritic cell markers such as DRC-1. Hsu et al (1985) also
found negativity with a wide range of T and B cell markers and suggested an
origin for RS cells from interdigitating reticulum cells from a similar antigenic
phenotype, and the frequent involvement of the T cell zones in Hodgkin's
disease (where the interdigitating reticulum cells are localised). However,
Meiss et al (1986) and Watanabe et al (1982) both found negativity with the
interdigitating reticulum cell marker - S100 protein.
The current consensus is that the RS ceil is an activated lymphoid cell
with an aberrant phenotype (although proposals of a follicular dendritic cell
origin are currently gaining popularity). Distinct similarities between RS cells
and transformed lymphocytes (large with vesicular nuclei and prominent
nucleoli) have been demonstrated ultrastructurally (Biniaminov & Ramot
1974). The finding that lymphokines including IL-4, IL-5, IL-6 and IL-9 are
produced by HD tissues also supports the argument that RS/H cells derive
from lymphocytes.
There is however no consensus as to whether the RS cell is of T or B cell
origin.
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Nodular LPHD as a B Cell Lymphoma
The exception to this is the Nodular Lymphocyte Predominance sub¬
type which is now widely accepted to be a B cell lymphoma. Investigators
favouring a T cell origin for the RS cell treat the LP sub-type as the
exception and either omit it from their studies or demonstrate its negative
staining with any T cell marker. It can be distinguished immunohistologically
from the other sub-types (LCA positive, CD15 negative, back-ground
population of polyclonal B cells) and Timens et al (1986) proposed that it
was actually a germinal centre lymphoma - the result of abnormal
proliferation of cell types present in the normal follicles and germinal
centres, the L and H cells being transformed B cells. Another feature which
distinguishes LPHD is the much higher CD57 reactivity of the back-ground T
cells, with characteristic 'ringing' of the L and H cells (Kamel et al 1993).
The L and H cells have been shown to contain cytoplasmic J chain, a
polypeptide synthesised exclusively by B cells (Stein et al 1986) and these
CD57 positive background T cells may be relevant as functional studies
have shown that CD57 positive T cells may play a role in the regulation of Ig
production by B cells (Banerjee et al 1988). However, the biological
significance of these T cells in NLPHD remains uncertain.
In several studies, the L and H cells have been shown to stain with B
cell markers such as L26 (CD20) and MB2 in over 90% of cases (Norton &
Isaacson 1987, Hall et al 1988, Nicholas et al 1990, Poppema 1992a). It
should be noted that in most cases, the L and H cells show polytypic
(presumably endocytosed) immunoglobulin (Ig) light chain expression.
However, it has been reported that in some cases L and H cells express
monotypic kappa or lambda light chain. This provides strong evidence for
the monoclonality and therefore neoplastic nature of these L and H cells and
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their B cell origin (Schmid et al 1991a, Momose et al 1992). This was
confirmed by in situ hybridisation for light chain mRNA (Hell et ai 1993).
However, most studies have failed to demonstrate Ig gene rearrangements
(Algara et al 1991,Said et al 1991).
The cellular origin of the RS cell is not so clear cut in the other sub¬
types of Hodgkin's disease (NS,MC,LD) with conflicting phenotypic and
genotypic studies.
Phenotvoic Studies in Other HP Sub-types (NS, MC, LP)
The fact that initial lesions often arise in the T cell zone of the
affected lymph node or spleen, has prompted some investigators to suggest
that the RS cell may have its origin in a transformed T lymphocyte, perhaps
antigenically altered by a viral infection. They hypothesise that HD is an
interaction between the transformed T lymphocyte and the normal T cells
and reactive B cells (Biniaminov & Ramot 1974, Berard et al 1980). The
discovery by Samoszuk & Nansen (1990) that RS cells strongly express IL-5
mRNA prompted them to suggest that RS cells may be functionally related to
T cells. Some investigators have found evidence of RS cells expressing T
cell antigens (including CD3 which is highly specific for T cells). Kadin et al
(1988) found that in 8/30 cases of Hodgkin's (NS.MC), the RS cells stained
positively with T cell markers (CD2,3,4). Many investigators argue that it is
difficult to distinguish RS cell staining with T cell markers from the small T
lymphocytes surrounding them, but Kadin et al confirmed the surface antigen
staining of RS cells by the deposit of a dark linear reactive product along the
cell membrane in electron micrographs. They suggested a T cell origin for
RS/H cells in some cases of HD.
16
Dallenbach and Stein (1989) found positive staining of a sub-
population of the RS/H cells in 14/65 cases of Hodgkin's (NS,MC,LD) with a
T cell receptor p chain antibody. The staining was usually localised on the
membrane, presumably reflecting endogenous TcR p chains, although it was
stated that positive staining of the RS cells could not be determined
precisely in some cases because of the surrounding TcR p positive T cells.
The TcR p positive staining was backed up by positive staining with T cell
(CD2,3,4) but not B cell (except LPHD) markers. Falini et al (1987)
performed immunostaining on lymph node cytospins to distinguish the RS
cell staining, although it was stated that the RS cells were still frequently
surrounded by a rim of T lymphocytes. They found positive cytoplasmic
and/or membrane staining of RS cells with T cell markers (CD3,4,5,6,8) in
8/30 cases (MC,LP,LD sub-types).
It is clear that these reports are not pointing to an exclusive T cell
origin for the RS cell. Those who included B cell markers on their panel
found the presence of T and B cell markers in the cases of Hodgkin's
Disease studied (Casey et al 1988, Oka et al 1988, Agnarrson & Kadin
1989). In fact most of these investigators favouring a T cell origin for RS
cells conclude that Hodgkin's Disease is a phenotypically heterogeneous
disease of either T (most common) or B (less common) cell origin.
Many studies have shown positive staining of RS/H cells with
immunoglobulin of both kappa and lambda light chain sub-types (Curran &
Jones 1978, Poppema et al 1978, Isaacson 1979, Stein et al 1981, Lauritzen
et al 1992, Hell et al 1993) and therefore polyclonal, making intracellular
synthesis by the RS cells unlikely. Some argue that the uptake of
exogenous polyclonal immunoglobulin by the RS cells masks detection of
endogenous immunoglobulin of a monotypic nature (Isaacson 1979).
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However, one study found that these RS cells do not stain for J chain
providing strong evidence that the immunoglobulin was not synthesised
endogenously by the RS cell and therefore not of B cell origin (Isaacson
1979).
In situ hybridisation studies have also failed to demonstrate
immunoglobulin light chain mRNA in RS cells (NS,MC sub-types) (Ruprai et
al 1991) even when a more sensitive method using digoxygenin labelled
probes able to detect low to medium copy numbers of mRNA species was
employed (exception was 1 case of MCHD) (Hell et al 1993).
However, many studies have shown immunostaining with B cell
markers in RS cells of all sub-types of Hodkgkin's. Agnarsson & Kadin
(1989) found in NSHD that 100% of cases expressed CD20, and 33% of
cases expressed CD22. Norton and Isaacson (1987), investigating L26
reactivity of RS cells, found positive staining in 50% of MCHD cases and in
20% of NSHD cases. In a study by Hall et al (1988), 43 cases of Hodgkin's
were studied, no case showing immunoreactivity with any T cell markers -
however, a proportion of each sub-type (MC, NS, LD) was positive with the B
cell markers L26 and MB2. Schmid et al (1991b) found in 87% of cases
(MC, NS sub-types) that RS cells were reactive with at least one B cell
marker (CD19, CD20, CD22, CD75, MB2). O'Grady et al (1994a)
demonstrated strong expression of the CD40 B cell activation antigen in
23/33 cases of Hodgkin's (MC, NS, LD sub-types) studied - of the 23 CD40
positive cases, 10 co-expressed one or more B cell markers.
Imam et al (1990), used an anti-BLA.36 antibody which recognises a
36kD glycoprotein antigen termed B lymphocyte antigen (BLA.36). This
antigen is expressed on normal and malignant B cells but not on T cells or
macrophages. Reed-Stemberg cells of all sub-types of HD were found to
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express this antigen strongly, lending support to the B cell origin of RS/H
cells.
A recent report identified a novel B cell activation antigen recognised
by monoclonal antibody FUN-1 (Nozawa et al 1993). FUN-1 recognises a
75kD protein present on activated B cells, EBV-transformed B cells, large B
cell lymphomas and LCAL. Resting lymphocytes, activated T cells and low
grade B cell leukaemias do not react with the antibody. Reed-Sternberg
cells of all sub-types of HD were found to express this antigen, also lending
support to the B cell origin of RS/FI cells.
Therefore, a proportion of the FID sub-types other than LPFID are
found to stain with B cell markers.
Some investigators simply take the view that RS cells represent
malignant counterparts of lymphoid cells of either T or B cell origin that are
in an activated state (Stein et al 1985).
Another approach used to define the cellular origin of Hodgkin's
disease is genotypic analysis of immunoglobulin or T cell receptor gene
rearrangements.
Genotypic Studies in Other FID Sub-types (NS, MC, LP)
During the differentiation of B and T cells, the immunoglobulin (Ig)
and T cell receptor (TcR) genes undergo specific recombinations. One out
of several V (variable), D(diversity) and J(joining) genes are recombined
together to form an active V-D-J complex for the immunoglobulin heavy and
T cell receptor beta chains, and a VJ complex for immunoglobulin light and
T cell receptor alpha chains. The T cell receptor gamma and delta genes
also recombine in this way and are expressed on a small fraction
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(approximately 10%) of T cells. The rearrangements of the Ig and TcR
genes are individual for each T and B cell clone. Therefore, these
rearrangements can be used as markers for the clonal origin of a sub-set of
T or B cells in a heterogeneous population, and since tumours are
characterised as a clonal proliferation of cells which display the same
receptor molecules, these rearrangements are good tumour-specific
markers. The Ig and TcR gene rearrangements are easily identified by
Southern blotting.
Several groups have investigated this, and again conflicting ideas
have arisen.
In gene rearrangement studies in Hodgkin's Disease, different
investigators find Ig only, TcR only, both or none. Greisser et al (1987)
found TcR beta rearrangements in 4/22 cases and TcR gamma
rearrangements in 15/22 cases, including 3 Lymphocyte Predominant cases.
They also found IgH rearrangements in 2/22 cases, both Lymphocyte
Depleted, and conclude that different rearrangements patterns may be
associated with different sub-types. However, in the majority of studies,
TcR rearrangements have not been detected in Hodgkin's disease (Knowles
et al 1986, Weiss et al 1986, Sundeem et al 1987, Roth et al 1988, Gledhill
et al 1990, Tesch et al 1990).
Roth et al (1988) and Knowles et al (1986) found no rearrangements
of Ig or TcR genes in their studies concluding that RS cells do not represent
clonal B orT cell populations.
The majority of studies detect some Ig gene rearrangements in
Hodgkin's Disease. Tesch et al (1990) found rearrangements of JH genes in
2/7 cases and of the Jk gene in another case. No TcR rearrangements
were found. Gledhill et al (1990) found both IgH and IgL gene
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rearrangements in 3/9 cases, all 9 cases had germline TcR beta and gamma
genes. One could argue that the lack of detectable TcR gene
rearrangements in many studies could be due to insufficient numbers of RS
cells in the biopsies, but Sundeem et al (1987) and Weiss et al (1986) both
used cases with a high number of RS ceils, either selected solely on the
basis of high RS cell content, or enriched for RS cells by cell separation
techniques. No TcR gene rearrangements were detected in either of these
studies. However, Sundeem et al (1987) found at least one Ig gene
rearrangement in 3/5 cases and Weiss et al (1986) in 6/7 cases.
These results suggest that clonal cell populations with uniform Ig
gene rearrangements are present in the tissue in some cases of Hodgkin's
Disease. The fact that these rearrangements are present in enriched RS
cell suspensions, and increased in cases with high RS cell number,
suggests that the rearrangements are taking place in the RS cells.
Therefore, both phenotypic and genotypic studies have given
conflicting results on the histogenesis of the RS/H cells. Hence, a new mode
of investigation is necessary.
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1.2 The Non-Hodqkin's Lymphomas
1.2.1 Clinical Features
The malignant lymphomas other than Hodgkin's lymphoma are commonly
referred to as the non-Hodgkin's lymphomas (NHL). They are a
heterogeneous group of lymphoproliferative malignancies whose clinical
behaviour and prognosis vary widely according to histologic sub-type, stage
and bulk of disease. The most common mode of presentation is
lymphadenopathy, although they can arise extra-nodaliy i.e. skin, Gl tract
etc. Other presenting features are haematological cytopenia, night sweats,
fever, weight loss, hepatosplenomegaly, abdominal masses or compression
of internal organs. The NHL are the 8th most commonly diagnosed
malignancy. In the Western world, a large majority of NHL appear to arise
from B lymphocytes or their precursors. Practically all the malignant
lymphomas occurring in child-hood (except for HD) are high grade blast cell
neoplasms. All the common low grade B cell NHL are neoplasms of later
life, only rarely encountered under the age of 25 and practically unknown
under the age of 18 (O'Reilly & Connors 1992).
The treatment chosen for NHL is determined by the age and health of
the patient, the stage of the lymphoma which is determined by the Ann Arbor
classification system and the particular histologic sub-type. Surgery is
curative in rare patients with localised extra-nodal NHL but is rarely
recommended as the sole treatment. Radiotherapy alone is usually used
with Stage I disease, combination chemotherapy with or without radiotherapy
is given for the more advanced stages of the disease (Armitage et al 1993).
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1.2.2 Classification
Unlike Hodgkin's disease, NHL can be classified into T or B cell lymphomas,
low or high grade. Over the years, numerous classification systems have
been employed - one of the earliest being the Rappaport Classification
(Rappaport 1966). The 2 most commonly used classifications today are the
Working Formulation (Nat Can Inst Study 1982) and the modified Kiel
Classification (Lennert 1978, Stansfeld et al 1988) - the latter being the
preferred terminology in most cases (Table 1.1).
This study uses the up-dated Kiel classification system, however the
recently established REAL (Revised European American Lymphoma)
classification may be the system used in the future. The REAL system
includes extra-nodal lymphomas, specifically excluded from the Kiel
classification. It produces an international consensus on terminology,
commonly used terms are retained with minimal creation of new terminology.
The classification is a list of biological entities as defined by multi-parameter
studies (Chan et al 1994).
1.2.3 T Cell NHL
T cell NHL are a heterogeneous group of tumours that are difficult to identify
and classify (Wright 1986). They are relatively uncommon and only account
for 10 - 15% of the NHL (Weiss et al 1985, Krajewski et al 1988). The
neoplastic cells express one or more of the pan T cell antigens (although in
some cases, particularly in large cell categories, loss of pan T cell antigens
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Table 1.1 Up-dated Kiel Classification of Non-Hodqkin's
Lymphomas
B T
Low Grade Low Grade
Lymphocytic - chronic lymphocytic
and prolymphocytic leukaemia;
hairy cell leukaemia






- follicular + diffuse
- diffuse
Centrocytic





(AILD, LgX) T zone
Pleomorphic, small cell (HTLV-1 +)
Hiqh Grade Hiah Grade
Centroblastic
Immunoblastic
Large Cell Anaplastic (Ki-1+)
Burkitt's Lymphoma
Lymphoblastic
Pleomorphic, medium and large
cell (HTLV-1 +)
Immunoblastic (HTLV-1 +)
Large Cell Anaplastic (Ki-1+)
Lymphoblastic
Rare Types Rare Types
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can be found) as well as either CD4 or CD8 - the majority being CD4 positive
(Krajewski et al 1988, Jaffe et al 1992).
The lymphomas of T cell lineage can be divided into 2 main groups
based on their origin from immature or mature T cells. The lymphoid
neoplasm of immature T cells is the lymphoblastic NHL whereas all the
lymphomas derived from mature T cells can be grouped as 'peripheral T cell
lymphomas' (Waldron et al 1977). However, mycosis fungoides and
Sezary's syndrome correspond to mature T cells which home in and reside
in the skin and as such represent a special sub-set of peripheral T cell
lymphomas (Grogan et al 1985, Horning et al 1986).
1.2.4 B Cell NHL
The B cell NHL constitute the majority of the NHL. The cells of B-NHL are
lymphocytes or lymphoblasts with different morphologies that
characteristically express membrane Ig. Some may secrete Ig, but for the
most part do not, and Ig secretion when seen is usually limited. B-NHL cells
are related to B cells that have completed V-(D)-J Ig gene rearrangements in
the bone marrow but which have not matured into plasma cells (Potter
1992).
NHL represent neoplastic counterparts of normal reactions taking
place in the lymphoid tissues, each malignant cell type has its benign
analogue in the non-neoplastic lymph node - this concept has been worked
out in some detail for the B-NHL. The majority of NHL are derived from
follicle centre cells.
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2 main cell types are found in the follicle centre - termed centrocytes
and centroblasts. Centrocytes vary in size from a little larger than
lymphocytes to double that size and may have indented or cleaved nuclei
with dark chromatin and no nucleoli. Centroblasts have round, pale-staining
nuclei which are not indented and which usually contain several prominent
nucleoli apposed to the nuclear membrane. The distribution of centroblasts
and centrocytes is uneven within the follicles dividing it into so-called light
and dark zones. Centroblasts are concentrated in the basal dark zone and
centrocytes in the apical light zone. Most experimental evidence supports
the assumption that in the development of a germinal centre, the
centroblasts appear first and the centrocytes develop from them at a later
time (Nieuwenhuis & Keuning 1974). Indeed the centroblasts appear to be
the dominant cell type present in early germinal centre formation. There is
no doubt that these 2 cell types are 2 different stages in the B lymphocyte
life cycle and the fact that one transforms into another is supported by the
presence of intermediate cell types within the fully established germinal
centre. Other lymphoid cells in the follicle centre include immunoblasts,
occasional plasma cells and small lymphocytes. Immunoblasts have a large,
'vesicular' nucleus with a prominent, usually central, nucleolus. The
resemblance of such cells to plasma cells increases as the cell matures.
In addition to follicle centre cells, other B cell subsets may be involved
in lymphoma such as the CD5 positive mantle zone cell and the CD5
negative marginal zone cell.
The morphological relationship of the lymphoid cells in the follicle
centre and their related lymphomas are shown in Figure 1.3. This is based
on morphological, immunological and experimental studies (Stein et al 1980,
Van der Valk & Meijer 1988). Lymphomas associated with the plasma cell
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reaction are shown in Figure 1.4. This is based on morphological and
immunological studies (Weissman et al 1978, Harris & Bahn 1985, Van der
Valk & Meijer 1988).
The various sub-types of NHL (all B-NHL) encountered in this project
will be described in some detail in the following sections.
1.2.5 Malignant Lymphoma: Centroblastic-Centrocvtic
Follicular (ML Cb-Cc Foil)
This low grade B-NHL is the commonest NHL accounting for 25-50% of
cases in Europe and North America (Lennert 1981). ML Cb-Cc almost
always shows a follicular pattern in the affected lymph node, although a
diffuse pattern is also seen (ML Cb-Cc Diffuse). The neoplastic follicles are
composed of a variable mixture of centrocytes and centroblasts usually with
the former predominating, together with the non-neoplastic cells that are
found in the normal germinal centre - dendritic cells, macrophages and T
cells (Stansfeld 1992a) (Figure 1.5).
As with all the other low grade B-NHL, ML Cb-Cc Foil is a neoplasm
of adults, the incidence in the 2 sexes is almost equal. The usual mode of
presentation is lymphadenopathy, frequently found to be wide-spread at the
time of presentation (Jones et al 1973). The neoplasm occupies most of the
lymph node and may extend through the capsule into the surrounding fat.
There is always a certain number of centroblasts in the neoplastic follicles,
although they are sometimes very scanty (1-2%), but usually make up 3-
10%. Generally, these centroblasts resemble the centroblasts in the normal
germinal centre (Levine & Dorfman 1975), but occasionally there are some
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Figure 1.3 Follicle Centre Cells and Corresponding
Lymphomas
The thick arrows indicate recirculation. As shown on the left, the route a
reciculating (memory) cell will take after renewed contact with antigen is
uncertain. MZ = mantle zone; a = immunoblast; b = plasmablast; c = plasma
cell; d = recirculating lymphocyte.
The lymphomas arising from the depicted cells are : (1) lymphoblastic;
(2) centroblastic; (3) centroblastic/centrocytic; (4) polymorphic
immunocytoma; (5) mantle zone lymphoma (REAL classification, centrocytic
in Kiel); (6) dendritic reticulum cell sarcoma
Adapted from Van der Valk & Meijer 1988
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Figure 1.4 Plasma Ceil Reaction and Corresponding
Lymphomas
The thick arrow indicates recirculation.
The lymphomas arising from these cells are: (1) B-immunoblastic;
(2) lymphoplasmacytoid/-cytic; (3) plasmacytoma / multiple myeloma
Adapted from Van der Valk & Meijer 1988.
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blast cells with very prominent central nucleoli more like those of
immunoblasts. Very occasionally there may be a highly atypical binucleate
form resembling RS cells. The centrocyte is the predominant cell type and
within a single case there is often variation in the size - sometimes medium-
sized or large centrocytes predominate instead of the usual small centrocyte.
Surface immunoglobulin of a monoclonal type is a regular feature of
the neoplastic centrocytes - occasionally there may be evidence of
cytoplasmic immunoglobulin in such tumours as well (Stansfeld 1992a).
ML Cb-Cc Foil are consistently associated with the t(14; 18)
translocation which results in inappropriate expression of the bcl-2 protein
(Cotter 1990). However, the bcl-2 protein can be expressed in follicular
lymphoma (90% of cases) in the absence of the 14; 18 translocation
(Pezzella et al 1990, Pezzella et al 1991).
There is often a surprisingly large number of reactive T cells present
in ML Cb-Cc Foil. Most take the view that this is merely reactive and
associated with indolent behaviour of the B cell neoplasia and good
prognosis (Jaffe et al 1984).
ML Cb-Cc Foil lymphomas that contain a larger number of
centroblasts have a worse prognosis than those composed mainly of
centrocytes (Warnke et al 1977). Transformation from a low grade tumour
into a high grade centroblastic lymphoma is seen in about 40% of cases of
ML Cb-Cc Foil (Lennert 1981). A loss of follicular pattern and a marked
increase in the number of centroblasts especially if they are found in large ,
solid clumps or if many of the blast cells are atypical signals the
transformation into a high grade centroblastic lymphoma. Very occasionally,
transformation into a B immunoblastic lymphoma is seen (Stansfeld 1992a).
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1.2.6 ML Centroblastic (ML-Cb)
This tumour accounts for around 40% of NHL. It is the most common type of
high grade B cell lymphoma in the Western world and is slightly more
common in males (Hui et al 1988). It is usually categorised as an
intermediate grade in the Working formulation and high grade in the Kiel
classification - it is not as aggressive as the high grade immunoblastic and
lymphoblastic lymphomas but certainly more aggressive than the low grade
B cell lymphomas.
The centroblastic lymphoma can arise de novo as a high grade
lymphoma or from the transformation of a pre-existing low grade ML Cb-Cc
lymphoma as stated above. Centroblastic lymphomas may occasionally
exhibit a follicular pattern, but are more usually follicular and diffuse, or
diffuse. They are usually composed of a mixture of centroblasts and
immunoblasts with scanty centrocytes (called the polymorphic sub-type) but
occasionally almost pure centroblastic tumours are seen (the monomorphic
sub-type). Also found is the multi-lobated sub-type in which a large
proportion of the blast cells have bizarre, multi-lobated nuclei and the
centrocytoid sub-type in which the majority of the neoplastic cells resemble
large centrocytes, although some typical centroblasts are also present
(Stansfeld 1992b).
Many of the tumours show monotypic surface immunoglobulin -
occasionally cytoplasmic immunoglobulin is also found (Stansfeld 1992b).
There is no sharp border between the monomorphic and polymorphic
variants, or even between centroblastic and immunoblastic lymphoma - the
main problem is distinguishing between a polymorphic centroblastic
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Centroblastic lymphoma (Case G) comprised mainly of centroblasts, with a few
immunoblasts.
Figure 1.5 Histological Appearance of Follicular and Centroblastic
Lymphoma
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1.2.7 ML Immunoblastic - B Type (ML Ib-B)
These are large cell, high grade malignant lymphomas of diffuse type. They
are slightly more common in males. They may arise de novo or occasionally
as a result of transformation of a pre-existing low grade B cell lymphoma -
usually of lymphoplasmacytoid or lymphocytic type.
Typically, the neoplastic immunoblasts are large cells with large round
or ovoid nuclei, displaying a prominent, central nucleolus with abundant,
pale-staining cytoplasm - generally more than that of a centroblast. In most
tumours, some of the cells show plasmacytoid differentiation i.e. they are
smaller, have more clumped chromatin, darkly-staining cytoplasm which may
show a pale area adjacent to the nucleus corresponding to the position of
the golgi apparatus (Figure 1.6).
B immunoblastic lymphomas vary not only in degree of plasmacytoid
differentiation but also in cell size. At one end of the range there are
tumours composed of small blast type cells whilst at the other end the cells
may be almost double that size. In any given tumour, cell size tends to be
uniform though exceptions occur and pleomorphic ML Ib-B are sometimes
seen containing bizarre giant blast cells. ML Ib-B show a high mitotic rate
and atypical mitoses are often seen especially in the pleomorphic sub-type.
Spontaneous necrosis is also a common feature accompanied by a heavy
infiltration of macrophages and neutrophils (Stansfeld 1992b).
B immunoblastic lymphomas always synthesise immunoglobulin.
Monotypic immunoglobulin is found on the surface of the cells and
occasionally intra-cellular deposits of immunoglobulin are found in the
cytoplasm. In these cases of ML Ib-B showing strongly developed
plasmacytoid characteristics, cytoplasmic immunoglobulin is readily shown
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by appropriate immuno-staining. Lennert (1978) states that as a rule,
immunoblastic lymphomas reveal a great increase in immunoglobulin in the
tumour tissue and/or blood.
1.2.8 ML Large Cell Anaplastic Lymphoma (LCAL) or Ki-1
Lymphoma - B Cell Type
Prior to the recognition of the distinct features of LCAL, many of these
lymphomas had been mistakenly diagnosed as metastatic carcinoma,
pleomorphic immunoblastic sarcoma, lymphocyte depleted Hodgkin's
disease or malignant histiocytosis (Stein et al 1985).
LCAL predominantly involves lymph node or skin (Agnarsson & Kadin
1988). The affected lymph node shows a large cell infiltrate with a
prominent sinus distribution that extends from the sub-capsular sinuses into
the paracortical region often surrounding residual germinal centres. The
tumour cells are very large, pleomorphic and often polyploid cells. The large
nuclei are highly irregular and sometimes multiple, nuclear pleomorphism
with some folding and lobation is common. Prominent nucleoli are seen,
while the cytoplasm is abundant. Mitotic figures are frequent and very often
atypical. Tumour giant cells are often present and may be Reed-Sternberg-
like although there is generally more nuclear pleomorphism in LCAL than
Hodgkin's disease (Glick et al 1976). In addition, small reactive cells such
as lymphocytes, macrophages, plasma cells and eosinophils may be present
(Figure 1.6).
The tumour cells express the CD30 antigen (Ki-1) uniformly and
strongly (Stein et al 1985). Although some LCAL fail to express any T or B
34




* &• * * •" " ? ^ £ »
t ¥
. * z,. * «* * ® Q _ ■ t
*
|■ • J % Va«OV A «# V ft
« « " % ->*' a * .7 «, & « V# * . 8
, ® •„ "* *;• v m ^ ... * •
*
« y a ~ " % •-%*i •& ~ *
'
#,- * f t ■ *i *,§ . J| 9 ♦ T+ /• $ii (
'*-w® ■ a** » » » . T r O A ^:*i *r •* r i)0 g 4-> % J ' - - ,, -> - .a» jf £#*
^ V » •- .•»% , « f »6 « , ■ &
„ e , ■ »- - . • •« % % »■• • c0 " ,.» 5 <-• <r «fi Ik* "* ** ,■.
* I1 **■♦ •-" • .»;.*V .v •» ■ «# iS
^*1 @'*<6 • • • ^ J I f!<?
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Figure 1.6 Histological Appearance of Immunoblastic Lymphoma
and LCAL (B cell type)
35
cell markers, immunophenotyping and genotyping studies have shown that
the B cell type is less common (Chan et al 1989, Herbst et al 1989). The few
cases that show both T cell receptor and immunoglobulin gene
rearrangements are interpreted as of B cell origin since 5-10% of B cell
lymphomas show T cell receptor gene rearrangements (O'Connor et al
1985). Additional marking has been noted with antibodies against HLA-DR,
IL-2 receptor, transferrin receptor and the Ki-67 proliferation marker
indicating the activated, proliferative state of the neoplastic cells (Chan et al
1989). Weak leucocyte common antigen (LCA) positivity is usually present
(Hall et al 1988) and many may express the epithelial membrane antigen
(EMA) (Chan et al 1989).
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1.3 Aetiology of Hodgkin's and Non-Hodgkin's
Lymphomas
1.3.1 Hodqkin's Disease
The cause of Hodgkin's disease remains unknown. Tilly et al (1991) found
abnormal karyotypes found in around 50% of cases. More recently,
Poppema et al (1992b) showed abnormal metaphases in 23/28 HD cases.
The most common structural abnormalities were in 14q, including the region
of the Ig heavy chain, 14q32. By in situ hybridisation, cells with numerical
clonal abnormalities were shown to be RS/H cells (Poppema et al 1992b).
No chromosomal abnormality appears with sufficient frequency to suggest a
pathogenic association - karyotyping in Hodgkin's disease is however made
difficult by the paucity of the neoplastic RS cells. Recently, the
t(2;5)(p23;q35) translocation found in T-cell derived LCAL was found in
11/13 cases of HD of NS and MC sub-types (Orscheschek et al 1995) -
however, this was not found in several other studies (Chan et al 1995,
Downing et al 1995, Lucey & Shearer 1995, Poppema 1995).
Studies of oncogene involvement in HD have also been hindered by
the scarcity of RS cells with studies largely restricted to HD cell lines.
Although a number of oncogene products have been found in HD cell lines,
including c-myc, p53, c-jun, c-raf, N-ras and others, no characteristic pattern
has emerged. Also, the in vivo relevance of this is uncertain (Jucker et al
1990). However, recent studies using HD biopsy material have investigated
bcl-2, p53 and c-myc.
The bcl-2 proto-oncogene is deregulated via the t (14; 18)(q32;q21)
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IgH -bcl-2 translocation seen in 90% of follicular lymphomas (a low grade
NHL) and 20% of other high grade NHL. Bcl-2 protein inhibits apoptosis and
therefore increases cell survival (Hockenbery et al 1990). Some studies
have detected the bcl-2 translocation in HD (Stetler-Stevenson et al 1990,
Lorenzen et al 1992, Reid et al 1993) whereas others have failed to detect
the bcl-2 translocation (Louie et al 1991, Said et al 1991, Athan et al 1992).
Immunohistochemical studies have also given rise to conflicting results with
some detecting bcl-2 in RS/H cells in a proportion of HD cases (Armstrong et
al 1992a, Khan et al 1993, O'Grady et al 1994b) and others failing to find
detection of the protein (Algara et al 1991, Louie et al 1991). There is
however no correlation between the presence of the bcl-2 protein in RS/H
cells and the t(14; 18) translocation detectable by PCR (Lorenzen et al
1992). It therefore seems unlikely that bcl-2 plays a major role in the
pathogenesis of HD.
The c-myc oncogene is involved in cell proliferation and differentiation
and seems to play an important role in cell cycle control. Activation of the
c-myc proto-oncogene by the t(8; 14) c-myc-IgH translocation is involved in
Burkitt's lymphoma (Dalla-Favera et al 1982). Studies of c-myc expression
in HD are more limited (Mitani et al 1988, Jiwa et al 1993). However, Jiwa et
al found expression of the c-myc protein in 94% of cases of HD, restricted to
the RS/H cells. Bcl-2 has been found to synergise with c-myc in tumour
progression (Strasser et al 1990, Fanidi et al 1992) and Jiwa et al (1993)
found that in 72% of their HD cases the RS/H cells expressed both bcl-2 and
c-myc and suggest that the co-operation of bcl-2 and c-myc may be involved
in the pathogenesis in a substantial number of HD cases.
The p53 tumour suppressor gene is thought to have a role in the
regulation of the normal cell cycle, apoptosis and response to DNA damage
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(Lane 1992). Mutation of this gene is thought to be the most frequent
abnormality in human tumours. Normal p53 is undetectable by
immunohistochemical staining, but stabilisation by mutation or binding to
cellular or viral proteins allows detection. P53, restricted to RS/H cells, has
been detected in 32 - 74% of HD cases (Doglioni et al 1991, Gupta et al
1992, Niedobitek et al 1993) in all sub-types except LPHD. This suggests
that p53 may play a role in some cases of Hodgkin's disease. Recently,
Trumper et al (1993) examined one case of HD using single cell PCR
technique and detected a mutation in exon 7 of the p53 gene in 5 out of 7
RS cells.
1.3.2 Non-Hodqkin's Lymphomas
As stated before, Non-Hodgkin's lymphomas represent neoplastic
counterparts of reactions which usually take place after antigenic stimulation
- each malignant cell type has its benign analogue in the non-neoplastic
lymph node (Van der Valk & Meijer 1988). The derailment causing a NHL
can be a block in the normal differentiation process or an increased and
uncontrolled proliferation. Abnormal chromosomal karyotypes are presumed
to occur in 100% of cases (Offit & Chaganti 1991). The most common
abnormalities involve translocations (or inversions) at Ig and TcR loci.
Various chromosomal abnormalities have been described for the T
cell NHL involving any of the TcR chain genes. Examples are
t(8;14)(q24;q12) involving c-myc and TcRa (Shima et al 1986) and
t(7;9)(q34;q33) involving probably the c-abl proto-oncogene and TcR(3
(Hecht et al 1985) amongst many others (Greisser 1989). Some LCAL
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cases, especially those of T cell type, have a specific translocation
t(2;5)(p23;q35) involving a possible growth-regulating tyrosine kinase
(Mason et al 1990).
The most common translocations seen in B cell NHL are the
t(8;14)(q24;q32) c-myc - IgH which activates the c-myc oncogene seen in
Burkitt's lymphoma (Dalla-Favera et al 1982) and other high grade B-NHL
and the t(14;18)(q32;q21) IgH - bcl-2 which activates the bcl-2 oncogene
seen in 90% of centrocytic-centroblastic follicular lymphomas and 20% of
other high grade B-NHL. Another less common translocation seen in B-NHL
is the t(11; 14)(q13;q32) bcl-1 - IgH which activates the bcl-1 oncogene seen
in lymphocytic and centrocytic B-NHLs (Williams et al 1991, Withers et al
1991).
The p53 protein has also been found to be abnormally expressed in a
substantial proportion of NHL cases (Pezzella et al 1993).
The incidence of NHL has been rising steadily over the last 30 years
in several countries and has increased by over 50% in the USA in the last 6
years (Ries et al 1990). Several lines of evidence have attributed
occupational factors such as exposure to pesticides (Zahm & Blair 1992),
wood, solvent or related chemicals (Pearce & Bethwaite 1992) or poor
nutrition (Davis 1992) and use of hair dye (Pearce & Bethwaite 1992) as
having possible aetiological roles.
The most firmly established cause of NHL is immunodefiency whether
due to hereditary or acquired disease (such as AIDS) or to medical treatment
(such as post-transplant patients) (Kinlen 1992, Filopovich et al 1992).
Mounting evidence has suggested an aetiological role for EBV in these
situations (see section 1.4.2),
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There is also evidence that EBV may also play a role in both NHL and
HD in immunocompetent individuals. Another virus which has been clearly
shown to cause NHL is the Human T cell Lymphotrophic Virus Type 1
(HTLV-1) (Mueller et al 1991 & 1992). This retrovirus establishes a latent
infection in its target cell (activated T helper cells ) and can induce an adult
T cell leukaemia or lymphoma (ATL) (Table 1.1).
However, the most established link is between HD and NHL and the
Epstein-Barr virus, and because of the role of EBV in the SCID tumours
grown in this thesis, the EBV is discussed in more detail in the following
section.
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1.4 The Epstein-Barr Virus
1.4.1 The EBV Genome and Transforming Functions
The Epstein-Barr Virus (EBV) is a double-stranded DNA Herpes virus that
infects all human populations - greater than 95% of the adult human
population carries the virus, which is normally acquired asymptomatically in
early childhood. EBV usually initiates human infection in the oropharygeal
epithelium, which allows viral replication. In this primary infection, EBV
infects B lymphocytes which traffic close to the basement membrane of the
oropharygeal epithelium. EBV does not usually replicate in B cells but
instead establishes latent infection at a level of about 1 in 105-10®
peripheral blood mononuclear cells in healthy adults. It enters B
lymphocytes via the C3d receptor (CD21) and immortalises the infected
cells. These yield progeny which proliferate indefinitely, maintaining EBV in
a latent state (reviewed by Miller 1990, Kief & Liebowitz 1990).
The EBV genome is a linear duplex molecule of approximately 172
kilobase pairs which is not integrated but maintained as a circular molecule
in infected cells. The ends of the linear molecule contain direct repeats
(terminal repeats) which are joined together on circularisation in the infected
cell. EBV has the capacity to encode about 100 genes, but in latent infection
only a restricted number are expressed (reviewed by Middleton et al 1991,
Rogers et al 1992). 2 of these encode small, nonpolyadenylated non-coding
RNAs (EBER1 and 2). In latently infected cells, the EBERs are by far the
most abundant gene transcripts (10? copies/cell). They are located in the
nucleus where they are complexed to cellular proteins. Despite the high
abundance of the EBERs, their function is still unknown (Khan et al 1992).
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At least 9 virally encoded proteins are expressed during latent
infection, these include 6 nuclear proteins - the Epstein-Barr Nuclear
Antigens (EBNAs) and 3 Latent membrane Proteins (LMP 1, 2a, 2b). 3 of
these viral proteins have been studied in detail - EBNA-1 and 2 and LMP-1.
The EBNA-1 protein performs house-keeping functions - it is a DNA-binding
protein vital for replication and maintenance of the viral genome in a plasmid
form. Expression of LMP and EBNA-2 appear to be essential for the
immortalisation of B cells. Although the exact mechanism of the
immortalisation process is unclear, EBNA-2 and LMP are known to induce
certain activation and adhesion molecules including ICAM-1, LFA-1, LFA-3,
CD30, CD39, CD43, CD70, CD23 and CD40 (reviewed by Middleton et al
1991, Rogers et al 1992). CD23 and CD40 are of particular interest as they
are both involved in B cell growth and reduction in tumour cell apoptosis,
probably through induction of the bcl-2 onco-protein (Liu et al 1991a, Liu et
al 1991b). LMP also induces bcl-2 expression and protects the cell from
apoptosis (Henderson et al 1991). EBNA-2 and LMP co-operatively induce
high levels of CD23 and soluble CD23 is shed from the cell surface where it
may act as an autocrine B cell growth factor (Swendeman & Thorley-Lawson
1987, Wang et al 1990).
In B cells, 3 patterns of expression of the latent proteins have been
described :- in Type I Latency only the EBNA-1 protein is expressed, in Type
II EBNA-1 is expressed along with the LMPs and in Type III all 9 proteins are
expressed (Rowe et al 1992). This B cell immortalisation is demonstrated in
vitro in EBV-transformed B cell lines or Lymphoblastoid Cell Lines (LCL) -
cell lines of non-neoplastic, diploid origin grown from seropositive individuals
or in vitro artificial EBV infection of lymphocytes (reviewed by Tatsumi 1992).
These Lymphoblastoid cell lines express the full range of EBV proteins i.e.
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Latency Type III. They show high expression of the aforementioned
adhesion molecules (causing them to grow in 'clumps') and activation
molecules. They show surface and cytoplasmic immunoglobulin, are multi-
clonal in nature and show secretion of immunoglobulin (reviewed by
Middleton et al 1991, Tatsumi 1992).
1.4.2 Disease Association
Delayed primary EBV infection results in the development of a transient,
benign lymphoproliterative disorder known as Infectious Mononucleosis.
EBV is also associated with a range of lymphoid malignancies including
nasopharygeal carcinoma where EBV is regularly found in all cases of
undifferentiated and differentiated forms of the carcinoma, and Burkitt's
lymphoma (BL) - a high grade B cell lymphoma also involving translocation
of the c-myc oncogene (reviewed by Miller 1990). Burkitt's lymphoma shows
a Type I latency infection pattern as indeed do BL cell lines, retaining the
phenotype of the original tumour. They display very low or undetectable
levels of the activation and adhesion molecules that are abundantly
expressed on LCLs and instead display other markers (CD10, CD71). The
down-regulation of these molecules may provide a mechanism for the
tumour to escape immunosurveillance. On serial passage however, there is
a tendency for these BL cell lines to 'drift' and acquire an LCL-like phenotype
(Rowe et al 1992, Hamilton-Dutoit et al 1993).
A third group of patients in whom EBV-associated tumours have been
described is in the immunocompromised population. B cell NHL account for
43% of tumours occurring in primary immunodeficiences (Filipovich 1984).
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Post-transplant patients show a similar high incidence of NHL (although
Hodgkin's disease is rare in these patients) (Penn 1984) - these lymphomas
almost invariably contain EBV DNA (Crawford et al 1980). Patients with
AIDS not only show an increased risk of NHL but also Hodgkin's disease
with the great majority of all AIDS -associated lymphomas expressing EBV
(Uccini et al 1989, loachim etal 1991, Samoszuk & Ravel 1991).
Histologically, the EBV positive lymphomas seen in
immunocompromised individuals represent a spectrum of B cell proliferative
diseases ranging from polyclonal B cell proliferations (classified as
polymorphic diffuse B cell hyperplasia - PDBH) to monoclonal B cell
lymphomas (classified as polymorphic B cell lymphoma - PBL). PDBH is
characterised by a polymorphic, diffuse, invasive, B cell proliferation
involving centroblasts, centrocytes, immunoblasts, plasmacytoid cells and
typical plasma cells. The large cells do not show atypia. PBL is
distinguished from PDBH primarily by the presence of large immunoblasts
with marked nuclear atypia and extensive necrosis. The polyclonal
proliferations may evolve to monoclonal in association with appearance of
cytogenetic abnormalities (Frizzera et al 1981, Hanto et al 1983) They show
a Latency III EBV expression, and similar activation/adhesion molecule
expression as LCL (Thomas et al 1990). Recently, it was discovered that in
AIDS-related large cell lymphomas all 3 patterns of viral latency could be
found - Latency I similar to BL, Latency III reminiscent of LCL and
intermediate Latency II (the phenotype seen in Hodgkin's disease)
(Hamilton-Dutoit et al 1993).
Lymphomas arising on a back-ground of immunodefiency differ from
lymphomas arising in immunocompetent individuals in that they are
frequently extranodal (most commonly presenting in the central nervous
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system) and they are more commonly associated with EBV. The debate
continues over whether the presence of EBV is secondary to the
immunodeficient state of these patients or whether EBV plays a more direct
role in oncogenesis.
Recent evidence has accumulated indicating that EBV may play a role
in lymphomagenesis in immunocompetent individuals. Recent studies have
described the presence of EBV in both Hodgkin's and Non-Hodgkin's
lymphomas.
1.4.3 Association with Hodqkin's Disease
EBV has been implicated in Hodgkin's disease both serologically and
epidemiologically. Raised antibody titres to EBV were found in Hodgkin's
patients compared with other lymphoma patients (Levine et al 1971), and
later it was shown that these increased antibody titres occurred before
diagnosis of Hodgkin's (Mueller et al 1989). Several studies demonstrated
that patients with a history of infectious mononucleosis have an increased
incidence of HD compared with control populations (Rosdahl et al 1974).
Recent studies using southern blot analysis have demonstrated the
presence of EBV genomes in a proportion (18-41%) of Hodgkin's disease
cases (Weiss et al 1987, Anagnostopolous et al 1989, Gledhill et al 1991,
Jarrett et al 1991).
Infectious EBV virions contain linear double-stranded DNA with direct
terminal repeats (TR) of about 500 base pairs. The number of TRs at each
end of the viral DNA is variable. However, after infection of a cell, the
termini are joined to form a circular episome. If the multiplicity of the
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infection is not more than 1 (i.e. if that cell undergoes clonal expansion) all
the episomes within a cell and the progeny of that cell will have the same
number of TRs. This is assessed using a probe for the viral terminal
repeats, if monoclonal - one band only appears on the blot (Raab-Traub &
Flynn 1986).
Analysis of the terminal repeats of the EBV genome in these studies
has shown that the infected cells in the HD biopsies are clonal with respect
to EBV - consistent with the expansion of a single EBV-infected cell.
In addition, some studies have demonstrated the localisation of the
EBV to the RS/H cells in the HD biopsies using in situ hybridisation (for EBV
EBER RNA) and immunohistochemical studies (Brousset et al 1991, Weiss
et al 1991, Armstrong et al 1992b, Delsol et al 1992). Using the EBER in situ
hybridisation, it was shown that in a proportion of HD cases with EBV-
infected RS/H cells, an additional infection of very few small non-malignant
lymphoid bystander cells was seen. These cells were small lymphocytes -
no EBER positive blasts were seen. These EBV positive bystander cells in
the HD biopsies were found to correspond qualitatively with the occasional
EBV-infected cell in normal lymphoid tissue. Immunohistochemical studies
however showed that LMP expression was constantly restricted to the RS/H
cells, the EBER positive bystander cells being consistently negative for LMP.
It appears therefore that the EBER in situ hybridisation and LMP
immunostaining methods are more suitable for the determination of the EBV
status of Hodgkin's compared to non-morphological methods such as PCR
which cannot discriminate between cases containing infected tumour cells
and those cases only containing infected bystander cells (Hummel et al
1992, Khan et al 1992).
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The expression of LMP and EBNA-2 has been investigated using
immunohistochemistry. The LMP-1 protein is expressed in RS/H cells in
EBV positive cases but EBNA-2 has not been detected (Pallenson et al
1991a, Armstrong et al 1992b, Delsol et al 1992). A study on EBV latent
gene expression at the RNA level showed the presence of EBNA-1, LMP-1
and LMP-2 transcripts but absence of EBNA-2 mRNA (Deacon et al 1993) -
i.e. a Latency II infection pattern. EBV lytic cycle proteins have been
detected in only occasional RS/H cells in a minority of cases of Hodgkin's
(Pallenson et al 1991b). The expression of LMP by RS/H cells suggests that
EBV is playing some role in the pathogenesis of Hodgkin's disease.
LMP is known to induce certain cellular genes such as CD23, CD40
and bcl-2 (Section 1.4.1). CD23 (minority of cases ) and CD40 (majority of
cases) have been detected on RS/H cells (Herbst et al 1991, Armstrong et al
1992a, O'Grady et al 1994b). Some studies have detected the bcl-2 protein
in RS/H cells in a proportion of HD cases (Armstrong et al 1992a, Khan et al
1993, O'Grady et al 1994b) whereas others have failed to find such
expression of bcl-2 (Algara et al 1991, Louie et al 1991). However, no clear
correlation between LMP-1 expression and detection of these proteins in
RS/H cells was found (Armstrong et al 1992a, Khan et al 1993, O'Grady et al
1994b). Therefore the role of LMP-1 in Hodgkin's disease remains
unresolved but it appears to be independent of the upregulation of CD23,
CD40 and bcl-2.
There is also no evidence that LMP affects the eventual prognosis of
the associated cases (Vestlev et al 1992). It is possible that LMP-1
expression induces a cytotoxic T cell response against the host RS/H cells
(Murray et al 1988) which counterbalances any growth advantage provided
by the protein. The fact that a high frequency of LMP-1 positive cases of HD
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are found in AIDS patients (Audouin et al 1992) lends some support to this
possibility.
It is clear that EBV is only associated with a proportion (33-50%) of
cases. This does not detract from the importance of the viral association as
the pathological and epidemiological features of Hodgkin's disease suggest
that it is a heterogeneous condition likely to have more than one aetiology
(Macmohen 1966). Epidemiologically, HD can be divided into 3 main groups
corresponding to the age groups 0-14 years, 15-34 years and 50 years and
over. NSHD largely accounts for the peak incidence in the young adult age
group whereas MCHD is relatively more common in child-hood and older
adults (Alexander et al 1991). Risk factors for the development of HD differs
in the different age groups - young adult HD appears to be associated with a
high standard of living suggesting that a delayed exposure to a common
infectious agent may be involved (Macmohen 1966, Gutesohn 1982,
Alexander et al 1991).
EBV has been detected in the RS /H cells of all sub-types of HD.
However, Pallenson et al (1991a) found a significant increase in LMP
expression in the MC sub-type. This was subsequently confirmed in some
(Staal et al 1989, Weiss et al 1991, Delsol et al 1992, Murray et al 1992,
Weinreb et al 1992, O'Grady et al 1994a) but not all (Herbst et al 1991,
Jarrett et al 1991) studies.
Jarrett et al (1991) also reported an excess of EBV positive cases in
the paediatric (0-15 years) and older adults (50 years and over) age groups
compared to the young adult cases. Some, but not all studies have
confirmed this age distribution (Libetta et al 1990, Herbst et al 1990, Coates
et al 1991, Vestlev et al 1992, Weinreb et al 1992). The results of the Jarrett
et al (1991) study supports the hypothesis that HD involves different
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aetiologies in the different age groups with EBV involved in the pathogenesis
of paediatric and older adult cases (possibly explaining the higher incidence
of EBV positive MCHD cases). They speculate that de novo EBV infection is
important in the paediatric group with a reactivation of latent infection,
possibly as a result of declining T cell immunity occurring in the older age
group.
The low level of EBV positivity in the young adult age group (the
major sub-type being NSHD) suggests that other factors are involved in
these cases. This is interesting since this was the group originally most
thought to be associated with an infectious agent on epidemiological
grounds (MacMohen 1966, Gutesohn 1982, Alexander et al 1991).
Clustering of HD cases is also most likely to occur in cases aged under 35
years and in the Nodular Sclerosing sub-type (Alexander et al 1989,
Alexander et al 1991).
Therefore it is possible that another virus may be involved in the
pathogenesis of HD in the young adult group - viruses studied include the
herpesviruses HHV-6 and HHV-7 and cytomegalovirus (CMV). Serological
studies have implicated HHV-6 as HD patients, particularly those in the
young adult group, were found to have elevated antibody titres to HHV-6
antigens (Clark et al 1990). However, several groups have been unable to
detect HHV-6 or 7 in any HD cases using southern blotting or DNA insitu
hybridisation (Gledhill et al 1991, Khan et al 1993, Jarrett et al unpublished
results). One study was able to detect HHV-6 in 2 cases using southern
blotting (Torelli et al 1991). Studies on CMV have also given negative
results (Weiss et al 1987, Khan et al 1993)
O'Grady et al (1994a) investigated whether EBV in Hodgkin's disease
was related to the site of origin of the tumour. For Stage I Hodgkin's, LMP-1
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expression by RS/H cells was significantly associated with presentation in
neck nodes compared with non-neck nodes. (No correlation was seen in
Stages II - IV disease possibly because biopsy site does not necessarily
indicate site of origin in these stages of disease).
Therefore, detection of EBV in HD may be related to presentation in
nodes draining the oropharygeal lympho-epithelial tissue - the main site of
EBV proliferation after infection. In infectious mononucleosis, the tonsils and
cervical lymph nodes, but not the spleen or inguinal lymph nodes contains
many strongly LMP-1 positive RS-like cells (Isaacson et al 1992) and other
EBV-associated tumours such as Burkitt's lymphoma and Nasopharygeal
carcinoma tend to arise in the head and neck region. The cervical lymph
nodes are one of the commonest sites of origin in HD with axilliary and
mediastinal less common.
At present, the role of EBV in HD as a pathogen or passenger is not
clear. However, the localisation of EBV to the RS/H cells and the clonality of
the EBV episomes in HD suggests a pathological role for EBV in at least
some cases (30-50%). Other aetiological factors may be important in the
young adult (predominantly NSHD) sub-group.
1.4.4 Association with Non-Hodqkin's Lymphoma
Although there is very strong evidence that EBV is causally associated with
the occurrence of NHL under conditions of acquired or inherited immune
suppression, the evidence is much less clear in relation to the risk of NHL in
apparently non-immunocompromised individuals.
However, there has been a number of recent reports of EBV in
peripheral T-NHL in immunocompetent individuals (Su et al 1990, Su et al
1991). The EBV genome appeared to be clonotypically proliferated in the
neoplastic T cells using immunocytochemistry. Hamilton-Dutoit & Pallenson
(1992) also found a frequent association of EBV with peripheral T cell
lymphomas (10%), but surprisingly not as frequent in B-NHL (4%) - these
findings are in keeping with previous reports (Weiss et al 1987, Staal et al
1989, Sabourin et al 1993). The majority of these tumours displayed a
Latency Type II pattern of infection (LMP positive, EBNA-2 negative). Ott et
al (1993) found a found a higher incidence of EBV DNA in B-NHL (10% of
cases) however, this was still lower than in the T-NHL (33% of cases) in this
study.
This may be surprising given the B cell tropism of EBV. However,
increasing evidence from both in vitro and in vivo studies suggests that EBV
can infect T lymphocytes. An EBV receptor-like molecule has been
demonstrated in vitro on malignant T cell lines (Fingeroth et al 1988) and T
lymphocytes transfected in vitro with EBV DNA become immortalised
(Stevenson et al 1987). The route of entry of EBV into T cells and the role of
EBV in the pathogenesis of T cell lymphoma is yet to be established, but the
finding of clonotypic EBV in these tumours (Su et al 1991) suggests an
oncogenic role for EBV in these T cell lymphomas.
A high incidence of the EBV genome has also been detected in the
CD30 (Ki-1) positive NHL, including Large Cell Anaplastic Lymphomas
(LCAL) (Ross et al 1992) and non-LCAL (with 5 - 35% CD30 positive cells)
(Kanavaros et al 1992). 29/38 CD30 positive B-NHL, 9 of 20 CD30 positive
T-NHL and 2 CD30 positive NHL of undetermined lineage were found to be
EBV positive by PCR. Of 29 CD30 negative NHL, only 6 were EBV positive
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(5 B-NHL and 1 T-NHL). In situ hybridisation demonstrated the EBV genome
exclusively in the nuclei of the tumour cells in a proportion of the EBV
positive cases. Immunostaining again showed a Type II latency pattern of
infection, but LMP expression was only found in the CD30 positive NHL.
Although the biological modulation of this relationship is unclear, the
authors hypothesise that the presence of CD30 positive tumour cells in
NHLs increases the probability that these tumours harbour EBV and this may
have clinical significance since it is suggested that the presence of EBV in
peripheral T cell NHL is associated with a more aggressive course (Su et al
1991).
Mueller et al (1992) found evidence that among a group of 104 NHL
patients with blood samples taken several years before diagnosis, there was
an elevated antibody titre against EBV, which is quite similar to that seen in
immuno-suppressed patients prior to diagnosis - this pattern was most
evident in older patients. This suggests that EBV-associated NHL is more
common in older persons and may be related to more chronic viral activation
due to subclinical immune suppression due to ageing.
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1.5 Previous Models of Hodgkin's Disease
and Non-Hodgkin's Lymphoma
1.5.1 Cell Lines
Hodqkin's Lymphoma Cell Lines
The failure to define the cellular origin of Hodgkin's Disease is largely due to
the small number of neoplastic RS/H cells found within biopsy material.
Consequently, this causes difficulty in distinguishing the immunophenotype
or genotype of the neoplastic cells from the surrounding normal lymphoid
and histiocytic cells. There have been several attempts to purify RS/H cells
in vitro. Sitar et al (1989) attempted this using isopyknic centrifugation and
velocity sedimentation, this achieved a substantial purification. However this
approach has rarely been successful. In vitro cultivation techniques have
been used in attempts to enrich and purify RS/H cells in temporary or
permanent cultures. Development of HD cell lines has proven to be more
difficult than NHL cell lines. Only a few cell lines containing cells that
resemble RS/H cells have been established as the in vitro culture conditions
favour the out-growth of "contaminating" residual normal bystander cells
such as EBV-transformed B lymphoblastoid cells, fibroblasts, or
monocyte/macrophage monolayers. There is a striking heterogeneity of
morphological variations among the cell lines, but also within the population
of each cell line. Some cell lines express one or more markers associated
with T cells (CO, HDLM-2, HO, L-540) , B cells (DEV, HD-70, KM-H2, L-591,
SUP-HD1) or myelomonocytic cell iineages (SU, RH-HD-1). 2 of the cell
lines (ZO, L-428) appear to be devoid of cell lineage-associated markers.
The results of gene rearrangements studies are also heterogeneous with
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some cell lines showing TcR gene rearrangements (CO, HDLM-2, HO, L-
540), Ig gene rearrangements (DEV, HD-70, KM-H2, L-591, ZO) and both (L-
428, SUP-HD1) (reviewed by Drexler 1993).
The relationship of the Hodgkin cell lines to the RS/H cell remains to
be established - the artifactual expansion of non RS/H cells in culture cannot
be excluded. New strategies for the investigation of HD and the
histogenesis of the RS/H cell are therefore necessary.
Non-Hodgkin's Lymphoma Cell Lines
There are many established NHL cell lines. However, these cell lines are
established only by chance and are not applicable to a large number of
cases. NHL tumour cells have been found to be difficult to grow in vitro with
the exception of Burkitt's lymphoma possibly because of the involvement of
the Epstein-Barr virus. Most B cell lines are derived from BL, lymphoblastic
lymphoma or large cell lymphoma, although an immunoblastic cell line was
first established recently (Ho et al 1990). NHL cells do not usually grow
spontaneously in vitro, under standard in vitro culture conditions, and the use
of an exogenous lineage-specific growth factor (B cell growth factor) was
necessary to establish NHL-B cell lines (Ford et al 1990). Although many
lines have been shown to be useful in studying the characteristics and
molecular biology of NHL (Mohamed & Al-Katib 1988, Saltman et al 1988,
Dyer et al 1990), such cell lines occasionally show characteristics different
from those of the original tumour because of tumour progression in vitro.
Therefore, a satisfactory in vivo animal model of NHL would be more




These are also known as nulnu mice. These are mice with congenital
absence of the thymus, and whose blood and thymus dependent areas of
the lymph nodes and spleen are depleted of T lymphocytes. These mice are
homozygous for the gene 'nude', having no body hair.
Hodgkin's Disease
Neither HD-derived cell lines nor primary biopsy material could be grown in
nude mice (Epstein et al 1976, Watanabe et al 1980, von Kalle et al 1992).
Therefore it has not been possible to study the in vivo growth characteristics
of HD using nude mice. Growth of HD cell lines in nude mice was limited to
intracranial growth of one HD-derived cell line (Engert et al 1987) and
intracranial growth of EBV positive polyclonal cells from a HD biopsy
specimen (Schaadt et al 1979). It was necessary to use the intracranial
route of transplantation because the brain is an immunologically privileged
site, thus allowing better tumour take rates and latency periods.
Non-Hodgkin's Lymphoma
Growth of NHL biopsy material has also been attempted in nude mice. Most
trials using this model failed - for example, Kuga et al (1975) were unable to
maintain any of 12 biopsy specimens transplanted in nude mice. Later,
additional treatments were used to increase the chance of success. Epstein
et al (1976) used intracranial injection and succeeded in growing 8/14 NHL
biopsy specimens in nude mice. Watanabe et al (1980) used irradiation with
and without splenectomy and achieved a 29% growth rate. However, the
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majority of the cases required irradiation and splenectomy for growth to
occur. The most recent study using nude mice was that of Igarashi et al
(1989) who used total body irradiation as pre-treatment. 27% (6/22) of the
transplanted lymphomas were established as nude mouse lines, the
transplanted lymphomas substantially retaining the characteristics of the
original lymphomas. However, only lymphomas of advanced clinical stage
(one was of Stage III, the remaining 5 of Stage IV) grew in the nude mice.
The problem with the nude mouse model is the pre-treatment
necessary for lymphoma growth to occur. Also, these early studies did not
consider the possibility of the involvement of the EBV in these nude mouse
tumours, and it is possible that some were simply EBV-driven
lymphoproliferations (all of the nude mouse tumours grown by Igarashi et al
were found to be diploid).
Therefore, the nude mouse has been shown to be an unsatisfactory in
vivo model for the study of HD and a very limited model for NHL requiring
extensive pre-treatment.
Consequently, new strategies are necessary for the study of HD and
NHL, and the more immune-deficient SCID mouse model was used in this
thesis in an attempt to establish a satisfactory in vivo model to study HD and
NHL. The SCID mouse is described in more detail in the following section.
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1.6 The SCID Mouse
1.6.1 Biology. Immunology and Genetic Deficiency
The mutant C.B-17 SCID (Severe Combined Immune Deficient) mouse strain
has a heritable, recessive gene defect on chromosome 16 involving the V-D-
J recombinase system. V-D-J recombination is mediated by a site specific
recombinase that recognises short DNA signal sequences
(heptamer/nonamer sequences with either a 12 or 23 base pair spacer)
which lie adjacent to each coding V, D and J gene segment. The
recombination of any 2 coding elements is thought to involve double-
stranded DNA breaks at the coding/signal borders followed by formation of a
signal joint and coding joint. In immature SCID lymphocytes this reaction is
initiated with signal joint formation, however coding joint formation is reduced
5000 fold. This prevents correct TcR and Ig gene rearrangements and
results in a virtually complete functional T and B cell deficiency (Lieber et al
1988 & 1989, Bosma 1989, Harrington et al 1992).
Some developing SCID lymphocytes succeed in forming V-D-J and V-
J coding joints, in fact oligoclonal B and T cells have been detected in a low
percentage of young adult mice (5-20%) and in virtually all old SCID mice
(>1 year old). This "leaky" phenotype is possibly resulting from low
efficiency V-D-J recombinase activity or a reversion of the scid mutation.
(Osmond et al 1992, Hendrickson 1993, Kotloff et al 1993). However, the
scid mutation has very recently been bred into 2 additional murine strains.
SCID mice have been crossed with mice homozygous for the biege mutation
(SCID.BG mice) and the C3H strain (C3H SCID) and this has severely
depressed the leakiness of the scid mutation (Hendrickson 1993).
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SCID mice are deficient for both B and T cell function, however early
precursor B cells (showing abnormal V-D-J rearrangements) have been
detected in the bone marrow (Osmond et al 1992). Also, most SCID mice
show the Thy-1 marker on the majority of the recovered cells from the
thymus. SCID mice are lymphopenic and their lymphoid organs are 1/1 Oth
or less of normal size. They show a rudimentary thymic medulla with no
lymphocytic cortex, splenic follicles and lymph nodes virtually devoid of
lymphoid cells and under-developed bronchial and gastrointestinal
lymphocytic foci - Peyers patches are rarely visible in these mice. However
the bone marrow is within the norm, cells of the myeloid lineage appear
normal and remain active throughout life. They also have normal Natural
Killer cells, antigen presenting cells and splenic colony stem cells
(Dorshkind et al 1985).
Spontaneous T cell lymphomas occur in >10% of SCID mice. They
appear to arise in the thymus and are highly invasive and transplantable.
They are thought to be a direct or indirect consequence of the scid mutation
as they are rarely, if ever, observed in normal C.B-17 or BALB/c mice
(Bosma et al 1983, Custer et al 1985).
1.6.2 The SCID Mouse as an Animal Model System
for Studying Human Disease
The SCID mouse offers several advantages over the previously used
athymic T cell deficient nude mouse as an animal model system. The
immune defiency is more complete and there is therefore no need for further
immunosuppression such as whole body irradiation used with nude mice.
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They are also easier to breed and less expensive and indeed have been
shown to allow better growth of human material (Philips et al 1989) and
support growth of normal, non-transformed cells, not possible with the nude
mouse.
An example of this is the successful transfer of a functional human
immune system in the SCID mouse providing an in vivo model for a variety of
immunologic studies (Mosier et al 1988, Croy 1993, McKerrow & Ritter
1993). The SCID mouse has also been used to study a number of human
diseases. A variety of autoimmune diseases have been induced in SCID
mice, including systemic lupus erythematous (SLE), human autoimmune
thyroid disease (AITD), Graves disease and rheumatoid arthritis (Segal et al
1992, Taylor 1992). The SCID mouse has also provided a useful animal
model for human myeloid, lymphoblastic and lymphocytic leukaemias
(Cesano et al 1992, Kobayashi et al 1992) and has served as a relevant in
vivo model for malignant melanoma and lung tumours (Bankert et al 1989,
Taylor 1992) amongst others.
1.6.3 Previous Lymphoma Studies
EBV-associated Lymphoproliferative Disease
The SCID mouse has been used in many studies as an in vivo model to
study the pathogenesis of the EBV positive lymphomas seen in
immunocompromised individuals such as AIDS or post-transplant patients.
This is achieved by intraperitoneal injection of SCID mice with peripheral
blood lymphocytes from EBV seropositive donors or from EBV seronegative
donors followed by injection of EBV (Cannon et al 1990, Rowe et al 1991,
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Mosier et al 1992, Nadal et al 1992, Purtilo et al 1992, Veronese et al 1994)
This results in the development of fatal, high grade, EBV positive B cell
tumours occurring as abdominal solid tumours closely associated with the
liver; additional tumours were also found in the thymus or spleen. These
tumours showed a similar histological appearance (large B cell
immunoblastic lymphomas with plasmacytoid differentiation and well-defined
areas of necrosis), cell surface phenotype and EBV latent gene expression
(Latency III) to the large cell lymphomas seen in immunosuppressed
patients. They were found to be either polyclonal or oligoclonal which could
present at multiple sites as different poly/oligoclonal foci, although
monoclonal foci were also detected in some cases. These tumours were
found to exhibit the normal diploid karyotype with no abnormal translocations
such as bcl-2 or c-myc and were found to show secretion of high levels of
immunoglobulin.
Hodqkin's Disease
SCID mice have been found to support growth of Hodgkin's disease cell
lines. All 6 of the cell lines injected - L428, L591, DEV, HD-LM2, KM-H2
and sub-line L540Cy grew in the SCID mice retaining the karyotype and
expression of T or B cell markers of the cell lines before inoculation (von
kalle et al 1992). However, expression of the EBV was not investigated.
During this project, Kapp et al (1993) also transplanted fresh
Hodgkin's disease-derived biopsy tissue into SCID mice. 3/13 cases gave
rise to human EBV positive B cell lymphomas. These Hodgkin's disease-
derived tumours are discussed in more detail in the General Discussion -
Chapter 8 of this thesis.
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Non Hodqkin's Lymphoma
During this project, Itoh et al (1993) also transplanted NHL into SCID mice.
SCID tumours developed from 23 of 50 NHL specimens. Of these tumours,
10 were identical to the original NHL tumour but in 11 cases, unrelated EBV
positive lymphoproliferations developed and 2 cases showed a mixture of
original tumour clones and new EBV positive proliferations. These SCID
tumours will be discussed in more detail in the General Discussion - Chapter
8 of this thesis.
Therefore, despite many phenotypic and genotypic studies, the histogenesis
of the Reed-Sternberg cell in Hodgkin's disease remains unknown. Neither
in vitro cell lines nor the nude mouse in vivo model appear to be satisfactory
to study Hodgkin's disease. Consequently, in an attempt to study the
biology of Hodgkin's disease and to investigate the histogenesis of the
Reed-Sternberg cell, transplantation of fresh HD biopsy material into SCID
mice was carried out in this thesis.
In addition, fresh NHL biopsy material was injected into SCID mice in
an attempt to establish a satisfactory in vivo model to study the disease
without the need for further immunosuppression such as whole body




All chemicals were bought from Sigma Immunochemicals UK Ltd. unless
otherwise stated.
2.1 SCID Mice
The SCID mice used in this project were originally bought from the National
Institute for Medical Research, Mill hill, London. They were maintained as a
stock breeding colony by the staff of the Department of Medical Microbiology
Animal House by sister/brother matings. The off-spring were then again
selected for a sister/brother mating. The mice were housed in cages of 4 in
a half-suit isolator. The isolator was kept sterile by changing the filters once
a week and the large Hepa filter every year. All food was irradiated and
vacuum-sealed and all bedding and housing was autoclaved. These were
all sprayed with disinfectant and left in the port-hole for 20 minutes prior to
use in the isolator.
To prevent infections, mice were checked twice a year for Sendai
virus, M. Pulmonis virus, and Rodent Coronovirus using an Immunocomb. If
an infection did occur in the isolator, all the mice were removed to another
isolator. The infected isolator was then fumigated for 24 hours with
peracetic acid. Only new mice were then housed in that isolator, the
potentially infected mice were not returned.
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Screening for "leaky" SCID mice was carried out by ELISA as in
Section 2.10
2.2 Collection of Lymphoma Biopsies
Fresh Hodgkin's Disease and Non-Hodgkin's Lymphoma lymph nodes and
one spleen were obtained as routine biopsies from the Royal Infirmary and
the Western General Hospital, Edinburgh. They were trimmed under sterile
conditions and a small piece kept in sterile RPMI medium (Gibco BRL) for
use in this project.
2.3 Preparation of Tumour Cell Suspension and
Injection into SCID Mice
Initially, cell suspensions of Hodgkin's Disease lymph node biopsies
previously frozen down in liquid nitrogen were injected into the SCID mice.
No human tumour was grown from any of these cases (10 injected in total)
and therefore it was decided to only inject fresh biopsy material.
After removal of the capsule and fatty tissue, the fresh lymph
node/spleen was cut into small fragments in RPMI/L-Glut/Pen/Strep (all
Gibco BRL) and filtered through a fine mesh strainer. The lymph node cell
suspensions were simply centrifuged for 5 minutes at 1000 rpm and
resuspended in 1ml of RPMI. The cell number present per ml of suspension
was counted in white blood cell counting fluid using a Neubauer Counting
Chamber.
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Studies were made to determine the optimum method of
transplantation. The intraperitoneal mode of injection was found to be the
most convenient and gave rise to the greatest number of tumours. 250pl of
tumour cell suspension (containing 0.7 - 7x107 cells) was injected into the
peritoneal cavity of each of 4 mice. Injections were performed under sterile
conditions in the half-suit isolator.
2.4 Mouse Post-Mortem
The mice were checked twice a week for signs of illness by the staff of the
Animal House. Mice were sacrificed when there was detectable tumour
(usually abdominal swelling) or poor condition - this included weight loss,
lethargy, hunched appearance and poor coat condition. Mice were killed
using either ether or halothane inhalation.
Mice were dissected using sterile instruments, and a sample of aortic
blood was taken. The size and general appearance of the tumour (if
present), the abdominal organs and any visible lymph nodes present were
noted. The thoracic organs were checked for the presence of a thymic
remnant or a murine thymic lymphoma.
The main bulk of tumour was dissected out and blocks were taken for each
of the following:-
(a) A small piece was placed in sterile PBS to passage the tumour into a
further set of mice.
(b) A piece was snap frozen in OCT for frozen section
immunophenotyping.
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(c) A block was snap-frozen for DNA extraction and molecular analyses
(see Appendix C).
(d) Tumour and additional representative blocks of mouse organs
including heart and lungs, liver, gut, pancreas, spleen, kidneys,
thymus and lymph nodes were placed in 10% neutral buffered
formalin (Lothian Chemical Co.) for paraffin section immunotyping.
2.5 Passage of Tumour
The piece of tumour in sterile PBS (Oxoid Unipath Ltd.) was made into a cell
suspension in RPMI/L-glut/Pen/Strep as before (2.3) and injected
intraperitoneal^ into a further 4 mice.
2.6 Tissue Processing For Paraffin Sections
All material used for paraffin-embedded tissue sections was fixed in neutral
buffered formalin solution. This fixes by reacting primarily with basic amino
acids to form cross-linking 'methylene bridges'.
The various SCID organs removed at post-mortem were left to fix in the
formalin over-night. The tissues were then trimmed and clipped up in
labelled Tissue-Tek cassettes (Bayer Diagnostics) to be processed through
a Vacuum Impregnation Processor (VIP)(Bayer Diagnostics). The tissues in
the VIP were gently de-hydrated starting in 50% alcohol and slowly
increasing (80, 95, 99%) to absolute alcohol over a 14 hour schedule. They
were taken through xylene (Genta Medical) to paraffin wax, in which they
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were blocked up using a Tissue-Tek Embedding Console (Bayer
Diagnostics).
2.7 Preparation of Tissue Sections
2.7.1 Cryostat Sections For Immunocvtochemistrv
Previously snap-frozen material was partially thawed and transferred onto a
metal chuck. This was frozen in OCT (Bayer Diagnostics) onto the chuck
using liquid nitrogen or dry ice. 3pm sections were cut at -20°c using a
cryostat onto glass slides previously coated with poly-L-lysine tissue
adhesive. These were left to dry at room temperature for at least 15 minutes
and then fixed in acetone (Genta Medical) for 10 minutes. These slides
were wrapped in foil and stored at -20°c until use.
2.7.2 Paraffin Sections For Immunocvtochemistrv
3pm paraffin sections were cut from ice-cooled paraffin blocks using a
microtome and floated on warm water onto glass microscope slides. The
slides were then dried over-night in a 55°c incubator. One of the antibodies
used in this study (anti-LMP antibody) required that the paraffin sections
were floated onto poly-L-lysine coated slides and dried over-night at room
temperature.
2.7.3 Paraffin Sections For in situ Hybridisation
To ensure that the tissue sections did not 'lift off the slides during the
lengthy in situ hybridisation technique , they were floated onto slides pre-
coated with the strong tissue adhesive Tespa (3-aminopropyltriethoxysilane).
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Also, to prevent RNAse contamination, gloves were worn when cutting and
sections were floated onto distilled water. The sections were then dried
over-night at 37°c, wrapped in foil until use and only handled with gloves.
2.7.4 Paraffin Sections For Flow Cytometry
50pm paraffin sections were cut for use in flow cytometry. These were dried
over-night in a high temperature (70°c) air-dryer before use.
2.8 Immunocytochemistry
Paraffin and frozen section immuno-phenotyping was carried out using a
panel of B cell, T cell, monocyte and EBV markers - these are detailed in
Tables 2.1 and 2.2.
2.8.1 Assessment of Antibodies
All antibodies were titrated on appropriate control tissues to determine
optimum dilution before use on the SCID tumours. Antigen retrieval
techniques were required with some antibodies used.
Many epitopes are sensitive to heat, therefore in several cases
sections for use were cut onto poly-L-lysine coated slides and dried over¬
night at room temperature instead of high temperature drying. For some
antibodies, optimal incubation with primary antibody was found to be over¬
night at 4°c as opposed to the conventional 30 minutes at room temperature.
Antibodies for use with formalin-fixed paraffin sections were always titrated
with and without trypsinisation. Some antigens are not well demonstrated
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after formalin fixation as the formaldehyde may react with the amino acids
next to the epitope under investigation causing conformational changes.
However, in most cases this can be reversed by pre-digesting the sections
with trypsin which allows hidden determinants to be exposed. Trypsin
actually cleaves adjacent to lysine and arginine, the 2 amino acids most
likely to react with formaldehyde.
2.8.2 ABC Method
This method was used for all immuno-staining of paraffin sections of SCID
and original biopsy material. In each run of immunocytochemistry, a known
positive control was taken through. This was also run as a negative control
by ommitting the primary antibody and replacing this with normal serum.
A standard ABC method was used - the tissue sections were
deparaffinised in xylene and rehydrated in descending grades of alcohol.
Endogenous peroxidase activity was blocked by immersing the slides in 1%
hydrogen peroxide for 10 minutes. If necessary (Table 2.1), the sections
were then treated with pre-heated 0.1% trypsin (ICN Biochemicals) in 0.1%
calcium chloride pH 7.8 at 37°cfor 25 minutes.
The sections were then washed in Tris Buffered Saline (TBS) (Fisons) pH
7.6 for 5 minutes before blocking of non-specific binding by incubation in
normal serum - normal rabbit serum (Sapu) if using a mouse monoclonal
primary antibody and normal swine serum (Seralab) if using a rabbit
polyclonal primary antibody. The slides were also washed between each
stage with TBS. A 30 minute incubation with primary and biotinylated
secondary antibody (Dakopatts) was carried out prior to the AB Complex
step. In the later stages of this project, the AB Complex (Dakopatts) was
replaced by horse-radish peroxidase conjugated avidin (Dakopatts) on the
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Table 2.1 Details of Antibodies Used on Tissue
Paraffin Sections
ANTIBODY ANTIGENIC
... '9 DILUTION 1 piMRCS-1
SPECIFICITY SUB-TYPE
D/LCA CD45 igGl 1:20 Dako
L26 CD20 lgG2a 1:1000 Dako
MB1 pan B cell lgG1 1:40 BNS
MB2 pan B cell lgG1 1:20 T BNS
BU38 CD23 IgGl 1:100 T Binding Site
B-B20 CD40 IgGl 1:50 T Serotec
F8-11-13 CD45RA IgGl 1:500 Line
Kappa Ig kappa light
chain
polyclonal 1:500 T Dako
Lambda Ig lambda light
chain
polyclonal 1:1500 T Dako
IgM Ig pheavy chain polyclonal 1:2000 T Dako
IgG Ig y heavy chain polyclonal 1:5000 T Dako
igA Iga heavy chain polyclonal 1:2000 T Dako
T3 CD3 polyclonal 1:100 T Dako
UCHL1 CD45Ro lgG2a 1:500 Line
MT1 CD43 lgG1 1:10 BNS
LN3 HLA-DR lgG2a 1:20 Clonlab
KP1 CD68 lgG1 1:10 T Dako
D-M1 CD15 lgG1 1:20 T Dako
Ber-H2 CD30 IgGl 1:10 T Dako
E 29 EMA lgG2a 1:40 Dako
CS1-4 LMP IgGl 1:50 Dako
PE-2 EBNA-2 |gGi 1:10 Dako
KEY
T - requires trypsinisation
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D/T3 CD3 igGi 1:10 Dako
D/T4 CD4 IgGl 1:10 Dako
D/T8 CD8 IgGi 1:10 Dako
OKM1 CD11b lgG2b 1:10 Ortho
LFA1B CD18 lgG1 1:10 Dako
D/IL2 CD25 IgGi 1:10 Dako
UCHM1 CD14 lgG2a 1:10 Sapu
HD37 CD19 lgG1 1:10 Dako
T015 CD22 lgG2b 1:10 Dako
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grounds of cost and staining quality. The immuno-staining was visualised
with DAB (3,3'-diaminobenzidine)/hydrogen peroxide substrate solution.
DAB was applied to each section at a concentration of 0.5mg/ml with 0.1 ml
of 1% hydrogen peroxide for 4 minutes. After the visualisation step, the
tissue sections were washed in water, counter-stained in haematoxylin (BDH
Chemicals Ltd.) and 'blued up' in Scott's tap water. They were dehydrated in
ascending grades of alcohol and mounted in xylene with Pertex mounting
fluid (Cellpath Ltd.).
2.8.3 Indirect Peroxidase Method
Several monoclonal antibodies cannot tolerate formalin fixation (Table 2.2).
In these cases, the antibodies were used on acetone-fixed frozen tissue
sections and the immuno-staining was carried out using the Indirect
Peroxidase Method.
The tissue sections stored at -20°c were allowed to come up to room
temperature. After washing in TBS, the sections were incubated in normal
rabbit serum as before. The slides were washed between each stage with
TBS as before. After incubation in primary antibody for 30 minutes, horse¬
radish peroxidase conjugated secondary antibody was then applied to each
section for 30 minutes. Immuno-staining was visualised with DAB as before
(2.8.2) and the sections were then counter-stained, dehydrated and mounted
as before.
Immuno-staining resulted in a brown reaction product as seen in
Figures 3.1, 4.7, 4.8, 5.3, 5.4, 6.1 & 6.2.
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2.9 In situ Hybridisation
This method was used to detect the EBV encoded RNAs (EBER) in formalin-
fixed paraffin sections using a fluorescein-conjugated EBER probe
(Dakopatts).
To prevent RNAse contamination, gloves were worn at all times
throughout this technique. All glass-ware and instruments for use were
washed over-night in Decon then heat-sterilised at 225°c for 4 hours. They
were then stored covered in foil at a designated place exclusively for use
with in-situ hybridisation. The use of DEPC (Diethylpyrocarbonate) treated
water as a dilutent for the various chemicals used in this technique also
inhibited RNAse.
The tissue sections were dewaxed in xylene and rehydrated through
descending grades of alcohol. In order to expose the target RNA to the
incoming probe, the sections were then digested with proteinase K (5pg /ml)
for 1 hour in a moist chamber at 37°c. To stop any residual proteinase K
activity, the sections were then post-fixed in pre-cooled 0.4%
paraformaldehyde solution for 20 minutes at 4°c. Non-specific binding was
blocked with pre-hybridisation buffer (Appendix A) for at least an hour in a
moist chamber at 37°c. The hybridisation solution was prepared by adding
the fluorescein conjugated EBER probe at a dilution of 1:20 to the pre-
hybridisation buffer. 20pl of this solution was applied to each section,
covered with gelbond (FMC Bio-products) and incubated over-night at 37°c.
The second day of the technique involved visualisation of the in situ
hybridisation. Following hybridisation, non-specifically bound probe was
washed out of the sections by a series of washes in decreasing
concentrations of SSC at 37°c. The sections were then washed in TBS with
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added BSA (1%)/2mM MgCI2/1% Triton-X 100 (BDH Chemicals Ltd.). The
sections were also washed between each of the following stages in this TBS.
Non-specific binding was blocked with normal swine serum before 30 minute
incubations with the previously absorbed primary antibody (rabbit anti FITC)
and the biotinylated swine anti rabbit secondary antibody. The Strept AB
Complex/AP (Dakopatts Ltd.) was applied as 2 separate stages as this was
found to be more sensitive. Streptavidin was applied first for 30 minutes
before addition of biotinylated alkaline phosphatase for 30 minutes. The in
situ was visualised using the alkaline phosphatase substrate BCIP/NBT (5-
bromo-4-chloro-3-indoxyl phosphate/Nitro Blue Tetrazolium) (Appendix B).
The visualisation step was carried out in the dark at 4°c. Staining was
checked after 10 minutes and every 10 minutes thereafter - usually complete
by 20-30 minutes. The BCIP/NBT mixture is soluble in alcohol and xylene,
therefore Crystal Mount (Biogenesis Ltd.) was first applied to the sections
before mounting in xylene/Pertex. No counter-stain was used. This resulted
in a dark blue/purple reaction product as seen in Figures 5.1 & 5.2,
2.10 Enzyme Linked Immuno-Sorbent Assay
(ELISA)
This method was used to detect human immunoglobulin in the SCID mice
sera.
SCID mice sera were diluted 1:100 and 1:1000 in
carbonate/bicarbonate buffer pH9.6 and applied as the first layer
(100pl/well) on a 96 micro-well ELISA plate (Nunclon Ltd.). Normal human
serum and normal mouse serum were also applied (both at 1:3000 dilution)
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to serve as positive and negative controls respectively. This plate was
incubated at 4°c over-night. The plates were washed x3 with washing buffer
(PBS/0.1% BSA/0.05%Tween 20) prior to incubation with serial dilutions of
horse-radish peroxidase conjugated goat anti-human polyvalent
immunoglobulin or rabbit anti-mouse immunoglobulin ( to check that the
SCID mouse sera did not contain any mouse immunoglobulin). These were
diluted in PBS/1% BSA, and incubated for 2-3 hours at room temperature or
over-night at 4°c. After washing x3 as before, the ELISA was visualised
using the chromogen O-Phenylene Diamine (OPD) in citrate/phosphate
buffer pH5.0 (0.2M Na2HP04 (M&B Lab Chemicals)/0.1M citric acid (BDH
Chemicals Ltd.)). This was applied at a concentration of 0.4mg/ml with the
addition of H202 just before use. The colour was allowed to develop until
the negative control wells were showing colour (usually 10-15 minutes).
Absorbence was measured using a Dynatech MR5000 plate reader.
A positive result was recorded if the reading was higher than the negative
control. Actual readings were recorded by subtraction of the negative
reading. If a particular SCID serum was found to contain human
immunoglobulin, then the specific immunoglobulin isotype was determined
using peroxidase conjugated goat anti-human IgG, M, A, kappa and lambda.
All of the positive SCID sera were run on the same plate in quadruplicate at
a concentration of 1:1000. All of the secondary antibodies were applied at a
concentration of 1:500.The 5 plates (i.e. IgM, G, A, kappa and lambda) were
run on the same day and included positive (normal human serum) and
negative (normal SCID serum, coating buffer only wells) controls.
Towards the end of the project, the SCID mice sera showing no trace
of human immunoglobulin at the previous dilutions used were re-checked
where possible using the lowest feasible dilution (1:2).
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2.11 Flow Cytometry for DNA Ploidv
This was used to measure the DNA ploidy of all original biopsies and SCID
tumours. For the original Hodgkin's and Non-Hodgkin's lymphoma biopsies,
parts of the lymph node considered to have the greatest number of RS/H
cells or the most disease involvement were selected for use.
Nuclei suspensions were extracted from paraffin sections using the
method of Hedley et al (1983). Briefly, 50pm paraffin sections were de-
waxed in xylene, then rehydrated through descending grades of alcohol into
distilled water. The sections or areas on slides were then digested with a
1ml solution of 0.5% pepsin in 0.9% NaCI (pH 1.5) for 1 hour at 37°c to
obtain a nuclear suspension. The sections were vortexed every 10 minutes.
After incubation, the sections were washed thoroughly in PBS by
centrifugation then filtered through cotton wool and the nuclei were then
stained with a 100pg/ml solution of propidium iodide/0.04% RNAse for an
hour at room temperature.
DNA ploidy was measured on a Coulter Epics CS flow cytometer. An
argon laser tuned to 488nm was used with a 570 long pass filter. The PMT
gains were kept the same for every sample analysed, the diploid peak
occurred between channel number 43-48 for each sample. 10.000 nuclei
were counted and the resulting histogram analysed using Linear S Phase
Analysis on Cytologic Histogram Analysis for FCM on the Easy-2 program.
The computer subtracted back-ground from the histogram before cell cycle
analysis. The first peak was regarded as the diploid peak. Samples were
considered to be aneuploid when in addition to the G0/G1 and G2/M peaks,
one or more DNA peaks were detected. The DNA Index was calculated for
all samples from the ratio of channel numbers for the aneuploid G0/G1 and
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the diploid G0/G1 peak. Samples with DNA indices between 1.8 and 2.2
and in which the proportion of tetraploid cells exceeded 15% of the total cell
count were regarded as tetraploid anueploidy (Kallioneimi et al 1988). After
analysis on the flow cytometer, every sample was checked under a
fluorescence microscope to make sure no 'doublet nuclei' were present - 200
nuclei were counted, and in every case, under 2% of the population were
found to be doublets.
The Molecular analyses of the original biopsies and the SCID tumours were
carried out by Alice Gallagher in the Department of Veterinary Pathology in
the University of Glasgow Veterinary School. Therefore, these protocols are
given in Appendix C.
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The following Chapters 3 - 8 are the results and discussion section of this
thesis. Initially, the tumour yield from the HD and NHL biopsies is
presented, then the characteristics of the SCID tumours are described and
discussed. This includes morphology, phenotyping, EBV status, Ig gene
rearrangement analysis, Ig expression and secretion and DNA ploidy.
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Chapter Three
Tumour Yield From SCID Mice
3.1 Tumour Yield
A total of 42 fresh lymphoma biopsies were injected into SCID mice
(each biopsy being injected into 4 or 5 mice). Of these, 17 were HD
biopsies, the remaining 25 being NHL biopsies. 4 reactive lymph nodes
were also injected.
5 cases of HD (29%) and 7 cases of NHL (28%) gave rise to human
tumours in the SCID mice. None of the reactive lymph nodes gave rise to
human tumours in the mice.
With the remaining 30 lymphoma biopsies , and including the cage-
mates of the mice that developed tumours, a total of 184 mice were injected
that did not develop human tumour.
Of these 184 mice, 28 (15%) were found dead in their cages, the time
ranging from 3 weeks to 48 weeks after injection (mean was 25 weeks).
79 of these mice (43%) appeared to be sick (weight loss, hunched
appearance, poor coat condition) but upon dissection, no evidence of tumour
growth was found. Occasionally, these mice had symptoms such as slight
spleen or liver enlargement but the vast majority were asymptomatic. The
time between biopsy injection and death in these mice ranged from 7-80
weeks (mean was 36 weeks).
22 of these mice (12%) were found to have developed murine thymic
lymphomas - these were morphologically different from the human tumours
showing a more monomorphic cellular pattern and also failing to express the
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human leucocyte common antigen (LCA) (Figure 3.1). DNA analysis was
carried out on one of these murine thymic lymphomas, no human DNA was
detected. These murine tumours developed in mice aged between 24 and
52 weeks (mean was 35 weeks).
2 different infections arose in the Animal House during the 3 year
period. Together these were responsible for the mortality of 51 SCID mice
(28%).
3.2 Post-Mortem Examination in Tumour Bearing
SCID Mice
In general, sick mice were underweight with a hunched appearance
and a poor coat condition. Occasionally, laboured breathing was seen, and
abdominal swelling was often present.
On dissection, the subcutaneous fatty tissue had a pinkish
appearance and the superficial veins were often dilated with the appearance
of inflammation. The lymph nodes were often visible. A main solid white
tumour mass measuring around 2cm in diameter was found juxtaposed to the
liver, stomach and spleen where the bulk of the pancreas would normally be
sited. The tumour either invaded the liver tissue or simply surrounded it.
The liver was often infarcted and enlarged as was the spleen. A
macroscopic view of a typical SCID tumour is shown in Figure 3.2.
In some cases, all other abdominal organs appeared normal whilst in
other cases, tumour nodules were found the length of the intestine (5mm
diameter) and occasionally surrounding or invading the kidneys. Again in
some cases the heart and lungs appeared normal with only the thymic
remnant seen in SCID mice present, whereas in other cases thymic
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Figure 3.1 SCID Mouse Lung
This shows a section from a SCID mouse lung demonstrating human immunoblastic tumour
(SCID tumour B2) expressing the human antigen CD43, growing along-side a murine thymic
lymphoma showing no expression of the human CD43 antigen. A similar result was seen
with the LCA. Mag x250
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Figure 3.2 Macroscopic View of a SCID Tumour
This figure shows SCID tumour H1, but is typical of most of the SCID tumours, with a main
tumour mass found in the liver and stomach region. In some cases, tumour nodules were
also found the length of the intestine and surrounding the kidneys.
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involvement was seen with either spread of the human tumour or a
concurring murine thymic lymphoma.
3.3 Details of Human Tumours Arising in SCID mice
Details of the original HD and NHL biopsies and the corresponding SCID
tumours grown from these are shown in Tables 3.1 and 3.2.
The original HD and NHL biopsies are named Case A, Case B and so
on upto Case L. Thus the HD biopsies are Cases A - E and the NHL
biopsies are Cases F - L. The SCID tumours grown from transplantation of
the original biopsies are given the same letter as the biopsy from which they
were derived, plus a number. Even if there was only one SCID tumour
grown from the injected biopsy, this is still given a number (i.e. 1) to
distinguish it from the original biopsy. This nomenclature also allows
distinction of different primary or passaged SCID tumours i.e. B1 and B2, K1,
K2, K3 and K4. Collectively, the SCID tumours are referred to HD-derived or
NHL-derived SCID tumours - this term is actually referring to the SCID
tumour obtained from transplantation of the original HD or NHL biopsies, and
does not infer that they have been proven to actually be derived from the
malignant clone in the original biopsies.
SCID tumours were grown from 3 cases of LPHD (A, B, C), 1 case of
NSHD (D) and 1 case of MCHD (E) (Table 3.1). Most of the HD cases only
gave rise to 1 primary SCID tumour, the exception being Case C - LPHD
which gave rise to 2 primary SCID tumours (C1 and C2). Of the HD-derived
SCID tumours, only one case (B) passaged successfully - B1 is the primary
tumour and the passaged tumour is denoted B2. There was no significant
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Table 3.1 Details of SCID Tumours Arising After
Transplantation of Hodgkin's Disease
ORIGINAL BIOPSY SCID TUMOURS
Case
Number
Diagnosis SCID Tumours Latent
Growth
Period













D NSHD D1 - PRIMARY 13 wks
E MCHD E1 - PRIMARY 12 wks
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Table 3.2 Details of SCID Tumours Arising After
Transplantation of Non-Hodqkin's Lymphomas
ORIGINAL BIOPSY SCID TUMOURS
Case
Number
Diagnosis SCID Tumours Latent
Growth
Period











G Centroblastic G1 - PRIMARY 29 wks
H Centroblastic H1 - PRIMARY 19 wks
1 Immunoblastic 11 - PRIMARY 16 wks
























difference in the number of weeks taken for each HD-derived SCID tumour
to grow and this time did not appear to decrease on passage of B1.
SCID tumours were grown from 3 cases of centroblastic (F, G, H), 1
immunoblastic (I), 1 follicular (J) and 2 large cell anaplastic lymphomas,
although the 2 LCAL cases (K and L) were actually sequential biopsies from
the same patient (taken 4 weeks apart) (Table 3.2).
Cases F, G, H, I and J all only gave rise to one primary SCID tumour,
whereas in Cases K and L, 100% SCID tumour development was achieved
(4 and 5 primary SCID tumours respectively).
Case F was the only NHL case to produce SCID tumours that
passaged successfully, and it did so very well - following passage of the only
primary tumour (F1), 3 passages were carried out and gained 100% tumour
take each time. SCID tumours F2-5 correspond to the first passage, F6-9 to
the second and F10-13 to the third passage. After this, no more passages
were carried out but a cell suspension from F13 was frozen down in liquid
nitrogen. Later, this was thawed, reconstituted in RPMI/10% FCS and re¬
injected back into 4 SCID mice resulting in one further tumour (F14 - fourth
passage).
There was no significant difference in the time taken for each NHL-
derived SCID tumour to grow, being similar to that for the HD-derived
tumours. The exception was tumour G1 which took slightly longer to develop
(29 weeks).
A slight decrease in time taken for tumour growth was seen in the first
passage of SCID tumour F, although this was not evident in the following
passages.
Cell number injected into the mice did not appear to play any role in
the development of the SCID tumours (range was 0.7 - 7x107 cells).
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3.4 Comment
Over a 3 year period, 42 lymphoma biopsies were available for injection into
SCID mice. Although some biopsies received were insufficient to use in the
project, this number was still lower than expected. Therefore the number of
biopsies received was not favourable.
58% of the SCID mice used were found dead in their cages several
weeks after injection or appeared sick but were found to be tumour-free. A
large proportion of these mice would simply have died of old age. A small
number of deaths were accidental due to a malfitted water bottle.
12% of the mice developed murine thymic lymphomas and this is in
agreement with that reported for SCID mice (10-15%) (Custer et al 1985).
SCID tumours developed from 5/17 cases of HD and 7/25 cases of
NHL. Each sub-type of Hodgkin's disease grew in the SCID mice (LDHD not
being encountered). However, it is interesting that only 1 low grade NHL
(Cb-Cc Foil - Case J) gave rise to a SCID tumour, the other 6 cases
classified as high grade NHLs.
These lymphomas certainly appear to be more difficult to grow
compared to other tumours such as melanoma, prostate and pancreatic
carcinoma (Philips et al 1989) and to lymphomas induced by inoculation with
EBV positive PBL (Cannon et al 1990, Nakamine et al 1991, Rowe et al
1991, Mosier et al 1992, Nadal et al 1992, Purtillo et al 1992, Veronese et al
1994)). However, in a similar study, Kapp et al (1993) only achieved growth
of SCID tumours in 3/13 cases of HD injected - a slightly lower success rate
than this project.
The time taken for these SCID tumours to grow matches that seen in
a variety of tumours (the average latency period being 13 weeks) (Custer et
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al 1985), and other HD-derived SCID tumours (11-20 weeks) (Kapp et al
1993).
Only 1 of the HD-derived SCID tumours and 1 of the NHL-derived
SCID tumours passaged successfully. However, SCID tumour G1 was not
passaged as it was too small and SCID tumour J1 was reported in my
absence and therefore not passaged. 3 sets of 4 'passage' mice (from cases
H, I and K) were killed by an Animal House infection. The HD-derived SCID
tumour that did passage (B2) was too small for further passage. Therefore,




Morphology and Phenotypic Analysis of
Original Biopsies and SCID Tumours
The morphology and phenotypic characteristics of the SCID tumours were
investigated to determine how they compared to the original biopsy injected.
Morphology was investigated using a standard Haematoxylin and Eosin
stain. Phenotyping was carried out using a range of B cell, T cell ,
macrophage and activation markers (Tables 2.1 & 2.2).
4.1 Morphology of the SCID Tumours
In general, these SCID tumours showed numerous mitoses, some appearing
abnormal, and apoptosis and necrotic areas were also found.
SCID Tumour A1
This tumour was derived from an LPHD (Case A). It was mainly comprised
of immunoblast-type cells showing a prominent nucleolus. A few small
lymphocytes were also present and cells with poly-lobated nuclei were also
seen. A few large, multi-nucleated RS-like cells could be seen - in some
cases these were surrounded by neutrophils. On the whole, this tumour
appeared to be monomorphic showing only some plasmacytoid
differentiation. This tumour invaded the liver however the gut and pancreas
appeared normal, as were the kidneys, heart and lungs. The mesenteric
lymph nodes were colonised by tumour.
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SCID Tumour B1
This tumour was also derived from an LPHD (Case B). It was also
comprised of immunoblasts. There were many more small lymphocytes
present in comparison with SCID tumour A1 and much plasmacytoid
differentiation was seen. A few large cells with poly-lobated nuclei were
seen as were large, multi-nucleated RS-like cells. Tumour infiltration was
present in the mesenteric lymph nodes, liver and lung.
SCID Tumour B2
This is the passaged SCID tumour from B1. Again, this was a mixture of
immunoblasts some with poly-lobated nuclei, small lymphocytes, some
plasmacytoid differentiation and a few multi-nucleated RS-like cells, some
with surrounding macrophages. The tumour had invaded the mesenteric
lymph nodes and liver but all other abdominal organs appeared normal.
This mouse had also developed a murine thymic lymphoma and a mixture of
human and murine lymphomas could be seen in the lungs (distinguished
both morphologically and phenotypically) (Figure 3.1).
SCID Tumours C1 and C2
These 2 primary SCID tumours were derived from a LPHD (Case C). Some
areas of the C1 SCID tumour were monomorphic showing immunoblasts
whereas other areas were made up of large pleomorphic cells with poly-
lobated nuclei showing large nucleoli and more abundant cytoplasm,
showing some features of large cell anaplastic lymphoma. The liver and
mesenteric lymph nodes were invaded by tumour as were the lungs. All
other organs appeared normal.
The other primary SCID tumour derived from Case C (designated C2)
was not as pleomorphic as C1 showing more of an immunoblastic pattern
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with some plasmacytoid differentiation present. The liver was invaded in this
case with some tumour present in the lungs.
SCID Tumour D1
This SCID tumour was derived from a NSHD (Case D). Many large
immunoblasts were present and a few centroblast-type cells. A few multi¬
nucleated cells were also present. There was a lot of plasmacytoid
differentiation present and many classical plasma cells were seen. Some
areas were made up of blast cells while other areas were comprised mainly
of small lymphocytes. In this SCID tumour, there was a huge tumour mass
invading the liver and a smaller mass near the stomach. The kidneys were
invaded in this case.
SCID Tumour E1
This SCID tumour was derived from a MCHD (Case E). It was comprised
mostly of immunoblasts, some large showing poly-lobated nuclei. Some
areas showed a mixture of blasts, small lymphocytes, plasma cells and a few
multi-nucleated RS-like cells, whereas other areas showed undifferentiated
blast cell proliferation. This SCID tumour remained localised to the site of
injection (this was the only tumour to grow from a sc. injection) with no
spread to any other organ.
The general morphological appearance of the HD-derived SCID tumours is
depicted in Figure 4.1. The morphological appearance of the RS/H-like cells
found in these SCID tumours is also shown in Figure 4.1. The LCAL-like
features of SCID tumour C1 is shown in Figure 4.2.
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General morphology showed immunoblasts, some centroblasts and plasmacytoid
differentiation (SCID tumour D1). Mag x250
SCID tumour B1 showing an RS-like cell. Mag x250
arrow
Figure 4.1 Morphology of the HP-Derived SCID Tumours
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KEY FOR FIGURES 4.1 - 4.6
Cb - centroblast
lb - immunoblast
pc - plasmacytoid differentiation
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Figure 4.2 Morphology of SCID Tumour C1
This SCID tumour showed some LCAL-like features - the blasts cells are much larger, and
have more abundant cytoplasm. Mag x250
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SCID Tumours F1 - F14
The original Case F biopsy was comprised of centroblasts, with some
nuclear poly-lobation seen. This pattern was also seen in all of the SCID
tumours, appearing morphologically identical to the original biopsy. There
did not appear to be an increased nuclear poly-lobation throughout passage
of the SCID tumours. In this set of SCID tumours, a main tumour mass was
found in the pancreas area, in some cases the liver was invaded. In 5
cases, the tumour invaded the lungs. A distinctive pattern was seen in this
set of SCID tumours which all had small discrete tumour nodules situated
down the length of the intestine. In many cases, the tumour surrounded the
kidneys (Figure 4.3).
SCID Tumour G1
This SCID tumour was derived from a centroblastic lymphoma (Case G). It
was unusual in that it was only present associated with the male
reproductive tract, in particular the epididymis. All other organs appeared
normal. Morphologically, this SCID tumour was very similar to the original
biopsy although it was slightly more pleomorphic as it contained both
immunoblasts and centroblasts whereas the original biopsy was made up
mostly of centroblasts (Figure 4.3 - see Figure 1.5 for morphology of the
original biopsy Case G).
SCID Tumour H1
Another centroblastic lymphoma (Case H) gave rise to this SCID tumour.
The original biopsy was made up mostly of centroblasts with a few
centrocytes. The SCID tumour looked very like the original although a mild




SCID tumour F6, comprising centroblasts, some of which showed nuclear poly-lobation -
this was morphologically identical to the original biopsy. Mag x250
- lb
-Cb
SCID tumour G1. This was slightly more pleomorphic than the original biopsy as it
contained both centroblasts and immunoblasts. Mag x250
Figure 4.3 SCID Tumour Morphology
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However, it was comprised mostly of centroblasts with some immunoblasts
present. This SCID tumour invaded the intestine only (Figure 4.4).
SCID Tumour 11
This was derived from an immunoblastic lymphoma (Case I). The original
biopsy was comprised mainly of immunoblasts with very few centroblasts.
The SCID tumour resembled this very closely although the immunoblasts
here showed more abundant cytoplasm i.e. more plasmacytoid
differentiation. This tumour invaded the mesentery and pancreas but all
other organs were clear (Figure 4.4).
SCID Tumour J1
This SCID tumour was derived from a Cb-Cc Follicular lymphoma (Case J).
The original biopsy showed a predominance of centrocytes over
centroblasts. However, the SCID tumour did not appear to resemble the
original biopsy, being comprised of a large immunoblastic proliferation . This
SCID tumour showed extensive necrosis and did not exhibit a follicular
pattern. This SCID tumour invaded the liver but all other organs were clear
(Figure 4.5 - see Figure 1.5 for morphology of the original biopsy Case J).
SCID Tumours K1 - K4
These 4 primary SCID tumours were derived from Case K - a B cell LCAL.
The original biopsy showed a sinusoidal and paracortical infiltration of the
malignant cells showing large, pleomorphic nuclei with one or more
prominent nucleoli and abundant cytoplasm. Bi- and multi-nucleated forms
were present.
SCID tumour K1 infiltrated the gut, liver, spleen, kidneys and
mediastinal lymph node. In some areas, the tumour morphologically
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resembled the original biopsy very closely and in other areas it appeared
more polymorphous with large blasts, occasional multi-nucleated cells and
some plasmacytoid differentiation. A small number of lymphocytes and
plasma cells were also present.
SCID tumour K2 was not as invasive as K1, infiltrating only the liver.
Both SCID tumours K3 and K4 did not appear to be invading any
organ but merely lying around them. They were all morphologically as K1
(Figure 4.5).
SCID Tumours L1 - L5
This case (Case L) was a sequential biopsy from Case K. This also showed
a pleomorphic large cell infiltrate. The cells showed round and oval nuclei
with prominent often multiple nucleoli. Bi-nucleate, multi-nucleate and poly-
lobated nuclear forms were present.
SCID tumour L1 appeared to be histologically identical to the original
biopsy perhaps showing more multi-nucleated forms. There also appeared
to be small focal areas of lymphoproliferation with plasmacytoid
differentiation and plasma cells present. This tumour spread into the liver,
spleen, mesenteric lymph nodes and lungs.
SCID tumours L2, L3, L4 and L5 were much less invasive with the
exception of L4 which infiltrated the liver. They all appeared histologically
identical to the original biopsy, again with the exception of L4 in which focal
areas of lymphoproliferation and plasmacytoid differentiation were
additionally seen (Figure 4.6 - see Figure 1.6 for morphology of the original
biopsy Case L).
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In contrast, SCID tumour L4 contains areas of monomorphic immunobiastic proliferation
shown here, although areas resembling the original biopsy were also present (see Figure
5.4). Mag x250
Figure 4.6 Morphology of SCID Tumours
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4.2 Phenotvpic Characteristics of the
Original Biopsies
Hodqkin's Disease Biopsies
The phenotypes of the RS/H cells in the HD biopsies are detailed in Tables
4.1, 4.3 and 4.5. Antigen expression, when detected, was seen in the
majority, if not all, of the RS/H cells. As expected, Class II MHC (LN3)
expression was ubiquitous. LCA expression was seen in the 3 LPHD cases
(A, B & C) but absent in the other sub-types. The 3 LPHD cases (A, B & C)
also expressed CD20, unusually for this sub-type of HD, Case B expressed
CD15. Various B cell markers were expressed by all the cases of HD except
Case E. No T cell or macrophage markers were expressed by any case.
Both CD15 and CD30 were expressed by the NSHD (Case D) and the
MCHD (Case E).
NHL Biopsies
The phenotype of the NHL biopsies is detailed in Tables 4.2a, 4.2b, 4.4,
4.6a and 4.6b. As expected, in the 3 centroblastic, the immunoblastic and
the follicular lymphomas (Cases F, G, H, I and J), the tumour cells expressed
the LCA and various B cell markers, but failed to express any T or
macrophage markers, although residual T cell and macrophages were
detected in the lymph node. Case H centroblastic lymphoma was unusual in
that it was the only case expressing the CD43 antigen The LCAL (Cases K
and L) showed a very restricted antigen expression, the malignant cells
stained positively only with MB2 and EMA. Case L also showed some
staining for CD23. This LCAL was unusual in that it did not express the Ki-1
antigen (CD30).
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4.3 Phenotypic Characteristics of the SCID Tumours
The phenotypic results are shown in Tables 4.1, 4.2a, 4.2b, 4.3, 4.4, 4.5,
4.6a and 4.6b. The key set out below applies to all these tables:-
The immuno-staining was assessed in a semi-quantitative manner as
follows:- +++ over 70% positive cells
++ 40-70% positive cells
+ 10-30% positive cells
+/- 1-5% positive cells
NEG no staining seen
w weak staining. All other results not denoted showed good
moderate/strong staining.
Frozen section morphology is of a lower standard than paraffin section
morphology, and this caused a few problems in the assessment of the
immuno-staining.
(d) Difficult to assess
PQ Poor Quality. No assessment could be made.
ND Not Distinguishable. Applies to the RS/H cells in the HD biopsies
frozen sections.
NM No Material. If the SCID tumour was very small, material was taken in
formalin for paraffin sections only.
NS Not Stained. Refers to the EMA column in Table 4.6b.
The immuno-staining results for the HD biopsies refer to the RS/H cells only,
and are given as positive (POS) and negative (NEG) only.
Each original biopsy and its corresponding SCID tumour(s) are shown
together on each table for ease of comparison.
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B Cell Markers
Included in this section is the LCA (CD45) expression.
HP-Derived SCID Tumours
Table 4.1 shows the B cell phenotype of the HD-derived SCID tumours. All
of the HD-derived SCID tumours showed strong expression of the leucocyte
common antigen (CD45) (Figure 4.7) and the B cell markers CD20 (Figure
4.7), CD22, CD23 and CD40 (exception was SCID tumour A1). The CD19,
MB2 and CD45RA antigens were strongly expressed in some cases but not
others and the MB1 marker was expressed weakly or not at all.
NHL-derived SCID Tumours
The B cell phenotype of the SCID tumours derived from Case F centroblastic
lymphoma (total = 14 including all the passages) are shown on Table 4.2a.
Each one (SCID F1 - F14) showed over 70% expression of LCA, as with
CD20 and MB1 in 12/13 tumours - the exception being F1 having a lower
percentage of CD20 and MB1 positive cells. In the case of MB2, CD45RA,
CD22 and CD40, the majority of the Case F SCID tumours showed over 70%
expression, the others showing over 50% expression. CD19 however was
not as strongly expressed and CD23 was only weakly expressed in a
minority of cells in one case (SCID tumour F4), the rest being CD23
negative.
The B cell phenotype of the SCID tumours from NHL cases G, H, I
and J is shown in Table 4.2b. They again all showed expression of LCA and
L26 in the majority of the tumour cells.
SCID tumour G1 showed moderate expression of MB1 and MB2 and
high CD40 expression. It also showed slight expression of the CD23
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Figure 4.7 Antigenic Expression of the SCID Tumours
SCID tumour A1 showing strong expression of both CD45 (LCA) (top) and CD20 (bottom).
Mag x400
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CaseK-LCAL SCIDTumourK1 SCIDTumourK2 SCIDTumourK3 SCIDTumourK4
NEG +++ ++ +++
+
NEG +++ +++ +++ ++
NEG PQ NM NM NM








1EGN ++ h++ H+++/- H++NEG
CaseL-CAL SCIDTumourL1 SCIDTumourL2 SCIDTumourL3 SCIDTumourL4 SCIDTumourL5
NEG +/- NEG NEG +/- NEG
NEG +/- NEG NEG +/- NEG
NEG PQ NEG NEG NEG NEG
NEG PQ NEG PQ NEG NEG
NEG NEG NEG NEG NEG NEG
W+++ +++ +++ +++ +++ +++
NEG NEG NEGH NEG NEGH NEG
+NEG
►++NEG H++NEG K++NEG H++NEG H++NEG
antigen, retaining the phenotype of the original biopsy. No material was
available for frozen section immuno-phenotyping.
SCID tumour H1 showed expression of all the B cell antigens except
CD23 as did SCID tumour 11 although it showed no CD40 expression.
SCID tumour J1 showed moderate expression of the CD40 and MB2
antigens although high expression of the CD23 antigen was seen.
The 2 LCAL biopsies (Cases K and L) produced 2 phenotypically very
different sets of SCID tumours. The first set (derived from Case K) showed
LCA, CD20, MB2 and CD23 expression, less so CD45RA and MB1. In
contrast, the SCID tumours derived from Case L showed a very limited
phenotypic pattern - only showing expression of MB2 and CD23. The
exception was SCID tumour L1 and L4 which only showed LCA and L26
expression in a minority of the SCID tumour cells, these cells being of the
immunoblastic morphology described as present in small focal areas.
The LCAL biopsies and their SCID tumours were also stained for the
epithelial membrane antigen (EMA) as this is commonly found in these
lymphomas (Chan et al 1989). Both original biopsies were positively
stained, however only 2 of the SCID tumours from case K stained with EMA
and only in a minority of cells whereas all the SCID tumours from Case L
were strongly positive with this marker.
T Cell Markers
The SCID tumours were stained with the T cell markers CD3, CD4, CD8,
CD43 and CD45Ro. None of the SCID tumours were positive for any of the
T cell markers except the CD43 antigen (Figure 4.8). All of the HD-derived
SCID tumours stained positively for this antigen. The NHL-derived SCID
tumours from Cases H, J and K also expressed this antigen to varying
degrees (Tables 4.3 and 4.4).
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Figure 4.8 CD43 Expression
SCID Tumour C2 showing high expression of the CD43 antigen.
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Table 4.3 T Cell Antigen Expression in Hodqkin's Disease




pCD3 CD3 CD4 CD8 CD43 CD45RO
Case A - LPHD NEG ND ND ND NEG NEG
SCID Tumour A1 NEG NEG NEG NEG +++ NEG
Case B - LPHD NEG ND ND ND NEG NEG
SCID Tumour B1 NEG NEG NEG NEG ++ NEG
SCID Tumour B2 NEG NEG NEG NEG +++ NEG
Case C - LPHD NEG ND ND ND NEG NEG
SCID Tumour C1 NEG NEG PQ PQ +++ NEG
SCID Tumour C2 NEG NEG NEG NEG +++ NEG
Case D - NSHD NEG ND ND ND NEG NEG
SCID Tumour D1 NEG NEG NEG NEG +++ NEG
Case E - MCHD NEG ND ND ND NEG NEG
SCID Tumour E1 NEG NEG NEG NEG +++ NEG
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Table 4.4 T Cell Antigen Expression in Non-Hodqkin's
Lymphoma Biopsies and SCID Tumours
CASE
{NHL Bioosv/SCID Tumour)
T CELL ANTICEN EXPRESSION
pCD3 CD3 CD4 CD8 CD43 CD45Ro
Case F - NHL Cb NEG NEG NEG NEG NEG NEG
SCID Tumours F1-F14 NEG NEG NEG NEG NEG NEG
Case G - NHL Cb NEG NEG NEG NEG NEG NEG
SCID Tumour G1 NEG NM NM NM NEG NEG
Case H - NHL Cb NEG NEG NEG NEG ++ NEG
SCID Tumour H1 NEG NEG NEG NEG +++ NEG
Case I - NHL ImmB NEG NEG NEG NEG NEG NEG
SCID Tumour 11 NEG NEG NEG NEG NEG NEG
Case J - NHL Cb/Cc Foil NEG NEG NEG NEG NEG NEG
SCID Tumour J1 NEG NEG NEG NEG ++ NEG
Case K - LCAL NEG NEG NEG NEG NEG NEG
SCID Tumour K1 NEG PQ PQ PQ ++ NEG
SCID Tumour K2 NEG NM NM NM +++ NEG
SCID Tumour K3 NEG NM NM NM +++ NEG
SCID Tumour K4 NEG NM NM NM +/- NEG
Case L - LCAL NEG NEG NEG NEG NEG NEG
SCID Tumour L1 NEG NEG NEG NEG NEG NEG
SCID Tumour L2 NEG NEG NEG NEG NEG NEG
SCID Tumour L3 NEG NEG NEG NEG NEG NEG
SCID Tumour L4 NEG NEG NEG NEG NEG NEG
SCID Tumour L5 NEG NEG NEG NEG NEG NEG
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Table 4.5 Antigen Expression in Hodqkin's Disease Biopsies





CD15 CD30 LN3 CD25 CD18 CD11b CD14 CD68
Case A - LPHD NEG POS POS ND ND ND ND NEG
SCID Tumour A1 NEG ++ +++ +/- +++ NEG NEG NEG
Case B - LPHD POS NEG POS ND ND ND ND NEG
SCID Tumour B1 NEG w+ +++ +/- + NEG NEG NEG
SCID Tumour B2 NEG w+ ++ +/- ++ NEG NEG NEG
Case C - LPHD NEG NEG POS ND ND ND ND NEG
SCID Tumour C1 NEG +++ ++ PQ +++ NEG NEG +/-
SCID Tumour C2 NEG +++ +++ NEG +++ NEG PQ NEG
Case D - NSHD POS POS POS ND ND ND ND NEG
SCID Tumour D1 NEG +++ +++ +/- ++(d) +(d) NEG NEG
Case E - MCHD POS POS POS ND ND ND ND NEG
SCID Tumour E1 ++ w+ +++ +/- ++ NEG NEG NEG
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Table 4.6a Antigen Expression in Case F Centroblastic
Lymphoma and SCID Tumours - Macrophage
& Other Markers
CASE F/SCID iiiiifriftPN FXPRFSSinN
TUMOUiS
CD15 CD30 LN3 CD25 CD18 CD11b CD14 CD68
Case F - NHL Cb NEG NEG ++ PQ ++ NEG NEG NEG
SCID Tumour F1 NEG NEG ++ + + NEG NEG NEG
SCID Tumour F2 NEG NEG +++ + NEG NEG NEG NEG
SCID Tumour F3 NEG NEG +++ + + NEG NEG NEG
SCID Tumour F4 NEG NEG +++ NEG +(d) NEG NEG NEG
SCID Tumour F5 NEG NEG +++ NEG +(d) PQ NEG NEG
SCID Tumour F6 NEG NEG +++ + ++(d) NEG NEG NEG
SCID Tumour F7 NEG NEG +++ NEG ++ +(d) NEG NEG
SCID Tumour F8 NEG NEG ++ +(d) ++ NEG NEG NEG
SCID Tumour F9 NEG NEG +++ + ++ + NEG NEG
SCID Tumour F10 NEG NEG +++ NM NM NM NM NEG
SCID Tumour F11 NEG NEG +++ NM NM NM NM NEG
SCID Tumour F12 NEG NEG +++ +(d) ++ + NEG NEG
SCID Tumour F13 NEG NEG +++ NEG ++ + NEG NEG
















































































































































































































































































The SCID tumours were stained with the CD14 monocyte marker and the
CD68 macrophage marker. Although none of the SCID tumours expressed
the CD14 antigen, in a few cases (SCID tumours C1, H1 and J1) a few
CD68-expressing macrophages were seen. The CD11b antigen was only
expressed on a minority of cells in SCID tumours D1 and a few of the
passaged Case F SCID tumours (Tables 4.5, 4.6a and 4.6b).
Other Markers
The SCID tumours were stained against the 2 antigens associated with HD -
CD15 and CD30. All of the NHL-derived SCID tumours were CD15
negative, however one HD-derived SCID tumour (E1) expressed CD15
(retaining the phenotype of the original biopsy). All of the HD-derived SCID
tumours expressed CD30 to varying degrees. CD30 was not expressed in
any Case F SCID tumour but was expressed in varying degrees in the
remaining NHL-derived SCID tumours including Case L LCAL.
All of the SCID tumours showed good expression of Class II MHC and
most with the CD18 LFA-1 antigen (except the SCID tumours L1 - L5),




In general, transplantation of HD into SCID mice produced high grade, B cell
immunoblastic lymphomas with a mixture of smaller lymphocytes and areas
of plasmacytoid differentiation. None of the HD-derived SCID tumours
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showed the morphological picture seen in HD, but SCID tumours C1 and C2
showed some features of LCAL and areas of increased cellular
polymorphism could be seen in most cases. Occasional bi-nucleate or multi¬
nucleated RS-like cells were also found in each of the HD-derived SCID
tumours.
As expected, the 3 LPHD expressed CD20 and various other B cell
antigens (Norton et al 1987, Hall et al 1988b, Nicholas et al 1990, Poppema
1992), however the NSHD (Case D) only showed MB2 and weak CD40
expression and the MCHD (Case E) did not express any B cell markers. The
HD-derived SCID tumours did not follow the phenotypic pattern of the
original biopsies, instead exhibiting an activated B cell phenotype. Although
the RS/H cells in all the HD cases (except Case E MCHD) expressed various
B cell markers, the same pattern and intensity of expression was not
matched in the SCID tumours (comparison of CD19 and CD22 expression
between the original biopsies and SCID tumours cannot be considered here
as RS/H cell staining could not be determined because of poor frozen
section morphology). Instead, the HD-derived SCID tumours displayed a
mature, activated B cell phenotype regardless of injected HD biopsy RS/H
cell phenotype. No B cell antigen expression was lost in the SCID tumours -
a notable pattern was the expression of the CD23 antigen, a B cell activation
antigen associated with EBV (Wang et al 1990), which was not expressed by
the RS/H cells in any of the HD biopsies but highly expressed in all of the
HD-derived SCID tumours.
None of the SCID tumours expressed the HD-associated antigen
CD15 despite 3 original cases expressing this antigen. The exception was
Case E MCHD in which the SCID tumour E1 retained the original phenotype.
All of the HD-derived SCID tumours expressed the CD30 antigen to one
degree or another - however this was seen even when the original HD cases
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were negative (Cases B and C) and may well simply reflect the activation
phenotype of the SCID tumour blasts. However, CD30 positivity was noted
in these RS-like cells seen in the HD-derived SCID tumours.
None of the SCID tumours, like the RS/H cells in the original biopsies
expressed any T cell or macrophage -associated antigens, therefore the
growth of any residual T cells or macrophages from the injected lymph node
suspensions was not supported in our SCID mouse model, although in one
case (SCID tumour C1) a very few macrophages were present. The
exception was the expression of the CD43 antigen. This antigen was not
expressed by the RS/H cells in any HD case, but was highly expressed in all
7 HD-derived SCID tumour. This is a T cell associated antigen but it also
marks neoplastic B cells , staining most low grade B cell lymphomas and
some high grade B cell lymphomas (Norton & Isaacson 1989). It is also
associated with EBV infection and is highly expressed on EBV positive cell
lines (Stoll et al 1989).
High expression of the MHC Class II (LN3) served to again
demonstrate the activated state of the SCID tumour cells (all HD cases also
expressed this antigen), therefore weak CD25 expression was surprising
although poor frozen section morphology did effect interpretation some-what.
NHL-derived SCID Tumours
This set of SCID tumours, unlike the HD-derived tumours differed
histologically and phenotypically.
The SCID tumour J1, derived from an NHL Cb-Cc follicular lymphoma
(Case J) did not retain the morphology of the original biopsy instead
resembling the HD-derived SCID tumours being a B cell immunoblastic
proliferation. The original follicular lymphoma (Case J) expressed high
levels of LCA and B cell antigens (CD20, CD19, CD22, MB1 and CD45RA)
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being unusual in that no expression of MB2 was seen (Hall et al 1988a,
Salter et al 1988, Norton & Isaacson 1989). This SCID tumour expressed
various B cell markers quite different to those expressed in the original
tumour with some loss of antigen expression in the SCID tumour. However,
as with the HD-derived SCID tumours, CD23 (and CD40 ) antigen
expression was high (neither being expressed in the original). No T cell
markers were expressed but again as with the HD-derived SCID tumours,
the CD43 antigen was highly expressed. The activation state of the tumour
cells was demonstrated by MHC Class II (LN3) and perhaps CD30
expression. Again CD25 was surprisingly not expressed although the frozen
section morphology was poor, but there were a few scanty macrophages
present.
In contrast, the SCID tumours derived from the 3 centroblastic
lymphomas and the immunoblastic lymphoma - SCID tumours F1 - 14, G1,
H1 and 11 appeared to retain the morphology of the original biopsies,
although a little more pleomorphic than the originals. Perhaps the length of
time growing in the SCID mouse and the lack of host immune intervention
allowed tumour progression.
As expected, the 3 centroblastic and immunoblastic lymphomas
(Cases F, G, H & I) showed high expression of the LCA (CD45). They were
quite unusual in that they were CD19 negative although frozen section
morphology made this difficult to interpret in Cases F and I. As expected
they all expressed the various B cell antigens (CD20, CD22, MB1, MB2,
CD40, CD45RA) in over 50-70% of the tumour cell population and showed
no expression of any of the T cell markers (Hall et al 1988a, Salter et al
1988, Norton & Isaacson 1989).
With very few exceptions, these SCID tumours also retained the
original tumour phenotype. A notable difference in these SCID tumours was
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the lack of expression of the CD23 and CD43 antigens, so heavily expressed
in the HD-derived SCID tumours and the J1 SCID tumour. The exception
was SCID tumour G1 showing weak CD23 expression however the original
biopsy also expressed CD23 weakly. CD23 is expressed in a small
proportion of high grade B NHLs (Salter et al 1988). SCID tumour H1
expressed the CD43 antigen, however again this was simply retaining the
original phenotype of Case H. CD43 expression is seen in around 10% of
high grade B NHL (Norton & lsaacson1989).
The SCID tumours F1 - F14 from Case F centroblastic lymphoma
appeared to retain the phenotype throughout the passages - progressive
expression of any one marker was not seen throughout passage.
The 2 LCAL biopsies (Cases K and L) gave rise to 2 morphologically
and phenotypically different sets of tumours.
The original LCAL biopsy showed a very restricted antigenic profile.
Some, but not all, LCAL express the LCA (Hall et al 1988b). This case did
show weak LCA expression but only on frozen section, not on paraffin
sections, a pattern recognised previously (Delsol et al 1988, Hall et al
1988b). The LCAL in this study was of B cell type, but the only B cell
antigens expressed were MB2 and CD23. These 2 antigens are both found
to be expressed in a proportion of LCAL (Herbst et al 1989, Norton &
Isaacson 1989). Little data is available on the B cell type of LCAL as they
are rare compared to T cell LCAL. In a previous study CD19 and CD22
have been shown to be expressed in B cell LCAL (Herbst et al 1989).
However, these 2 B cell markers were negative in the case studied in this
thesis. EMA expression was seen in both Cases K and L, an antigen shown
to be highly expressed in LCAL (Hall et al 1988b, Norton & Isaacson 1989,
Chan et al 1989).
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SCID tumours K1 - K4 appeared to be morphologically a 'mixture' of
tumour cells resembling those present in the original biopsy and the
immunoblastic proliferation with plasmacytoid features as seen in SCID
tumour J1 and the HD-derived SCID tumours. This is reflected in the
activated B phenotypic profile of these 4 SCID tumours,.as apposed to the
restricted phenotype of the original biopsy.
In constrast, the SCID tumours from Case L (L1 - L5) tended to retain
the morphology and restricted phenotype of the original biopsy, although L1
and L4 both showed an immunoblastic sub-population, this being reflected in
the minor expression of LCA and L26 seen with these 2 SCID tumours. The
CD30 antigen, expressed by over 90% of LCAL (Norton et al 1989) was
surprisingly absent in Cases K and L. However, it is interesting to note that
this antigen is highly expressed on all 9 of the LCAL-derived SCID tumours.
Perhaps the SCID mouse environment allows expression of this antigen,
down-regulated in the original biopsies.
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Chapter Five
EBV Status of the Original Biopsies and
the SCID Tumours
Because of the known association of the Epstein-Barr virus with HD and
NHL, and the fact that innoculation of SCID mice with PBL from EBV-
seropositive donors will produce high grade B cell lymphomas, the original
HD and NHL biopsies and the resultant SCID tumours were investigated for
the presence of EBV to determine if it played a part in these SCID tumours.
This was carried out using in situ hybridisation for EBER,
immunocytochemistry for LMP and EBNA-2, and southern blotting for the
presence of the EBV genome. The clonality of any EBV genomes present
was also assessed using terminal repeat analysis to determine if any EBV
positive SCID tumour was derived from the EBV positive malignant clone in
the original biopsy.




Only 1 of the HD cases - Case E MCHD - showed expression of EBER in the
RS/H cells. A strong nuclear signal was seen in the majority if not all of the
RS/H cells (Figure 5.1). A small proportion of the surrounding lymphocytes
were also EBER positive. In the remaining 4 biopsies, the RS/H cells did not
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Table 5.1 EBV Status of the Original Hodqkin's and
Non-Hodqkin's Biopsies and SCID Tumours
ORIGINAL BIOPSY TRANSPLANTED SCID TUMOUR
'
■ -A ACASE EBV STATUS SCID TUMOUR EBV STATUS
A - LPHD NEG A1 EBER/LMP/EBNA-2








D -NSHD NEG D1 EBER/LMP/EBNA-2
E - MCHD EBER/LMP E1 EBER/LMP/EBNA-2
F- NHL Cb NEG F1 -F14 ALL NEG
G - NHL Cb NEG G1 NEG
H - NHL Cb NEG H1 NEG
1 - NHL ImmB NEG 11 NEG
J - NHL Cb/Cc Foil NEG J1 EBER/LMP/EBNA-2























Case E HDMC, the only EBV positive original HD biopsy showing strong EBER expression
in the RS/H cells. Mag x250
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Figure 5.1 EBER Expression in HD Original Biopsy and SCID Tumour
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express EBER, only a minority of the back-ground lymphocytes showed
expression
HP-derived SCID Tumours
All of the HD-derived SCID tumours showed EBER expression. A strong
nuclear signal was detected in 50-70% of the tumour cells in each case
(Figure 5.1).
NHL Biopsies
The tumour cells in the NHL biopsies F, G, H, I and J were EBER negative.
However, in the 2 LCAL biopsies (Cases K and L) the large anaplastic
tumour cells were found to show strong nuclear expression of EBER (Figure
5.2). In most cases, a minority population of EBER positive lymphocytes
were found.
NHL-derived SCID Tumours
The SCID tumours derived from Cases F(F1-F14), G(G1), H(H1) and 1(11)
were all EBER negative. SCID tumour J1 however showed strong nuclear
EBER expression in around 20% of the tumour cell population. The SCID
tumours derived from Cases K and L (LCAL) were all found to be EBER
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In the EBER positive HD biopsy - Case E MCHD - the majority of the RS/H
cells were also found to express LMP - EBNA-2 however was not expressed.
In the other 4 HD biopsies, the RS/H cells showed no LMP or EBNA-2
expression.
HP-derived SCID Tumours
All 7 of the HD-derived SCID tumours were found to express both LMP and
EBNA-2 - each one tending to show the same staining pattern. Within each
SCID tumour population LMP expression was detected in the larger blasts
and the multi-nucleated RS-like cells present and in some of the smaller
lymphocytes/plasmacytoid cells. EBNA-2 expression was mainly limited to
the smaller cells but was present in a proportion of the large blasts i.e. the
majority of the larger blasts and RS-like cells had a LMP positive/EBNA-2
negative EBV phenotype while the smaller lymphocytes/plasmacytoid cells
and a proportion of the large blasts had a LMP positive/EBNA-2 positive
EBV phenotype (Figure 5.3).
30-40% of the large blasts and 5-10% of the smaller blasts in SCID
tumour A1 were LMP positive. EBNA-2 expression was seen in 20% of the
cell population, mostly in the smaller blasts and plasmacytoid cells, the
RS/H-like cells being negative.
In SCID tumour B1, a slightly higher number of cells were LMP
positive (around 50%), again showing the pattern of staining as in A1.
EBNA-2 expression was seen in 20% of cells, mostly smaller blasts and
lymphocytes. The RS/H-like cells were negative. This was also seen in B2




Figure 5.3 LMP/EBNA-2 Expression Pattern of HP-Derived
SCID Tumours
The top figure shows LMP expression seen in the large RS/H-like cells of HD-derived SCID
tumour B1 (Mag x400), whilst the bottom figure shows a x250 view of EBNA-2 expression
from the same case, confined to small blasts and a few large blasts. The multi-nucleated
RS-like cell (arrow) is negative.
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SCID tumours C1 and C2, again showing the same pattern of
staining, showed around 20% of LMP and 10-20% EBNA-2 positive cells.
SCID tumour D1 showed strong LMP expression in the RS/H-like cells
and larger blasts (around 40%) and in around 5% of the smaller blasts.
EBNA-2 was expressed by 1-5% of the cell population mostly in smaller
cells.
SCID tumour E1 showed the same pattern of staining with LMP expressed in
50% and EBNA-2 in 30-40% of the cell population.
NHL Biopsies
No neoplastic cells in the NHL biopsies showed any expression of LMP or
EBNA-2. The exception was Case K LCAL in which a minority of the tumour
cells showed LMP but not EBNA-2 expression.
NHL-derived SCID Tumours
None of the SCID tumours derived from Case F, G, H or I expressed either
LMP or EBNA-2.
In SCID tumour J1 however, both LMP and EBNA-2 expression was
seen in around 20-30% of the blast cells.
The 2 sets of LCAL-derived SCID tumours (from cases K and L)
displayed different EBV phenotypes. The 4 SCID tumours from Case K (K1 -
K4) all showed LMP and EBNA-2 expression with the exception of K4 which
was LMP positive only. The LMP/EBNA-2 expression was as follows - K1
LMP(20%)/EBNA-2(5-10%), K2 LMP(20%)/EBNA-2 (20%), K3 LMP(10-
20%)/EBNA-2(10-20%), K4 LMP(50%).
2 of the SCID tumours derived from Case L LCAL (L3 and L5) were
found to be LMP/EBNA-2 negative. SCID tumour L2 showed LMP
expression only in a minority population (less than 0.001%). SCID tumour
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Figure 5.4 LMP/EBNA-2 Expression Pattern in SCID Tumour L4
This figure shows the morphological difference between an LMP negative area (top) and an
LMP positive area (bottom) of SCID tumour L4. These 2 figures are taken at the same
magnification (x250) and clearly show that the large anaplastic cells resembling the original
biopsy (Case L) are LMP negative, whilst only focal areas of the smaller immunoblastic cells
are LMP positive. The same pattern was seen with EBNA-2.
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L1 showed a minority sub-population of LMP+/EBNA-2+ cells (0.01%) - the
positive cells were those of the lymphocyte/plasmacytoid sub-population
found in L1. The same pattern was seen in SCID tumour L4, although this
contained more obvious focal areas of LMP+/EBNA-2+ lymphoproliferations
mixed in with the LMP/EBNA-2 negative large anaplastic cells (Figure 5.4).
5.3 EBV Detection by Southern Blot Analysis
This was carried out by Alice Gallagher in the Department of Veterinary
Pathology in the University of Glasgow Veterinary School as part of a
collaborative study with Dr Ruth Jarrett in whose lab I spent 4 weeks
learning the basics of the techniques used.
HP Biopsies
EBV was also detected in Case E MCHD by Southern blot analysis.
Terminal repeat sequence analysis of the EBV genomes was consistent with
the presence of a clonal EBV-infected population in this case. EBV was not
detected in any of the remaining 4 HD biopsies (Table 5.2).
HP-derived SCID Tumours
The material from the HD-derived SCID tumours A1, B1 and B2 was not
satisfactory for the Southern blot analysis. However, EBV was detected in
SCID tumours derived from Cases C, D and E. Terminal repeat sequence
analysis was carried out on SCID tumour E1 only, since this was the single
case in which the original HD biopsy also showed EBV expression in the
RS/H cells. However, the EBV genomes present in the SCID tumour were
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Table 5.2 Detection and Clonalitv of the EBV Genome in
the Original Hodqkin's Disease Biopsies and
SCID Tumours Using Southern Blot Analysis
CASE SOUTHERN BLOT ANALYSIS
(HD Biopsy/SCID Tumour)
EBV-SB EBV-CLONALITY
Case A - LPHD NEG ND
SCID Tumour A1 NS ND
Case B - LPHD NEG ND
SCID Tumour B1 NS ND
SCID Tumour B2 NS ND
Case C - LPHD NEG ND
SCID Tumour C1 POS ND
SCID Tumour C2 POS ND
Case D - NSHD NEG ND
SCID Tumour D1 POS ND
Case E - MCHD POS CLONAL
SCID Tumour E1 POS OLIGOCLONAL
KEY:-
NS - Not Satisfactory




found to be oligoclonal and the single clone of EBV-infected cells present in
the original Case E was not detected here (Table 5.2).
NHL Biopsies
The material from Case H centroblastic lymphoma was found to be
unsatisfactory for the Southern blot analysis. In NHL cases F, G, H, I and J,
the EBV genome was not detected.
However, in both of the LCAL biopsies - Cases K and L - the EBV
genome was detected and terminal repeat sequence analysis showed that
these 2 biopsies both contained the same single clone of EBV infected
tumour cells (Table 5.3).
NHL-derived SCID Tumours
EBV was not detected in the SCID tumours F1 - F14, G1, H1 and 11.
However, it was detected in the J1 SCID tumour. Terminal repeat analysis
was not carried out on this case since the original biopsy was EBV negative.
The EBV genome was detected in all of the LCAL-derived SCID
tumours (K1 - K4 and L1 - L5). Terminal repeat sequence analysis was
carried out on these SCID tumours since EBV was detected in both Cases K
and L original biopsies. In each case, a dominant episome was detected i.e.
a dominant clone in episomal, closed circular form. However, for each case,
linear forms of the virus were also present seen as additional discrete bands
on the Southern blot. If the virus is linear, it will give rise to a different sized
band even if it is the same EBV. Therefore, where a dominant clone is
detected with other bands on the Southern blot, it is difficult to interpret
whether these are different EBV clones in smaller populations of cells or if
they are linear forms of the dominant clone. No definite conclusion was
reached with regard to this, although some of the bands were too small to be
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Table 5.3 Detection and Clonalitv of the EBV Genome
in the Original Non-Hodqkin's Lymphoma






Case F - NHL Cb NEG ND
SCID Tumours F1 - F14 NEG ND
Case G - NHL Cb NEG ND
SCID Tumour G1 NEG ND
Case H - NHL Cb NEG ND
SCID Tumour H1 NEG ND
Case I - NHL ImmB NEG ND
SCID Tumour 11 NEG ND
Case J - NHL Cb/Cc Foil NEG ND
SCID Tumour J1 POS ND
Case K - LCAL POS CLONAL
SCID Tumour K1 POS 1DE+L
SCID Tumour K2 POS 1DE+L
SCID Tumour K3 POS 1DE+L
SCID Tumour K4 POS 1DE+L
Case L - LCAL POS CLONAL
SCID Tumour L1 POS 2DE+L
SCID Tumour L2 POS 2DE+L
SCID Tumour L3 POS 2DE+L
SCID Tumour L4 POS 1DE+L
SCID Tumour L5 NS ND
Negative POS Positive
Not Done NS Not Satisfactory
Dominant Episome + Linear Forms
Dominant episome is different to the clone in the original biopsy








Figure 5.5 EBV Clonalitv of Case L - LCAL ■ and SCID Tumours
This figure shows the EBV clonality blot of original biopsy Case L - LCAL - and SCID
tumours L1, L2, L3 and L4 (L5 DNA was degraded). It demonstrates that the dominant
clone of Case L original biopsy is also present in SCID tumours L1, L2 and L3. The
dominant clone present in L4 is however different from that of the original biopsy. A very
faint band was seen on the original blot in the L4 lane at the same position as the dominant
clone of the original biopsy, but unfortunately it was not possible to show this on the photo¬
copy above.
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linear forms and therefore this result was interpreted as follows - there is a
dominant clone present with other linear forms or episomes present.
However, in the cases of SCID tumours K1, K2, K3 and L4, the
dominant clone present was different in each case and different to the clone
in the original biopsy (both cases K and L having the same clone of EBV
positive cells present as they are sequential biopsies from the same patient).
However, in the case of L4, a very faint band was seen in the same position
on the Southern blot corresponding to the original biopsy clone. The result is
not yet complete on K4.
The dominant clone present in L1, L2 and L3 was however identical to
that present in the original biopsy. Unfortunately, L5 tumour material was
unsatisfactory for further genotypic analysis (Table 5.3) (Figure 5.5).
5.4 Comment
These results show that the Epstein-Barr virus does play a role in a
proportion of the SCID tumours. The EBV status of the SCID tumours fell
into 3 main groups - a non-restrictive EBV phenotype with expression of a
broad range of EBV latent gene products - EBER, LMP and EBNA-2 i.e. a
Latency III pattern of infection - this included all 7 of the HD-derived SCID
tumours and Cases J and K NHL-derived SCID tumours, a restricted EBV
phenotype showing EBER expression only i.e. a Latency I infection pattern -
this included the Case L derived SCID tumours, and EBV negative SCID
tumours from Cases F, G, H and I. It is assumed here that all the EBV
positive cases also expressed EBNA-1 , however this was not looked at
because of technical problems.
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All 7 of the HD-derived SCID tumours expressed EBER, LMP and
EBNA-2 in a proportion but not all of the tumour cells - this staining pattern
has been noted in similar tumours (Itoh et al 1993). EBV has been shown to
be important in the aetiology of HD in a proportion of cases, but only one of
our original HD biopsies contained EBV positive RS/H cells (Case E MCHD).
However, the SCID tumour derived from this case (E1), as with all of the HD-
derived SCID tumours, showed a different EBV latency. The SCID tumour
cells expressed EBER, LMP and EBNA-2 (Latency III), not retaining the
Latency II EBV infection pattern seen in HD i.e. EBER positive, LMP
positive, EBNA-2 negative. There was however a sub-set of large blasts and
multi-nucleated RS/H -like cells in these SCID tumours which did follow this
Latency II pattern of infection.
Also, Southern blotting analysis demonstrated that whilst the original
EBV positive HD biopsy (Case E) contained a single EBV-infected clone of
cells, this clone was not present in SCID tumour, suggesting that the SCID
tumour was not derived from the EBV-infected clone in the original biopsy.
Instead, this E1 SCID tumour was shown to contain oligoclonal EBV
genomes consistent with the development of new clones of EBV-transformed
B cells.
Therefore, it is a strong possibility that the EBV positive SCID tumours
seen after transplantation of HD may simply be secondary to proliferation of
normal bystander B cells containing EBV present in the injected lymph
nodes rather than proliferation of the neoplastic RS/H cells or their
precursors. Most of the original biopsies contained a minority population of
EBV positive small lymphocytes. Out-growth of the infected B cells would be
controlled by virus-specific cytotoxic T cell immunosurveillance in the
immunocompetent human host but once injected into the SCID mouse, the
lack of immunosurveillance would allow out-growth of these cells.
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It is well documented that normal peripheral blood or tonsillar B
lymphocytes from EBV seropositive donors will in most cases produce B cell
lymphoproliferations following innoculation into SCID mice (Section
1.6.3)(Cannon et al 1990, Nakamine et al 1991, Rowe et al 1991, Mosier et
al 1992, Nadal et al 1992, Purtillo et al 1992, Veronese et al 1994). The
EBV positive HD-derived SCID tumours exhibit the same Latency III EBV
expression pattern seen in the these EBV-induced lymphoproliferations, also
seen in LCL and the EBV positive lymphomas associated with
immunocompromised individuals.
It was also apparent that the HD-derived SCID tumours were also
morphologically similar to these EBV-induced lymphoproliferations being
immunoblastic lymphomas with a mixture of small lymphocytes, plasmacytoid
differentiation and well-defined areas of necrosis. The HD-derived SCID
tumours did show occasional bi-nucleated or multi-nucleated RS-like cells
however this morphology could be EBV-induced - RS-like cells have been
found in the benign EBV-associated condition infectious mononucleosis
(Isaacson et al 1992). Nevertheless, these RS-like cells in the HD-derived
SCID tumours did exhibit a Latency II EBV expression pattern seen in HD.
However, reviewing the phenotypic data, it can be seen that the HD-
derived SCID tumours showed the same mature, activated B cell phenotype
as EBV-transformed B cells (not as the RS/H cells in the original biopsies)
with strikingly high expression of the EBV-associated antigens CD23 (Wang
et al 1990) and CD43 - an antigen highly expressed on EBV-transformed cell
lines (Stoll et al 1989), both being negative in the original biopsy. The CD18
antigen, highly expressed in LCL (reviewed by Middleton et al 1991, Rogers
et al 1992) was highly expressed in most but not all of the HD-derived SCID
tumours, but the CD43 antigen was a notable feature of the EBV positive
SCID tumours, and its expression was obviously not associated with T cells
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as no CD3, CD4, CD8 or CD45Ro expression was seen in the SCID
tumours. Perhaps the CD30 expression seen in the HD-derived SCID
tumours is also a consequence of the EBV 'activated' phenotype (reviewed
by Middleton et al 1991, Rogers et al 1992) as opposed to the HD RS cell
phenotype seen in the original biopsy, this is supported by CD30 expression
in SCID tumours even when the original biopsy RS/H cells were negative.
SCID tumour J1 (derived from follicular lymphoma Case J) shared the
Latency III EBV expression pattern seen in the HD-derived SCID tumours,
showing expression of EBER, LMP and EBNA-2 even though the tumour
cells in the original biopsy were EBV negative. Again, SCID tumour J1 did
not retain the morphology and phenotype of the original biopsy but instead
(like the HD-derived SCID tumours) resembled the EBV-induced
lymphoproliferations described before. Again this tumour showed very high
expression of the EBV-associated antigens CD23 and CD43 and it is again a
strong possibility that this SCID tumour is simply an out-growth of the EBV-
transformed back-ground B cells present in the injected node.
The 2 sets of LCAL-derived SCID tumours exhibited different EBV
latency patterns of infection. In the original biopsy, the first biopsy (Case K)
was EBER positive with a minority of LMP positive cells. These cells were
not present in the second biopsy which was EBER positive only (Latency I).
3 of the SCID tumours derived from Case K - K1, K2 and K3 - all exhibited a
Latency III EBV pattern of infection expressing EBER, LMP and EBNA-2, not
retaining the original biopsy phenotype. SCID tumour K4 however appeared
to retain the original biopsy EBV phenotype (EBER+, LMP+/-). The
genotypic analysis showed that all 4 Case K-derived SCID tumours
contained a dominant EBV episome but that this was different to the EBV
positive clone in the original biopsy. Therefore it appears that these SCID
tumours are not derived from the EBV positive malignant clone in the original
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biopsy, but from new clones of EBV positive B cells, obviously from
expansion of EBV positive bystander B lymphocytes present in the injected
lymph node. Perhaps the other bands seen on the Southern blots from
these cases are not linear forms of the dominant clone but different sub¬
clones of EBV-transformed bystander B cells. It is unusual that these 4
SCID tumours showed a degree of morphological similarity to the original
biopsy - described as a 'mixture' of large, anaplastic cells similar to the
tumour cells in the original biopsy and immunoblast-like cells with some
plasmacytoid differentiation. It was initially thought that these K1 - K4 SCID
tumours may be a 'mixture' of the original EBER positive malignant clone
and new EBV (EBER, LMP, EBNA-2 positive) clones of transformed
bystander B cells. However, if this were true, one would expect to see at
least a small band on the Southern blot corresponding to the malignant
clone in the original biopsy together with the dominant episome present in
each K1 - K4 SCID tumour (which was different from the original biopsy).
However, the phenotypic analysis also points to an 'activated B ' phenotype
with high expression of the EBV-associated antigens CD23 and CD43 seen
in the other EBV positive SCID tumours (HD-derived & J1 SCID tumours) not
retaining the very restrictive antigenic phenotype of the original biopsy, and
it must be concluded at this stage that the K1 - K4 SCID tumours are merely
EBV-induced lymphoproliferations derived from the bystander B cell present
in the injected lymph node.
Of the 5 SCID tumours derived from Case L (L1 - L5), L3 and L5
showed expression of EBER only, thus retaining the Latency I EBV pattern
of expression of the original LCAL biopsy. L1 and L2 also contained a
minority sub-population of LMP/EBNA-2 positive and LMP positive
immunoblast cells respectively, but the genotypic analysis showed that the
dominant EBV episome present in SCID tumours L1, L2 and L3 was identical
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to that present in the original biopsy. Therefore it appears that these 3 SCID
tumours are derived from the EBER positive malignant clone in the original
biopsy. Although this could not be proved for L5, the restricted EBV
phenotype of this SCID tumour points to this also being derived from the
EBER positive clone in the original biopsy. The minority sub-population of
LMP/EBNA-2 positive cells in L1 and L2 may be represented by the other
minor bands seen on the southern blot - however, whilst the sub-population
present in L1 was seen morphologically and phenotypically (expression of
LCA and CD20 was seen in these cells as with the immunoblastic population
in the HD-derived and J1 SCID tumours), the LMP positive cells present in
L2 were so infrequent (<0.001 %), that they were not picked out
morphologically by H&E and LCA/CD20 staining was not seen in this SCID
tumour. These SCID tumours also retained the morphology and restricted
antigenic phenotype of the original biopsy and it is concluded that these 4
SCID tumours (L1, L2, L3, L5) are derived from the malignant clone in the
original biopsy with L1 and L2 having a few and a very few respectively new
EBV positive B cell clones (from the EBV positive bystander B cells present
in the injected lymph node) growing alongside the tumour cells. It is
interesting to note that the EBER+ / LMP+/- phenotype of L2 was that seen
in the first biopsy of the LCAL (Case K). It is possible that down-regulation
of LMP occurred as the tumour progressed (Case L), but the SCID
environment allowed expression of this protein again, seen in SCID tumour
L2.
SCID tumour L4 appeared to have a similar EBV phenotype to that of
L1 i.e. EBER positive with a sub-population of LMP/EBNA-2 positive
immunoblasts. However, these immunoblast cells were more common in this
tumour with definite focal areas of LMP/EBNA-2 positive cells seen. Indeed,
although this SCID tumour contained a dominant episome, this was not the
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same as that seen in the other SCID tumours in this group or the original
biopsy, although a very faint band was seen at the same position on the
Southern blot corresponding to the clone in the original biopsy. This
suggests that this SCID tumour L4 is a 'mixture' of the malignant clone of
cells from the original biopsy, but the majority are EBV positive
immunoblastic cells derived from bystander B lymphocytes present in the
injected lymph node.
Again, it is unusual that the morphology of the L4 SCID tumour
appeared to suggest that the majority of the SCID tumour cells in L4 were
identical to the large, anaplastic cells present in the original biopsy and
phenotypically, L4 retained the restricted antigenic phenotype of the original
biopsy, only showing LCA and L26 expression in the immunoblastic sub-
population. It is therefore surprising that the dominant episome present in
the L4 SCID tumour was not that of the malignant clone in the original biopsy
- perhaps the block of tissue from this tumour used for DNA analysis
contained more focal areas of immunoblastic proliferation than that seen in
the block used for histology, this may be possible as quite a bit of variability
between different tumour blocks was seen. Therefore, it is concluded at this
stage that this SCID tumour cannot be said to represent the original LCAL
biopsy.
The SCID tumours derived from the 3 centroblastic lymphomas
(Cases F, G and H) and the immunoblastic lymphoma (Case I) were all EBV
negative as were the tumour cells in the original biopsies. In contrast to the
EBV positive SCID tumours, these tumours retained the morphology and
phenotype of the original biopsies and expression of the CD23 and CD43
antigens was not seen here (except when these antigens were expressed in
the original biopsies) - further evidence that expression of these antigens is
induced by the EBV. Therefore, EBV does not play a part in these tumours
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and it appears that they are not merely EBV-induced lymphoproliferations
but are derived from the neoplastic cells in the original biopsies.
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Chapter Six
Immunoglobulin Status of the Original
Biopsies and SCID Tumours
The immunoglobulin (Ig) expression, as determined by
immunocytochemistry, of the SCID tumours was investigated to determine
how this compared to the original biopsy, and to determine the clonality of
the SCID tumours. Clonality was also investigated using Ig gene
rearrangement analysis. These techniques were used to compare clonal
populations present in the original and SCID tumours to determine whether
or not the SCID tumours were derived from the malignant clone in the
original biopsy. Because of the involvement of the Epstein-Barr virus in a
proportion of these SCID tumours, Ig secretion - a feature of EBV-
immortalised B cells - was investigated.
6.1 Immunoglobulin Expression
HP Biopsies
The RS/H cells in each of the original HD biopsies were found to show
diffuse cytoplasmic staining of polytypic immunoglobulin (Ig), always both
kappa and lambda light chain staining was seen in each case. Therefore,
this is shown in Table 6.1 simply as non-specific absorption.
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The Ig staining pattern observed in the NHL biopsies and the SCID tumours
was usually dense cytoplasmic and membrane staining with some granular
golgi and peri-nuclear clustering indicative of specific Ig synthesis.
Interpretation of the Ig staining was carried out with caution as a lot of back¬
ground staining was seen in some cases because of the presence of inter¬
cellular Ig 'sticking' non-specifically to surrounding cells or connective tissue.
HP-Derived SCID Tumours
Ig expression of the HD-derived SCID tumours is shown in Table 6.1. All of
the HD-derived SCID tumours expressed both heavy and light chain
immunoglobulin. These tumours were not monoclonal in nature, but there
appeared to be a marked predominance of a single heavy and a single light
chain indicating a dominant clone in most cases. The dominant heavy and
light chain comprised between 50-70% of the large immunoblasts and
plasmacytoid cells, with the sub-clones comprising 2-5% of the tumour cell
population - Figure 6.1 shows the.lg phenotype of SCID tumour A1.
The SCID tumour B1 showed a dominant clone of IgA.A, positive
tumour cells with a minor population expressing kappa. However, the
passaged B1 tumour (SCID tumour B2) only showed the growth of the
dominant clone lgA,X.
SCID tumours C1 and C2 did not show a predominance of a single Ig
heavy and light chain, however it was still possible to distinguish a higher
expression of IgM over IgG and lambda over kappa in the case of C1 and
kappa over lambda in the case of C2.
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Table 6.1 Immunoglobulin Expression of Original
Hodgkin's Disease Biopsies and SCID
Tumours Using Immunocvtochemical Analysis
CASE
<HD Biopsy SCID Tumours)














lgM,G,A.,k M>G / A.>k
lgG,k,A, (M,A) k>A,








Results in brackets indicate minor sub-populations
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Figure 6.1 Immunoglobulin Expression of SCID Tumour A1
This figure shows the dominant Ig heavy and light chain expression nature of the SCID
tumours - in this case IgG.x (M, X)- IgA was as the IgM and lambda.
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NHL Biopsies
The Ig expression of the tumour cells in the NHL biopsies is shown in Table
6.2. The tumour cell population in all of the NHL biopsies showed
monoclonal Ig expression. All cases showed both Ig heavy and light chain
expression except the LCAL which only expressed the IgA heavy chain,
showing no light chain expression.
NHL-Derived SCID Tumours
The Ig expression of the NHL-derived SCID tumours is shown in Table 6.2.
SCID tumour J1, like the HD-derived SCID tumours, was a polyclonal
tumour. However, again it showed a predominance of a single Ig heavy and
light chain - in this case IgG and Kappa expression with a sub-population of
IgM, A and lambda expressing cells - different from the original IgG,A,
follicular lymphoma (Case J).
In contrast, the SCID tumours derived from Cases F, G, H and I
showed monoclonal Ig expression identical to that seen in the original
biopsies. The Ig phenotype (lgM,K) was retained throughout the passages
of the SCID tumours derived from Case F.
The 2 sets of SCID tumours derived from the LCAL (Cases K and L)
again showed very different properties. The Ig expression of the 4 SCID
tumours derived from Case K (K1-K4) resembled that of the HD-derived
SCID tumours and SCID tumour J1. Again these were polyclonal tumours
but again showed a predominant expression of a single Ig heavy and light
chain. However, none of the 4 SCID tumours K1-K4 showed predominant
IgA expression like the original biopsy, although K4 contained an IgA-
expressing sub-population. SCID tumour K3 was the exception in that it only
showed expression of IgG and kappa.
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Table 6.2 Immunoglobulin Expression of Original
Non-Hodgkin's Lymphomas
Biopsies and SCID Tumours Using
Immunocvtochemical Analysis
CASE
(NHL Biopsy/SCID Tumours) ig ISOTYPE £
Case F - NHL Cb
SCID Tumours F1 - F14
lgM,k
all lgM,K






































Results in brackets indicate a minor sub-population
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igA
Figure 6.2 Immunoglobulin Expression of Original LCAL Biopsy
Case L and SCID Tumour
IgA expression is seen in the tumour cells of the original biopsy Case L (top) - this Ig
phenotype was retained in the SCID tumours L1, L2, L3 & L5. L2 is shown in the bottom
photograph. MagxIOO
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The 5 SCID tumours derived from Case L (L1-L5) all showed identical
Ig expression to that seen in the original biopsy (IgA) (Figure 6.2). However,
SCID tumour L1 also contained a sub-population of IgM.X, expressing cells.
In the case of L4, an lgM,K positive sub-population was also present
although more evident than the sub-population in L1. These cells were not
the large, anaplastic tumour cells seen in Case L and SCID tumours L1-L5
(they expressed IgA only), the positive cells were of the immunoblastic sub-
population found in L1 and L4.
6.2 Immunoglobulin Gene Rearrangements
Both PCR and Southern blotting were used for detection of Ig gene
rearrangements. This is because PCR only picks out around 80% of IgH
gene rearrangements so some are missed by this technique. Therefore,
southern blotting was carried out in these cases indicated in the text.
This was carried out by Alice Gallagher in the Department of Veterinary
Pathology in the University of Glasgow Veterinary School as part of our
collaborative study with Dr Ruth Jarrett.
The Ig gene rearrangement results for the HD and NHL original biopsies and
the resultant SCID tumours are presented in Tables 6.3 and 6.4.
HD Biopsies
No IgH gene rearrangements were detected in any of the original HD
biopsies by PCR. It was decided that there was no need to carry out
Southern blotting for IgH gene rearrangements on these cases since none
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Table 6.3 Immunoglobulin Gene Rearrangements in
the Original Hodgkin's Disease Biopsies and




Case A - LPHD No
SCID Tumour A1 IgR clonal
Case B - LPHD No
SCID Tumour B1 IgR clonal
SCID Tumour B2 NS -
Case C - LPHD No
SCID Tumour C1 IgR clonal
SCID Tumour C2 IgR clonal
C1 & C2 IgR different
Case D - NSHD No
SCID Tumour D1 IgR clonal
Case E - MCHD No
SCID Tumour E1 IgR clonal
KEY
IgR Immunoglobulin gene rearrangement was found
NS Not satisfactory (insufficient material or DNA degradation)
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Table 6.4 Immunoglobulin Gene Rearrangements in
the Original Non-Hodgkin's Lymphoma
Biopsies and SCID Tumours Detected by





Case F - NHL Cb






Case G - NHL Cb
SCID Tumour G1
clonal IgR
clonal IgR identical to original








Case I DNA degraded
(SB not done)
11 - clonal IgR with SB































All detected by SB
L1,L2 and L3 IgR all
identical to original
biopsy
L4 IgR different from
original biopsy
key
IgR Immunoglobulin gene rearrangement detected
NS not satisfactory (insufficient material or DNA degradation)
NC result not completed yet
SB southern blot analysis
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were detected by PCR even though the SCID tumours derived from these
cases all has detectable IgH rearrangements by this method.
HP-derived SCID Tumours
The material from SCID tumour B2 was found to be unsatisfactory for
genotyping.
A clonal IgH gene rearrangement was found in the remaining HD-
derived SCID tumours. The 2 primary SCID tumours derived from Case C
(LPHD) were found to exhibit different clonal IgH gene rearrangements.
NHL Biopsies
A clonal IgH gene rearrangement was detected in Cases F, G and H. In
Case I biopsy, no DNA was left for Southern blot analysis - PCR being
unable to detect an IgH gene rearrangement. In Case J, no IgH gene
rearrangement was detected by PCR, but Southern blotting was not carried
out as an IgH gene rearrangement was detected in the J1 SCID tumour by
PCR. There was insufficient material available from Case K for IgH gene
rearrangement studies, however a clonal IgH gene rearrangement was
detected in Case L using Southern blotting and all the SCID tumours (i.e.
from both K1 -K4 and L1 - L5) rearrangement analysis was compared to this
since Case K and Case L are sequential biopsies from the same patient.
NHL-derived SCID Tumours
An identical clonal IgH gene rearrangement was detected in all of the F1 -
F14 SCID tumours and this rearrangement was identical to that present in
the original Case F biopsy. This was also seen in SCID tumour G1, in which
the clonal IgH gene rearrangement detected was identical to that present in
the original Case G biopsy.
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Unfortunately, the DNA from SCID tumour H1 was not suitable for any
genotypic analysis, therefore comparisons of IgH rearrangements between
this SCID tumour and the original Case H biopsy were not possible.
No Ig rearrangement was detected in SCID tumour 11 by PCR, but a
clonal IgH gene rearrangement was detected using Southern blotting. A
clonal IgH gene rearrangement was detected in SCID tumour J1 by PCR.
Clonal IgH gene rearrangements were detected in SCID tumours K1,
K2 and K3 (K4 result is not available at the moment) by PCR, but these were
all different rearrangements and different from that detected in the original
biopsy. However, the clonal IgH gene rearrangements detected in SCID
tumours L1, L2 and L3 were identical and identical to that present in the
original biopsy. However, the clonal IgH gene rearrangement detected in
SCID tumour L4 was not the same as that in the original biopsy.
Unfortunately, the DNA available from SCID tumour L5 was insufficient for
Southern blotting analysis.
6.3 SCID Tumour Immunoglobulin Secretion
The aim of investigating the Ig secretion was not to quantitate the amount of
Ig secreted by the SCID tumours, but to determine if there was a link
between the EBV status of the SCID tumours and Ig secretion (a feature of
EBV-immortalised B cells). Therefore, this was not carried out in a
quantitative manner, although the separate Ig isotypes were looked at for
each Ig secretor case.
Blood was taken from every SCID mouse at the post-mortem
examination, whether or not they were tumour-bearing mice. Each was
tested for the presence of human Ig and murine Ig (to check if they were
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'leaky'). No tumour-free mouse exhibited any trace of human Ig in their
serum. However, of these non-tumour mice, 6% were found to contain
murine Ig in their serum, although always of a much lower level than that
found in normal mouse serum.
HP-Derived SCID Tumours
All 7 of the HD-derived SCID tumours showed secretion of human Ig. The
OD readings are given in Table 6.5. The readings shown are those obtained
after subtracting the back-ground reading given with normal SCID serum
(NSS). In column 7, the OD results are presented in a semi-quantitative way
as a means of summary of the OD readings. This matches the way that the
Ig expression (by immunohistochemistry) results were presented, with the
results in brackets indicating 'slight' secretion. It should be noted that each
tumour secreted very different levels of Ig, and what OD result may appear
as slight secretion for one tumour, may appear as one of the main Ig
isotypes secreted in another. For example, an IgA OD reading of 0.093 is
classed as slight secretion in SCID tumour A1, but a kappa OD reading of
0.091 is one of the main Ig isotypes secreted in SCID tumour E1 because of
the over-all lower Ig secretion in that tumour. Therefore, the Ig secretion
'summary' results given in column 7 cannot really be compared between
different SCID tumours. The reason for different over-all levels of Ig
secretion could be a consequence of different-sized SCID tumours - it is
interesting to note that SCID tumours B1 and B2 (passage of B1) secrete
identical main Ig isotypes, but B2 in much smaller quantities - this B2 SCID
tumour was much smaller than B1, so small it was inadequate for further
passage. Also, SCID tumours C1 and C2 were bigger than the other HD-
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Table 6.5 Optical Density Readings of Immunoglobulin
Secretion from SCID Tumours
SAMPLE CO READING AT 490nm MINUS BACK-GROUND (NSS OD}











































SCID Tumour D1 0.288 0.207 -0.002 0.068 0.403 lgG,A,,M (k)
SCID Tumour E1 0.041 0.082 0.013 0.091 0.043 lgM,k (G,A,)






















SCID Tumour L4 0.030 0.137 0.002 0.060 0.007 igM (k)
key
NSS Normal SCID Serum
NHS Normal Human Serum
Results in brackets indicate minor isotypes
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Table 6.6 Immunoglobulin Expression and Secretion
of SCID Tumours - Correlation with EBV Status
SCID EBV lg ISOTYPE 1'I fg ISOTYPE
TUMOUR STATUS EXPRESSION SECRETION (ELJSA]
r A1 POS lgG,k (M,A,A) lgG,k,M (A,A)
B1 POS IgA,A (k) IgA,A.
B2 POS IgA,A IgA,A
C1 POS lgM,G,A,k lgM,G,A,k
C2 POS lgG,k,A (M,A) lgG,A,M
D1 POS IgG,A (M,k) lgG,A,M (k)
E1 POS lgM,k (G,A) lgM,k (G,A)
F1 - F14 ALL NEG ALL lgM,k NON-SECRETORS
G1 NEG lgM,k NON-SECRETOR
H1 NEG igG,A NON-SECRETOR
11 NEG igG,k igG
J1 POS lgG,k (M,A,A) NO BLOOD
K1 POS IgG,A (M) IgG,A (M)
K2 POS lgM,A (G,k) lgM,A,G
K3 POS igG,k lgG,k,A
K4 POS lgM,k,A (G,A) NO BLOOD
L1 EBER(lmp/ebna-2) IgA (M,A) NON-SECRETOR
L2 EBER igA NON-SECRETOR
L3 EBER IgA NON-SECRETOR
L4 EBER(lmp/enba-2) igA (M,k) igM (k)
L5 EBER IgA NON-SECRETOR
Results in brackets indicate minor sub-populations or isotypes
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derived SCID tumours and these SCID tumours both secrete more Ig as a
whole.
However, as Table 6.6 shows, the specific Ig isotypes secreted by
each SCID tumour can be compared to the specific Ig isotypes expressed by
the tumour cells as determined by immunohistochemistry, and these
correlate very well. The dominant heavy and light chain present in each HD-
derived SCID tumour were also the dominant isotypes secreted in each
case, although in some cases (SCID tumours A1 and D1) one of the Ig
chains only found in a minor population was secreted in almost equal
quantities to that of the predominant Ig isotypes, and in another case (SCID
tumour C2) one of the dominant isotypes present was not secreted (kappa).
NHL-Derived SCID Tumours
The SCID tumours derived from Cases F, G and H did not show any Ig
secretion. No blood was available for Case J. Ig secretion was seen in
SCID tumours 11, K1, K2, K3 (no blood was available for K4) and from L4.
The OD results for these tumours are given in Table 6.5 - the results are
presented as for the HD-derived SCID tumours. Again, as can be seen from
Table 6.6, the specific Ig isotypes secreted by the SCID tumours correlate
very well to the Ig isotypes expressed as determined by
immunohistochemistry.
As can be seen from Table 6.6, all of the EBV (EBER, LMP, EBNA-2)
positive SCID tumours showed secretion of Ig. The EBER positive only
SCID tumours (L2, L3 and L5) were all non-secretors as was L1 which has
only a sub-population of LMP/EBNA-2 positive cells. SCID tumour L4, in
158
which focal LMP/EBNA-2 positive expression was seen, showed secretion of
Ig. These LMP/EBNA-2 positive cells seen within SCID tumour L4 were the
IgM.K positve immunoblasts, and it was only this isotype of Ig that was
secreted - the IgA isotype seen in the large anaplastic cells also present in
this tumour was not secreted.
None of the EBV negative SCID tumours secreted Ig except SCID
tumour 11 which secreted some IgG.
6.4 Comment
Although Ig light chain restriction has been reported in LPHD (Schmid et al
1991a, Momose et al 1992), all of the original HD biopsies here showed non¬
specific poly-typic Ig staining, presumably via endocytosis of exogenous
immunoglobulin. Therefore the malignant RS/H cells in the original biopsies
did not appear to be show specific expression of any Ig heavy or light chain.
However, all 7 of the HD-derived SCID tumours did show expression of both
heavy and light chain Ig, therefore not retaining the phenotype of the original
biopsies. None of the HD-derived SCID tumours were monoclonal in nature
using immunohistochemical analysis, although in each case a predominance
of a single heavy and light chain was seen. This would appear to indicate
that these SCID tumours are comprised of a dominant clone and indeed,
passage seemed to favour the growth selection of this clone - SCID tumour
B2 (the passaged B1) was comprised only of the IgA.X, dominant clone seen
in SCID tumour B1. This 'dominant clone' nature was confirmed by the
genotypic analysis of these SCID tumours - all 7 of the HD-derived SCID
tumours showed clonal IgH gene rearrangements, although this method was
perhaps not sensitive enough to detect the sub-clones present in each case.
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Unfortunately, no IgH gene rearrangements were detectable in any of the
HD biopsies, therefore comparison of Ig clonality was not possible.
Therefore, no definite conclusions can be drawn from the Ig analysis alone
on whether or not the dominant clone present in the HD-derived SCID
tumours is derived from the malignant clone in the original HD biopsy,
although the differences in Ig expression between the original biopsies and
the SCID tumours detected by immunohistochemical analysis and the EBV
positive nature of these SCID tumours makes this highly unlikely.
It appears that a single dominant EBV-transformed B cell clone is
present in each HD-derived SCID tumour - this has also been described in
the EBV positive SCID tumours derived from innoculation of PBL from EBV
sero-positive donors and in similar EBV-induced lymphoproliferative disease
in SCID mice (Rowe et al 1991, Nakamine et al 1993). These monoclonal
EBV positive SCID tumours were found to contain the normal diploid DNA
content and to exhibit no abnormal chromosomal translocations (Rowe et al
1991). Therefore, it appears that the 'dominant clone' nature of these HD-
derived SCID tumours is not suggestive of malignant transformation, but a
selection of a dominant EBV positive B cell clone based on growth rate. It is
well known that even during EBV-induced B cell immortalisation of
lymphoblastoid cell lines (LCL) in vitro , where there is no obvious selection
except on the basis of growth rate, the original polyclonal LCL can soon be
dominated by one or a few clones with serial passage in culture (Bechet et al
1974).
Further evidence that these SCID tumours were not derived from the
malignant clone in the original HD biopsy is that the 2 primary SCID tumours
derived from Case C LPHD showed different clonal IgH gene
rearrangements from each other.
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A similar pattern was observed in the other EBV (EBER/LMP/EBNA-2)
positive SCID tumours (J1, K1, K2, K3, K4), each expressing a dominant
single heavy and light Ig chain. Again, in these cases, comparison of Ig
expression detected by immunocytochemical analysis, demonstrated that the
dominant clone present in these J1, K1, K2, K3 and K4 SCID tumours did
not match that of the original biopsies. IgH gene rearrangement analysis
supports this in Case J - a rearrangement not being detected here by PCR
but detectable in the SCID tumour J1. This suggests that the rearrangement
in the original Case J was one of the 20% not picked up by PCR, the fact
that a rearrangement was picked up in the SCID tumour J1 by PCR indicates
that the rearrangement in the SCID tumour is not identical to that in the
original biopsy. Although DNA analysis is not yet complete for K4, IgH gene
rearrangement analysis of K1, K2 and K3 showed that these SCID tumours
all had different IgH gene rearrangements from their original biopsies,
demonstrating that these SCID tumours are not derived from the malignant
clone in the original biopsies and the 'dominant clone' nature of these SCID
tumours is as for the HD-derived SCID tumours.
However, the set of 5 SCID tumours derived from Case L - LCAL
displayed different Ig characteristics to that of the 4 Case K-derived SCID
tumours. Case L (and previous biopsy Case K) was unusual in that it only
expressed the a heavy chain with no light chain expression, a consequence
of neoplasia. This isolated heavy chain expression, although rare, has been
noted in NHL before (Gorden 1984) and may be caused by a defect in ability
to carry out light chain gene rearrangements, or rearrangements on all light
chain alleles may have occurred but none were productive.
SCID tumours L1, L3 and L5 all showed identical Ig expression to the
original biopsy, retaining this isolated IgA expression of the large anaplastic
cells, and the genotypic analysis from L1 and L3 confirmed that these SCID
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tumours contained an identical IgH gene rearrangement to the original
biopsy (unfortunately the L5 SCID tumour sample was inadequate for DNA
analysis). This confirms the EBV clonality results, demonstrating that these
SCID tumours are derived from the malignant clone in the original biopsy.
SCID tumour L1, although the majority population of large anaplastic
cells present showed identical Ig expression to the original biopsy, the
LMP/EBNA-2 positive minority sub-population of immunoblastic cells were
evidenced by IgM.X, expression. However, as with the EBV clonality
analysis, this sub-population was dismissable as the Ig analysis
demonstrated that this SCID tumour also showed an identical IgH gene
rearrangement to that seen in the original biopsy.
The SCID tumour L4, using immunohistochemical analysis, appeared
to be a 'mixture' of IgA expressing large anaplastic cells as the tumour cells
in the original biopsy and IgM.x expressing immunoblastic cells - the
LMP/EBNA-2 positive population present in this SCID tumour. The Ig
rearrangement analysis also confirmed the EBV clonality analysis on this L4
SCID tumour - the IgH gene rearrangement found in L4 was different to that
found in the original biopsy, indicating that this SCID tumour was not derived
from the malignant clone in the original biopsy. Perhaps the IgH
rearrangement present in this SCID tumour was that of the lgM,K expressing
immunoblast cell population. This result again seems unusual since it
appeared morphologically and phenotypically that the major cell population
present in this SCID tumour was the IgA expressing large anaplastic cells
identical to those present in the original biopsy. However, both the EBV
clonality and the IgH gene rearrangement analyses lead to the conclusion
that this SCID tumour cannot be said to represent the original LCAL biopsy.
In the remaining NHL cases - Cases F, G, H and I -
immunohistochemical analysis demonstrated that the SCID tumours all
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showed an identical monoclonal Ig phenotype to that of the original biopsies.
All of the original biopsies, as expected, showed monoclonal Ig expression -
lgM,K (cases F and G), IgG.X (Case H) and lgG,K (Case I). This Ig
expression is in keeping with the pattern observed for follicle centre cell-
derived NHL - although IgM is found to be the predominant isotype
expressed among all histologic types of NHL, there is a high expression of
IgG among follicle centre cell-derived lymphomas (Case J was also lgG,X).
IgG has also been reported to be the predominant isotype in immunoblastic
lymphoma (Gorden 1984).
Each SCID tumour retained the Ig isotype of their original biopsy, and
the lgM,K phenotype was retained throughout the passage of Case F SCID
tumours. This is consistent with these SCID tumours being derived from the
malignant clone in their original biopsies. Indeed, in cases F and G, an
identical clonal IgH gene rearrangement was found in the original biopsy and
the resultant SCID tumours, this clonal rearrangement being identical
throughout the passages of the Case F SCID tumours demonstrating that
this malignant clone is maintained successfully through passage of the SCID
tumour. Therefore, this confirms the Ig expression analysis, and there is
definite evidence that these SCID tumours are representative of the
neoplastic clone present in the original biopsies. Unfortunately, IgH gene
rearrangement analysis was not available to confirm the Ig expression
results of SCID tumour H1. An IgH gene rearrangement was not detected
either in Case I or SCID tumour 11 by PCR. Unfortunately Southern blot
analysis could not be carried out on Case I because of DNA degradation, but
a clonal IgH rearrangement was found in SCID tumour 11 by Southern blot
analysis. Although a direct comparison is not possible, the fact that neither
the original biopsy nor the SCID tumour showed an IgH gene rearrangement
on PCR suggests that the 2 rearrangements were both in the 20% not picked
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up by PCR. This is supportive of an identical rearrangement in the original
biopsy and SCID tumour - unfortunately however this cannot be proven.
Ig secretion is characteristic of EBV-immortalised non-neoplastic B
cells. Cells recently immortalised by EBV secrete Ig (reviewed by Nilsson
and Klein 1982)) and this was also found in the EBV positive SCID tumours
derived from innoculation with PBL from EBV sero-positive donors. These
mice had detectable mono, oligo or polyclonal Ig in their sera (Nadal et al
1992, Purtillo et al 1992, Veronese et al 1994). These SCID tumours are
obviously derived from proliferation of EBV-transformed normal B cells
present in the innoculate, allowed to grow in the immuno-deficient host.
Since it was suspected that our EBV (EBER/LMP/EBNA-2) positive SCID
tumours - all 7 HD-derived, J1, K1, K2, K3 and K4 SCID tumours - could be
derived simply from proliferation of EBV positive bystander B cells, one
would expect those SCID tumours to show secretion of Ig as a feature of
EBV-immortalised normal B cells, and the Ig secretion results confirmed this
hypothesis. As stated before, the EBV status of the SCID tumours fell into 3
main groups:- a non-restrictive Latency Type III EBV pattern of infection
(EBER/LMP/EBNA-2 positive) including all 7 of the HD-derived SCID
tumours and NHL-derived SCID tumours J1, K1, K2, K3 and K4; a restricted
Latency Type I EBV pattern of infection (EBER positive only) including Case
L-derived SCID tumours; and EBV negative including cases F, G, H and I-
derived SCID tumours. Using these groups, the Ig secretion analysis
showed an interesting pattern.
Although no blood was available for SCID tumours J1 and K4, all the other
EBV (EBER/LMP/EBNA-2) positive SCID tumours showed Ig secretion, thus
showing features of EBV-transformed normal B cells. The Ig isotypes
secreted correlated very well to the Ig isotypes expressed by the tumour
cells, corresponding to in each case an EBV-transformed dominant B cell
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clone secreting its immunoglobulin, the major Ig isotypes secreted being of
this clone because of its predominance in the SCID tumour, with the other
EBV-transformed B cell sub-clones also secreting their Ig, these being of a
lower secretion because they are minor clones within the SCID tumour.
The EBER positive only SCID tumours (Case L-derived SCID
tumours) however, did not secrete Ig. The characteristics of this restricted
EBV pattern of infection are demonstrated here - this Latency I EBV
phenotype is also seen in BL cell lines which retain the malignant phenotype
of the original biopsy, they also do not secrete Ig (only under exceptional
circumstances). EBV clonality analysis and IgH gene rearrangement studies
are consistent with these SCID tumours being derived from the malignant
clone in the original biopsy and they are not showing features of EBV-
transformed normal B cells, but retaining the malignant EBV phenotype of
the original LCAL biopsy. The 'mixed' EBV phenotype of SCID tumour L4 is
shown very neatly here, with 'mixed' characteristics of the 2 EBV phenotypes
present - the EBER positive IgA-expressing, large anaplastic cells present
do not secrete their Ig, only the EBV-transformed, EBER/LMP/EBNA-2
positive lgM,K -expressing immunoblasts are induced to secrete their Ig.
Again it is demonstrated here that the LMP/EBNA-2 positive immunoblasts
present in SCID tumour L1 are in such a minority as to be considered
dismissable, since no Ig secretion is seen in the SCID tumour.
Further evidence that the Ig secretion is linked to EBV is the fact that
none of the EBV negative SCID tumours secreted Ig. The exception was
SCID tumour 11, however this only secreted a low level of IgG - the O.D.
reading of 0.075 was much lower than the O.D. results of the major isotypes
secreted by the other SCID tumours. This was except for SCID tumour K3,
but this SCID tumour was much smaller than 11 and would be expected to
secrete less Ig because of its small size - 11 was a bigger SCID tumour and
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therefore it secreted comparatively less Ig. However, 11 was derived from an
immunoblastic lymphoma, which are known to secrete high levels of Ig,
possibly a reflection of an intermediate cell type developing toward Ig-
secreting plasma cells - plasmacytoid cells can be common in immunoblastic
lymphomas (Stansfeld 1992b). Indeed, it was noted that in the 11 SCID
tumour, although morphologically resembling the original biopsy very
closely, the immunoblasts showed more abundant cytoplasm i.e. more
plasmacytoid differentiation. Therefore, this Ig secretion in SCID tumour 11
seemed to be simply a reflection of its phenotype.
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Chapter Seven
DNA Ploidy of Original Biopsies and
SCID Tumours
Because of the involvement of the Epstein-Barr virus in a proportion of these
SCID tumours, DNA ploidy was carried out to determine whether the SCID
tumours were aneuploid as seen in malignant cells or had the normal diploid
DNA content, seen in EBV-transformed normal B cells.
7.1 DNA Ploidy of the Original Biopsies and SCID
Tumours
HP Biopsies
Aneuploidy was not detected in any of the 5 HD biopsies. A clear single
diploid G0/G1 DNA peak was detected in each case, with a small diploid G2-
M peak (G2-M cell population range was 0.2 - 4.8%). All DNA indices were
1 (Table 7.1) (Figure 7.1).
HP-Derived SCID Tumours
The results of the DNA ploidy are shown in Table 7.1. All 7 of these SCID
tumours were found to contain the normal diploid DNA content - one diploid
G0/G1 DNA peak and a small G2-M peak was seen. G2-M cell populations
ranged from 0.4 -12.2% and all had a DNA Index of 1 (Figure 7.1).
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Table 7.1 DNA Ploidv of Original Hodqkin's Disease Biopsies



























































Figure 7.1 DNA Ploidv of Original Hodqkin's Disease Biopsy
and SCID Tumour
Graph 1 Original HD biopsy Case C LPHD showing DNA diploidy






Aneuploidy was not detected in any of the NHL biopsies (G2-M cell
populations ranged from 0.6 - 11.9%) apart from Case F centroblastic
lymphoma which, with a DNA Index of 2.05 and a G2-M cell population of
19%, appeared to be tetraploid (Table 7.2)(Figure 7.2).
NHL-Derived SCID Tumours
The DNA ploidy results are given in Table 7.2. SCID tumour J1 contained
the normal diploid DNA content, with a G2-M cell population of 2.0 and a
DNA Index of 1.
The SCID tumours derived from Cases F, G, H and I were all
aneuploid. SCID tumour 11 was aneuploid, an extra aneuploid DNA peak
being present in addition to the normal diploid DNA G0/G1 and G2/M peaks.
The cell population in this aneuploid G0/G1 was 81%, the DNA Index being
1.21 (Figure 7.2). A small aneuploid G2-M DNA peak was also seen.
The remaining SCID tumours derived from Cases F, G and H showed
tetraploid aneuploidy with DNA indices ranging from 1.98 - 2.16, and all
having more than 15% of the total cell population in G2-M (Kallioniemi et al
1988). In most cases, a small normal diploid DNA peak, a very large
tetraploid G0/G1 peak (masking the diploid G2-M) and a clear tetraploid G2-
M peak were seen.
The SCID tumours derived from Case F were all tetraploid. A large
tetraploid G0/G1 peak with a clear tetraploid G2-M DNA peak was seen in
each case (Figure 7.2). The full list of F SCID tumour's G2-M cell
populations (entered in Table 7.2 as a mean result) are as follows
F1 =55.1 %, F2=46.1%, F3=55.3%, F4=58.1%, F5=46.1%, F6=50.1%,
F7=51.7%, F8=54.9%, F9=48.2%, F10=38.9%, F11=69.2%, F12=63.9%,
F13=47.2%. DNA ploidy analysis was not carried out on F14.
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Table 7.2 DNA Ploidv of the Original Non-Hodqkin's
Lymphoma Biopsies and SCID Tumours







Case F - NHL Cb 19.0 2.05 TETRAPLOID
SCID Tumours F1 - F14 Mean - 52.6 Mean - 2.08 ALL TETRAPLOID
SCID Tumour F5 46.1 0.59/2.05 HYPODIPLOID/
TETRAPLOID
Case G - NHL Cb 2.4 1 DIPLOID
SCID Tumour G1 28.3 1.99 TETRAPLOID
Case H - NHL Cb 0.6 1 DIPLOID
SCID Tumour H1 16.0 1.98 TETRAPLOID
Case I - NHL ImmB 2.2 1 DIPLOID
SCID Tumour 11 #81 1.21 ANEUPLOID
Case J - NHL Cb/Cc Foil 5.5 1 DIPLOID
SCID Tumour J1 2.0 1 DIPLOID
Case K - LCAL 11.9 1 DIPLOID
SCID Tumour K1 3.3 1 DIPLOID
SCID Tumour K2 6.3 1 DIPLOID
SCID Tumour K3 NM - -
SCID Tumour K4 8.3 1 DIPLOID
Case L - LCAL 3.0 1 DIPLOID
SCID Tumour L1 19.8 2.03 TETRAPLOID
SCID Tumour L2 78.2 2.11 TETRAPLOID
SCID Tumour L3 84.4 2.15 TETRAPLOID
SCID Tumour L4 80.2 2.16 TETRAPLOID
SCID Tumour L5 78.4 2.16 TETRAPLOID
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SCID tumour F5 was unusual in that it showed both hypodiploid (DNA
Index of 0.59) and tetraploid (DNA Index of 2.05) cell populations. A large
hypodiploid G0/G1 DNA peak, a normal diploid G0/G1 DNA peak, a
hypodiploid G2-M DNA peak, a large tetraploid G0/G1 DNA peak (masking
the diploid G2-M DNA peak) and a tetraploid G2-M DNA peak were all seen
(Figure 7.2).
SCID tumour G1 was also tetraploid with a G2-M cell population of
28.3% and a DNA Index of 1.99, as was SCID tumour H1 with a G2-M cell
population of 16% and a DNA Index of 1.98.
The 2 sets of SCID tumours derived from the LCAL (Cases K and L)
again produced different results. The 4 SCID tumours derived from Case K
all appeared to contain the normal diploid DNA content, each displaying a
single diploid G0/G1 DNA peak with a small G2-M DNA peak (Figure 7.3).
The G2-M cell populations ranged from 3.3 - 8.3, all having a DNA Index of 1
(SCID tumour K3 could not be analysed for DNA ploidy because of the
insufficient material available).
In contrast, the 5 SCID tumours derived from Case L (L1 - L5) all
displayed tetraploid aneuploidy. SCID tumour L1 contained the lowest
tetraploid peak, but the remaining 4 each showed a huge tetraploid peak,
and a clear tetraploid G2-M peak was seen in each case(Figure 7.3).
As can be seen from Table 7.3, all of the EBV (EBER/LMP/EBNA-2) positive
SCID tumours were found to contain the normal diploid DNA content (SCID
tumours A1, B1, B2, C1, C2, D1, E1, J1 and K1-4). In contrast, the EBER
positive only SCID tumours (even those with sub-populations of LMP/EBNA-
2 positive cells - L1 & L4) and the EBV negative SCID tumours - F1-14, G1,
H1 and 11 were all aneuploid.
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Table 7.3 DNA Ploidv of SCID Tumours - Correlation
With EBV Status
SCID






























































































Aneuploidy was not detected in any of the original HD biopsies in this study.
This is perhaps not surprising because of the scarcity of the neoplastic RS/H
cells amongst the normal diploid reactive cellular infiltrate. Aneuploidy has
been detected in HD (Morgen et al 1988), being more common in the NS,
MC and LD sub-types, possibly because of the higher numbers of RS/H cells
present in these sub-types. Over-all however, only 11% (13/115 cases)
showed aneuploidy in the Morgen et al study. This was also found by
Joensuu et al (1988) who detected DNA aneuploidy by flow cytometric
analysis in 11% (8/70) of their HD cases. In a study by Anastasi et al
(1987), DNA aneuploidy was only found in 1 of the 15 cases of HD studied
by flow cytometric DNA analysis alone, but evidence of DNA aneuploidy was
considered to be present in all 15 cases if a combined analysis of DNA
content and nucleolar antigens was performed. This technique was also
used by Erdkamp et al (1994), who detected DNA aneuploidy in 49%
(67/137) of HD cases studied.
Aneuploidy was detected in only one of the original NHL biopsies in
this study - Case F NHL Cb (tetraploid).
Karyotyping has been found to show chromosomal abnormalities in
between 75-95% of NHL cases. The most common abnormality in NHL
appears to be near-diploid chromosomal numbers i.e. 44-49. It has been
estimated that an increase or decrease in nuclear DNA has to be 5% before
detectable by flow cytometric analysis, therefore near-diploid aneuploidy
may not be picked up (Woolridge et al 1988). In another study, only 19% of
NHL cases were found to be aneuploid by flow cytometry (cytogenetic
analysis showed that 92% of these cases had chromosomal abnormalities),
however all specimens shown to have a chromosome number exceeding 50
by karyotypic analysis were DNA aneuploid by flow cytometric analysis
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(Lakkala et al 1990). Therefore, it appears that flow cytometry may be a
rather course method, only detecting aneuploidy when there is a major
increase in chromosome number.
Therefore, it is possible that the original NHL biopsies showed a near-
diploid aneuploidy which was not picked up by the flow cytometer. However,
this would seem especially unlikely in the LCAL biopsies (Cases K and L), a
high chromosome number being characteristic of large cell lymphomas
(Levine et al 1985). However, in a study of DNA ploidy analysis of LCAL
cases using the flow cytometer, aneuploidy was not detected in any case
and there was found to be no association between tumour histologic
characteristics and detection of DNA aneuploidy (Lakkala et al 1990).
Therefore, it is possible that near-diploid and even tetraploid
aneuploidy was present in the original NHL biopsies in this study and not
picked up by the flow cytometric analysis.
Normal non-neoplastic B cells, infected by EBV, retain their normal
diploid DNA content. Chromosomal analysis has been carried out on
hundreds of recently established LCLs, and without exception they had a
normal diploid karyotype (Nilsson and Klein 1982). Therefore, it can be
concluded that the EBV infection of a B cell, although conferring to the cell
one neoplastic feature (immortality), is not followed by any chromosomal
alteration whatsoever. The EBV positive SCID lymphomas derived from
innoculation of PBL from EBV sero-positive donors, were also all found to
contain the normal diploid DNA content (Cannon et al 1990, Nakamine et al
1991, Rowe et al 1991, Mosier et al 1992, Nadal et al 1992, Purtillo et al
1992, Veronese et al 1994). These SCID tumours are obviously derived
from proliferation of EBV-transformed normal B cells present in the
innoculate allowed to grow in the immune-deficient host, and it was
suspected that our EBV positive (EBER/LMP/EBNA-2) SCID tumours may
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simply be derived from EBV-transformed bystander B cells, and the DNA
ploidy results confirmed this hypothesis. The results showed that DNA
ploidy can be linked very well to the EBV status of the SCID tumours, by
grouping the SCID tumours into the 3 EBV status phenotypes - Latency III
EBV (EBER/LMP/EBNA-2) positive, Latency I EBER only positive and EBV
negative - a characteristic pattern emerged.
All 7 of the HD-derived and Cases J and K-derived SCID tumours
contained the normal diploid DNA content. This is in keeping with their non-
restrictive Latency III EBV phenotype, showing characteristics of EBV-
transformed normal B cells, indicative of their non-neoplastic origin. It could
be argued that near-diploid aneuploidy could have been missed by the flow
cytometric analysis, but this is unlikely owing to their EBV status and also, 2
cases that were analysed cytogenetically showed that a normal diploid 46
XY karyotype was present (data not shown).
In contrast, the restricted EBV phenotype (EBER positive only) SCID
tumours - L1-L5 - all showed tetraploid aneuploidy. A diploid DNA peak
was also seen in each case - this is probably existing diploid tumour cells, it
is unlikely to be normal reactive cells as no residual T cells or macrophages
were detected in any of the SCID tumours. The characteristics of this
restricted Latency I EBV pattern of infection are being displayed here. This
phenotype is also seen in BL cell lines which retain the malignant phenotype
of the original biopsy and are always aneuploid. These SCID tumours,
shown to be derived from the malignant clone in the original LCAL biopsy
are all showing aneuploidy. Again, these results confirm that the sub-
population of LMP/EBNA-2 positive immunoblastic cells present in SCID
tumour L1 are dismissable as this was found to be tetraploid. Even the SCID
tumour L4, with a more prominent population of LMP/EBNA-2 positive cells
was found to be tetraploid - this result confirms the morphological and
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phenotypic results but not the genotypic analysis. All 5 of the Case L-
derived SCID tumours displayed tetraploid aneuploidy even though this was
not detected in the original biopsy. There are 2 possible explanations for
this:- perhaps the original LCAL biopsy did display a near-diploid
aneuploidy (not picked up by the flow cytometer) and the SCID environment
(length of time growing in the SCID mouse and the lack of immune
intervention) has allowed tumour progression - it has been speculated that
doubling of the DNA content (i.e. tetraploidy) would be the first event in the
development of DNA aneuploidy (Mauro et al 1986) However, this may seem
unlikely because of the morphological appearance of the LCAL, the original
Case L biopsy could contain a small tetraploid population, this not being
picked up by the flow cytometer, but the SCID environment could have
allowed a growth advantage to this small tetraploid malignant clone. With
the purer population of tumour cells present in the SCID tumours, this
tetraploidy can now be picked up by the flow cytometer. It is interesting to
note that of the 2 LCAL biopsies, Case K contained the higher G2-M
population, indeed the highest of all the 'diploid' original biopsies (11.9%).
This may indicate that the tetraploid population in Case K (although too
small to be picked up by the flow cytometer) is more evident than in Case L
and it is unusual that Case K produced 4 non-related EBV-induced
lymphoproliferations, whilst the malignant clone present in Case L grew in
the resultant SCID tumours. Therefore, perhaps the size of the malignant
population present is not important for the growth of lymphomas in SCID
mice, and chance plays a part in whether EBV-induced lymphoproliferations
will dominate in these SCID tumours.
All of the EBV negative SCID tumours (F1-14, G1, H1, 11) displayed
aneuploidy. Therefore they are not displaying the same characteristics as
that of the EBV (EBER/LMP/EBNA-2) positive SCID tumours. This is again
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consistent with these SCID tumours being derived from a malignant clone in
the original biopsies as shown by the genotypic analysis.
Case F original biopsy displayed tetraploid aneuploidy and this
karyotype was retained throughout the SCID tumours. SCID tumour F5 was
interesting in that it displayed a hypodiploid and a tetraploid tumour cell
population. This may represent further tumour progression allowed by the
SCID environment - it is thought that an increase or decrease (as is here) of
chromosomal material in tumour cells with a tetraploid DNA content appears
to be related to a more pronounced anaplasia and enhanced malignant
potential (Kallioniemi et al 1988). It is unfortunate that this F5 SCID tumour
was not the one used for further passage.
SCID tumours G1, H1 and 11 were all aneuploid with G1 and H1 again
being tetraploid, and 11 displaying hyperdiploid aneuploidy (Dl of 1.21).
None of the original biopsies displayed aneuploidy and again the
explanation for this difference may be as that for SCID tumours L1-L5, the
SCID environment allowing a growth advantage of a small aneuploid
population present in the original biopsies. This theory is demonstrated by
the fact that the original Case F biopsy contained only a small tetraploid
peak, whereas the SCID tumours derived from this all showed much larger
tetraploid populations. The SCID environment allowing tumour progression
may be a feasible explanation and may explain the prevalence of tetraploid
aneuploidy amongst the SCID tumours - it was noted that morphologically,
although the EBV negative NHL-derived SCID tumours resembled the
original biopsies very closely, they did appear to show more nuclear
pleomorphism.
Therefore, the DNA ploidy results have demonstrated the
characteristics of the 3 different lymphoproliferations. It was shown that the
EBV(EBER/LMP/EBNA-2) positive SCID tumours contained the normal
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diploid DNA content, demonstrating that all of the HD-derived and Case J
and K-derived SCID tumours share characteristics of EBV-transformed
normal B cells and confirmed the hypothesis that they may be derived simply
from proliferation of EBV-transformed normal bystander B cells present in
the injected node. In contrast, the EBER positive only and the EBV negative
SCID tumours were all found to be aneuploid, confirming the genotypic
analysis that they are derived from the malignant clone in the original
biopsies.
However, flow cytometric analysis of DNA ploidy can be a rather
coarse method of detection of aneuploidy. Obviously, cytogenetic analysis
would resolve which DNA aneuploidy was exhibited by the original NHL
biopsies, if any. However, this is a time-consuming specialist technique, and
was only available for use with this study during the later stage. A viable cell
suspension is required for this technique, which was limiting especially from
early biopsies. This may still not resolve the karyotype of the HD biopsies,
as the neoplastic RS/H cells are so scarce and would be diluted by the
normal diploid reactive cellular infiltrate. However, this can be resolved
using the Highly Optimised Microscope Environment (HOME) - a
computerised microscope which, using an integrated image analysis system,
can be used to measure the DNA ploidy of individual cells. After an initial
set-up, ploidy measurements can be made quickly by pointing with the
mouse to the nucleus to be measured and pressing the mouse button. This
would allow the DNA ploidy of the individual RS/H cells to be measured, not
possible using flow cytometry (Gray et al 1994, Salto-Tellez et al 1994).
Indeed, initial results have shown that the RS/H cells do exhibit aneuploidy
(Krajewski - unpublished results). Unfortunately, this system was not




Although many phenotypic and genotypic studies have been carried out, the
histogenesis of the RS cell remains unknown. In order to investigate the
histogenesis of the RS cell and Hodgkin's disease, this thesis attempted to
establish a SCID mouse model to study the disease, and to investigate
whether non-Hodgkin's lymphomas could successfully be transplanted into
SCID mice.
This thesis has shown that transplantation of both Hodgkin's disease
and non-Hodgkin's lymphomas into SCID mice results in the growth of high
grade human B cell lymphomas. It was established that the Epstein-Barr
virus had a role in a proportion of these SCID tumours. 3 main types of
lymphoproliferations were obtained - EBV (EBER, LMP, EBNA-2) positive
SCID tumours expressing a non-restricted EBV latency III phenotype, EBER
positive only SCID tumours expressing a restricted EBV latency I phenotype
and EBV negative SCID tumours. The EBV positive SCID tumours arose
from both EBV positive and EBV negative original biopsies. These SCID
tumours were thoroughly characterised to determine whether or not they
were derived from the malignant clone in the original biopsy and thus
whether they represented a good in vivo model for Hodgkin's disease or non-
Hodgkin's lymphomas.
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The SCID Mouse Model of Hodqkin's Disease - Overview and
Conclusions
All 7 of the HD-derived SCID tumours displayed a non-restricted latency III
EBV pattern of expression - all EBER, LMP and EBNA-2 positive. This is not
the EBV latency pattern seen in RS/H cells in HD, indeed only one of the
original HD biopsies in this study contained EBV positive RS/H cells (Case
E) and terminal repeat analysis demonstrated that this EBV positive clone of
the original biopsy was not present in the SCID tumour. On this evidence
alone, it would appear unlikely that these SCID tumours are derived from the
neoplastic RS/H clone of the original biopsies. It is well documented that
innoculation of SCID mice with PBL from EBV sero-positive donors will
produce B cell lymphoproliferations in most cases (Cannon et al 1990,
Nakamine et al 1991, Rowe et al 1991, Mosier et al 1992, Nadal et al 1992,
Purtillo et al 1992, Veronese et al 1994). Therefore, it was a possibility that
these SCID tumours were simply derived from out-growth of EBV-
transformed bystander B cells present in the injected node, allowed to
proliferate in the immuno-deficient host, and extensive characterisation was
carried out to test this hypothesis.
Morphologically, the HD-derived SCID tumours resembled LCL, the
SCID tumours following injection of normal EBV positive PBL and the EBV
positive lymphomas seen in immunocompromised individuals, not RS/H cells
and the histological appearance of HD. Phenotypically, they possessed an
activated B cell phenotype with high expression of the EBV-associated
antigens CD23 and CD43 and furthermore displayed characteristics of EBV-
immortalised normal B cells in their diploid DNA content and Ig secretion.
Therefore, it was demonstrated that these SCID tumours derived from
injection of fresh HD biopsy material shared all the characteristics of EBV-
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immortalised normal B cells and were most probably simply derived from out¬
growth of EBV-transformed bystander B cells present in the injected lymph
node/spleen suspension, and this SCID mouse animal model is not a
satisfactory in vivo model for Hodgkin's disease. These SCID tumours did
express a predominant single immunoglobulin heavy and light chain and
showed a clonal IgH gene rearrangement by PCR, but monoclonal EBV
positive SCID tumours have been found in the PBL-derived SCID tumours
and in LCL (Rowe et al 1991, Nakamine et al 1993) and considering the
small number of EBV positive bystander B cells injected within the HD lymph
node, it is perhaps not surprising that only one dominant clone of EBV
positive B cells was seen.
During this thesis, another group carried out similar work. Kapp et al
(1993) grew human SCID tumours from 3/13 cases of fresh HD biopsy
material, a slightly lower success rate than this thesis, but in contrast to this
study, 100% tumour take was achieved in 2 cases (6/6 and 3/3) - perhaps
the mode of injection used in the Kapp study (sub-renal and intra-hepatic
implantation) was more suitable, although additional problems such as
inadequate tumour tissue for passage and 'passage' mice being killed by
infection were encountered in this thesis. The ip route of injection used in
this thesis also does not allow a proper study of metastasis, however the one
subcutaneous SCID tumour grown (E1) appeared to remain localised to the
site of injection, no spread to other tissues was seen.
In common with this thesis, all of the HD-derived SCID tumours
obtained in the Kapp study expressed EBER, LMP and EBNA-2, even
though 2 of the original HD biopsies were EBV negative. Kapp et al
described 3 distinct histological lesions in their SCID tumours - (i)
lymphoproliferative disease - lesions consisting of medium-sized B cells, B-
immunoblastic-like cells and cells with plasmacytoid features (ii) large cell
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anaplastic lymphomas (iii) HD-like lesions showing RS-like cells surrounded
by murine macrophages. The lymphoproliferative disease described by the
Kapp study resembles the polymorphous immunoblastic proliferations seen
in this thesis. None of our HD-derived SCID tumours showed lesions with
definite features of LCAL or were HD-like, but SCID tumours C1 and C2
showed some features of LCAL and areas of increased cellular
polymorphism could be seen in most cases. Occasional bi-nucleate or multi¬
nucleated RS-like cells were also found in each HD-derived SCID tumour.
Kapp et al hypothesised that because of the morphology of these LCAL
lesions and the RS/H-like cells in their so-called HD-like lesions, they were
likely to be derived from the RS/H cells in the original biopsies. However,
these cells, like the cells in their LPD lesions displayed a non-restricted
latency III EBV pattern of infection (EBER/LMP/EBNA-2 positive), not the
latency II EBV pattern of infection (EBER/LMP positive) seen in RS/H cells,
only one of the original biopsies being EBV positive in this Kapp study. Also,
RS/H-like cells have been found in the benign condition infectious
mononucleosis (Isaacson et al 1992), therefore perhaps this morphology
was EBV-induced, as with the high CD30 expression seen, not only seen in
their RS/H-like or LCAL-like cells but in 50-80% of the SCID tumour cell
population. Kapp et al did not carry out EBV clonality analysis to determine
whether the EBV positive clone in the only EBV positive original biopsy was
also present in the corresponding SCID tumour.
Kapp et al reported that their HD-derived SCID tumours showed a
high incidence of chromosomal abnormality, evidence that they were derived
from the malignant RS/H cells. However, of the karyotypes they reported,
some were diploid and others showed a near diploid chromosome number.
It is possible that near-diploid aneuploidy was missed in this thesis by the
flow cytometry analysis - abnormal mitoses could be seen in each SCID
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tumour, however 2 cases analysed cytogenetically showed a normal 46XY
karyotype (data not shown). Also, clonal chromosomal changes do occur in
the lymphomas arising in SCID mice innoculated with PBLs from normal EBV
sero-positive donors (Thangavelu et al 1992, Glaser et al 1993). Therefore,
it is possible that the chromosomal abnormalities detected by Kapp et al may
have arisen in normal cells spontaneously following transplantation into the
mice.
In this thesis, expression of the LMP and EBNA-2 was seen in only a
proportion of the tumour cells in the EBV (EBER/LMP/EBNA-2) positive
SCID tumours (LMP - 30-40%, EBNA-2 -10-20%). It has been noted before
that the EBV-transformed B cells in vivo (i.e. the EBV positive PBL-derived
SCID lymphomas) showed reduced EBV latent gene expression
(LMP/EBNA-2) compared to EBV-transformed B cells in vitro (LCL)
(Rochford & Mosier 1995). This is also shown when LCL are transplanted
into SCID mice (Rochford et al 1993). It is thought that this reduction in EBV
latent gene expression correlates with B cell differentiation in vivo as the
SCID tumour cells showed a plasmacytoid differentiation compared to the
lymphoblastoid phenotype of the in vitro LCL. This was also linked with lower
CD23 expression and higher Ig secretion in vivo (Rochford et al 1993).
This could explain the lower latent gene expression seen in the
EBV(EBER/LMP/EBNA-2) positive SCID tumours in this thesis as they did
show plasmacytoid differentiation and high Ig secretion, however they also
showed high CD23 expression. It is also possible that EBV has entered the
lytic cycle - recently Rochford & Mosier (1995) found correlation of lytic viral
gene expression with a more differentiated B cell phenotype (plasmacytoid
differentiation, high Ig secretion, low CD23 expression) in the EBV sero¬
positive donor PBL-derived SCID tumours. Rochford & Mosier (1995) have
proposed that the SCID environment allows proliferation of latently-infected
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B lymphoblasts which then differentiate to plasmacytoid cells with
reactivation of lytic cycle infection and release of new virus which infects
bystander B cells, some of which then proliferate as latently-infected
lymphoblasts - since most of these SCID tumours are oligoclonal, some
monoclonal, the rate of generation of secondary transformants must be low
(Rochford & Mosier 1995).
Lytic viral gene expression was not looked for in the EBV
(EBER/LMP/EBNA-2) positive SCID tumours in this thesis as it was not
central to the main objective of whether or not these EBV positive SCID
tumours were derived from the original HD or NHL clone. However, it is
feasible, and this could explain the lower latent gene expression in these
SCID tumours.
Also, it is not beyond all possibility that the HD-derived SCID tumours
obtained in this thesis did contain some RS/H cells grown from the original
biopsy. RS-like cells were seen in each HD-derived SCID tumour, but not in
the other EBV (EBER/LMP/EBNA-2) positive SCID tumours (J1, K1, K2, K3,
K4). It is possible that these RS cells were infected by EBV virus released
from the surrounding B cells in the SCID tumours.
However, the Latency II type of infection seen in the larger blasts and
the RS/H-like cells in the HD-derived SCID tumours (LMP+/EBNA-2
negative) cannot be taken as representing the Latency II pattern of
expression seen in RS cells of Hodgkin's disease, as Oudejans et al (1995)
recently found in post-transplant lymphomas, using combined EBER in situ
hybridisation and immunocytochemistry (including double-staining) to
investigate EBV expression at a single cell level, that cells expressing both
EBNA-2 and LMP were rarely detected. Although an overall Latency III
pattern was expressed, a mixture of at least 3 different cell populations were
identified - (I) EBER+/EBNA-1+, (II) EBER+/EBNA-1+/LMP+ and
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(Ill) EBER+/EBNA-1+/EBNA-2+ - ie a population of LMP+/EBNA-2 negative
cells were present here also. Therefore, the pattern of expression seen in
the HD-derived SCID tumours has also been found in post-transplant
lymphomas and may not be a consequence of the injection of RS cells or
their precursors. If the LMP+/EBNA-2 negative RS-like cells in the SCID
tumours were derived from injected RS cells, obviously these cells are the
absolute minority, completely out-numbered by the EBV positive
lymphoproliferation and as such would not represent an in vivo model for
HD. There can be no way to prove this however, and if further studies were
to be carried out, they would require cases of HD with clonotypic markers
such as clonal EBV, clonal Ig gene rearrangements or cytogenetic markers
to allow comparison with the SCID tumours. Obviously, it would be more
useful to include more cases of NS, MC and LD sub-types of HD since LPHD
is now widely accepted to be of B cell origin.
Recently, Shpitz et al (1994) established a SCID mouse model which
allowed improved engraftment of human lymphoid cells and tumours by pre-
treating the SCID mice with sub-lethal radiation and an anti-asialo-GM1
antibody to eliminate NK cell activity. However, it is possible that the SCID
mouse would never be a suitable model for HD - the histological picture of
HD is the scarce neoplastic RS/H cells amongst a significant reactive
lymphoid cellular infiltrate including B and T cells, eosinophils, neutrophils
and macrophages. Perhaps the growth of HD requires an intact, functioning
immune system with cell-cell and cytokine interactions between the RS/H
cells and the cellular infiltrate. Many cytokines have been detected in the
RS/H cells (Hsu et al 1986, Kretschmer et al 1990, Samoszuk & Nansen
1990, Jucker et al 1991, Merz et al 1991, Xerri et al 1992, Hsu et al 1993).
Expression of IL-6 and the IL-6 receptor have both been found in RS/H cells
(Jucker et al 1991) and it was suggested that this IL-6, either by an autocrine
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or paracrine (produced by back-ground CD4 positive T cells) loop may
stimulate the growth of the neoplastic RS/H cells. It would be ideal to inject
IL-6 into the SCID mice along with the HD biopsy material in the hope of
growth stimulation of the RS/H cells, however the problem being that this
would also stimulate growth of the EBV-transformed B cells (Nadal et al
1992).
It would be difficult to eliminate the EBV positive bystander B cells
present in the lymph node/spleen cell suspension prior to injection into the
SCID mice not only because of their small number, but because of the risk of
eliminating crucial cells such as RS/H cells or their precursors. Maybe the
injection of an anti-LMP antibody into the SCID mice would be a solution for
the growth of EBV negative HD cases. Alternatively, administration of the
anti-viral agent ganciclovir may inhibit the development of the EBV-induced
lymphoproliferations - this was shown to inhibit the EBV positive SCID
lymphomas derived from injection of PBL from EBV sero-positive donors
(Boyle et al 1992).
Therefore, the various phenotypic and genotypic studies carried out
on HD have allowed a detailed description of RS/H cell characteristics.
They express activation antigens, in some cases they express B cell-
associated and in others T cell-associated antigens. Genotypic analysis has
shown that they can exhibit Ig or TcR gene rearrangements, both or neither.
They exhibit chromosomal abnormalities but no unique and defining
aberration and can express a number of cytokines but again no unique
pattern is found. The Epstein-Barr virus is known to be associated in around
40-60% of cases - however, this does not imply that the RS/H cell is of B cell
origin as EBV has been found in T cell lymphomas (Weiss et al 1987, Staal
et al 1989, Hamilton-Dutoit et al 1992, Sabourin et al 1993) and to infect
epithelial cells in NPC (reviewed by Miller 1990). Therefore, these features
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do not offer a definitive nature or origin for the RS/H cell, at most they
describe a lymphoid cell.
The heterogeneous nature of HD suggests that it may be a syndrome
encompassing closely related but biologically distinct entities rather than a
single disease. As described earlier, the nodular LP sub-type of HD is
clearly a B cell variant of the disease. Recently, it was found that in cases of
LPHD with concurrent or subsequent B cell Large Cell Lymphoma, there was
a clonal relationship between the 2 diseases with the authors hypothesising
that the Large Cell Lymphoma represents a clonal progression of LPHD,
being part of a spectrum of B cell malignancy, with polyclonal Progressive
Transformation of Germinal Centres progressing to oligoclonal LPHD to
monoclonal Large Cell Lymphoma (Wickert et al 1995). It may well be that a
T cell variant of Hodgkin's disease also exists. When studying comparisons
between HD and the T cell lymphomas lymphomatoid papulosis, mycosis
fungoides and the Ki-1 positive LCAL (usually a T cell malignancy), this has
prompted some authors to suggest that these disorders are related and
represent a spectrum of T cell malignancy (Kadin 1985, Orscheschek et al
1995).
It has also been suggested that HD is a heterogeneous group of
disorders in which viral transformation of an immature lymphoid cell plays a
major role in the induction of the aberrant lymphoid cell phenotype of the
RS/H cells (Herbst et al 1989, Stein et al 1991). Khan & Coates (1994) have
recently hypothesised that LMP expression may interfere with the
differentiation pathway of the RS cell, as it is known to inhibit the
differentiation of epithelial cells, thought to be important in the pathogenesis
of Nasopharygeal Carcinoma. In Hodgkin's disease, undifferentiated cells
may show an activated phenotype also as a consequence of EBV infection
and it may correlate with the peculiar morphology of the RS/H cells.
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Therefore, LMP expression could account for 2 of the main features of
Hodgkin's disease, namely the undifferentiated phenotype and the
characteristic morphology of the malignant cell population. Obviously this
could only apply to those cases which were EBV positive.
It has also recently been suggested that there may be a relationship
between CD30 antigen expression by RS/H cells and the pathogenesis of
Hodgkin's disease (Haluska et al 1994) based on the knowledge that CD30
has been identified as a signal-transducing molecule in a specific sub-set of
CD45Ro+ T cells (Ellis et al 1993). CD30 has been shown to be
preferentially expressed by CD4+ T cells producing Type II cytokines (ie
TH2) such as IL-4 and IL-5 (Del Prete et al 1995), and Pizzolo et al (1994)
suggest that CD30 expression reflects a TH2-type fuctional attitude of RS/H
cells in Hodgkin's disease thus explaining the cytokine profile seen in
Hodgkin's disease. This pathogenic association is backed up by the fact
that a large series of Hodgkin's patients had high serum CD30 levels
correlating with stage of disease and symptoms present such that higher
CD30 levels were associated with a worse prognosis (Nadali et al 1994).
Recent work has shown that the CD40 ligand (CD40L) is strongly
expressed on the reactive CD4+ T cells surrounding RS cells. This suggests
that in Hodgkin's disease tissues, CD40L+/CD4+ T lymphocytes might
interact with the tumour cells via CD40 - this may result in the transmission
of growth signals to RS cells (Carbone et al 1995). Recent work has also
demonstrated that both the CD30 ligand and CD40 ligand present on
bystander cells cause enhanced cytokine secretion from CD30+ and/or
CD40+ RS/H cells (Gruss et al 1995). Therefore, the interaction of both
CD30 and CD40 on RS/H cells with their ligands present in the background
infiltrate may contribute to the pathogenesis and deregulated cytokine
network present in Hodgkin's disease.
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It may also be that the specific pattern of cytokine secretion from the
reactive infiltrate present may determine the differentiation pathway of the
RS/H cell. Trumper et al (1993) recently used a single cell based PCR
analysis system which allows general amplification of cDNA from single cells
and studied the gene expression pattern of single RS/H cells from cases of
HD. They found that single RS/H cells co-express genes characteristic of
several haemopoietic lineages, including macrophage, B and T cell. There
was considerable case to case heterogeneity of gene expression, even in
cases showing the same histology, with consistent expression of genes
within cases. A group of genes was expressed by the large majority of RS
cells examined; this included c-myc, the c-fes/fps oncogene, the fyn tyrosine
kinase, the IL-2 receptor beta chain, TNF-p and CD4. It appears from this
that RS/H cells represent activated haemopoietic cells capable of expressing
genes from several haemopoietic lineages. Differentiation of the tumour
cells from individual patients may occur along monocytoid or lymphoid
pathways, influenced by the micro environment e.g. cytokine release from
the surrounding reactive cells in different cases (Trumper et al 1993).
This type of analysis i.e. looking at single cells, appears to be the
most appropriate in the case of Hodgkin's disease where the scarcity of the
neoplastic RS/H cells, among the normal reactive cellular infiltrate, has been
the problem in the previous immunophenotypic and genotypic studies and
also in this thesis. Indeed, several groups have recently employed this
methodology to look at TcR and Ig gene rearrangements in Hodgkin's
disease. However, conflicting results have again arisen. Roth et al (1994)
did not find rearrangement of the IgH gene locus in isolated RS/H cells from
13 cases of Hodgkin's disease. Daus et al (1995) did not find rearrangement
of the TcR y gene in isolated RS/H cells in 13 cases of Hodgkin's.
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Delabie et al (1994), looking at single RS/H cells from 4 cases of
LPHD, found only polyclonal populations (they suggest that LPHD is
polyclonal at an early stage, but as the L & H cells slowly continue to
proliferate, they become progressively more oligoclonal and progress to
monoclonal Large Cell Lymphomas - as discussed previously - page 190).
However, Kuppers et al (1994), looking at single RS/H cells from 3 cases of
Hodgkin's disease, found clonal IgH gene rearrangements in all 3 cases. In
the MCHD case in this study, sequence analysis revealed only non¬
functional V gene rearrangements, suggesting a pre-B cell origin whilst in
the LPHD case, there was evidence of ongoing somatic mutation of the
rearranged V region genes within the tumour suggestive of a germinal centre
origin. They concluded that this indicates that RS/H cells can originate from
B cells at various stages of development.
At variance with these previous studies, Hummel et al (1995) found by
analysing single RS/H cells from 12 cases for IgH gene rearrangements, 3
cases contained a monoclonal population of RS/H cells, 6 cases polyclonal
and the remaining 3 a mixture of both polyclonal and monoclonal RS/H cells.
They suggest that technical factors may have contributed to the
failure of Roth et al (1994) to detect any IgH gene rearrangements in their
samples, and blame small case numbers on the discrepancy between their
results and those of Delabie et al (1994) and Kuppers et al (1994).
They suggest that polyclonal populations of RS cells arise from the
continuous recruitment of unrelated B lymphocytes, transformed into RS/H
cells if susceptible to genetic instability, by transforming agents such as
EBV, or an immune defect that impairs the elimination of abberant cells.
Therefore, although conflicting results have arisen using this single
cell technique, only a limited number of cases have been investigated as yet
and it is likely that future progress will depend on this kind of methodology.
193
The SCID Mouse Model of Non-Hodqkin's Lymphomas - Overview and
Conclusions
The transplantation of NHL into SCID mice was more successful in this
thesis. However, 2 cases (Cases J and K) again gave rise to EBV
(EBER/LMP/EBNA-2) positive SCID tumours, which did not share the
phenotypic and genotypic characteristics of the original biopsies, instead
resembling EBV-transformed normal B cells. Like the HD-derived SCID
tumours, these were most probably derived from proliferation of EBV positive
bystander B cells present in the injected lymph node and detailed analysis of
the SCID tumours demonstrated that they shared the characteristics of the
HD-derived SCID tumours (the activated B cell phenotype with high
expression of EBV-associated antigens, Ig secretion and normal diploid DNA
content). It is interesting that one of these cases was the only low grade
NHL to yield tumours in this study (Case J NHL Cb/Cc Foil). However, the
other case was a high grade lymphoma (Case K - LCAL), the morphological
appearance of which suggested a high malignant potential.
However, a second biopsy taken a month later from the same patient
(Case L) did give rise to SCID tumours derived from the original biopsy and
not simply EBV-driven lymphoproliferations. Perhaps the second biopsy was
more malignant than the previous one, although it was clear that in one of
the Case L-derived SCID tumours (L4), the dominant clone was that of an
EBV-transformed normal B cell clone, shown clearly in the genotypic data
and the Ig secretion results.
The only previous study using the SCID mouse as an animal model
for NHL was carried out during this thesis. Itoh et al (1993) developed SCID
tumours from 23/50 NHL specimens. Of these 23, 13 were found to originate
from EBV-infected bystander B cells. Therefore the proliferation of EBV-
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transformed B cells can be a problem in the growth and maintenance of
these NHL-derived SCID tumours.
2 of the SCID tumours in the Itoh study resembled SCID tumour L4 in
that the original NHL clone and a newly developed EBV positive B cell clone
co-existed. Like this thesis, Itoh et al found that high grade lymphomas were
more easily transplanted. SCID tumours from 9/11 cases in the Itoh et al
study were found to be derived from the original NHL clone.
In this thesis, the SCID tumours derived from Cases F, G, H, I and 4
of the SCID tumours from Case L (L1, L2, L3, L5) were shown to be derived
from the malignant clone in the original biopsies. In Cases F, G, H and I, the
Epstein-Barr virus was not involved in the original biopsies or the SCID
tumours. These SCID tumours retained the morphology, phenotype and Ig
expression of the original biopsies. Indeed, genotypic analysis showed in
the cases of SCID tumours F1-14 and G1 and suggested in the case of
SCID tumour 11 that these contaihed identical clonal IgH gene
rearrangements to that seen in the equivalent original biopsy. Unfortunately,
this could not be carried out on SCID tumours H1. Further analysis showed
that these SCID tumours did not share the characteristics of Ig secretion and
normal diploid DNA content of the EBV (EBER/LMP/EBNA-2) positive SCID
tumours. Therefore, in Cases F, G, H and I, the SCID tumours can be
regarded as representative of the original biopsies and as relevant in vivo
models for these NHL.
Case L (LCAL) displayed a restricted latency I EBV phenotype
expressing EBER only, not LMP or EBNA-2 (EBNA-1 was not investigated
but it is assumed that it would be expressed). In 4 of the resultant SCID
tumours, this EBV phenotype was retained along with morphology, restricted
antigenic phenotype and Ig expression. Indeed, genotypic analysis
demonstrated an identical clonal IgH gene rearrangement, and EBV terminal
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repeat analysis demonstrated that the malignant EBV positive clone in the
original biopsy was present in the SCID tumours. Further analysis also
demonstrated that these EBER positive SCID tumours did not exhibit
characteristics of the EBV (EBER/LMP/EBNA-2) positive SCID tumours in
that they showed no Ig secretion and displayed DNA aneuploidy. Therefore,
SCID tumours L1, L2, L3 and L5 can be regarded to represent the original
biopsy and serve as an in vivo model for B cell LCAL. This is the first study
to show such a model for B cell LCAL.
Again, Itoh et al achieved a much better passage rate than that seen
in this thesis, however additional problems such as inadequate tumour
tissue for passage and infection killing the 'passage' mice were encountered
in this thesis.
This study has demonstrated that NHL can be successfully
transplanted into the SCID mouse. This model can be used to study the cell
and molecular biology of NHL. Oncogene expression has been studied
using these NHL-derived SCID tumours in our lab (O'Grady et al 1993). It
was demonstrated that the SCID tumours known to represent the original
NHL i.e. Cases F, G, H, I and L-derived SCID tumours showed similar
patterns of oncogene expression (bcl-2, c-myc, p53) as that in the original
NHL biopsies. Case F-derived SCID tumours showed relatively constant
expression of the oncogenes throughout the passages. Therefore, these
results suggest that these SCID tumours may provide a useful in vivo model
for the study of aberrant oncogene expression in lymphoma.
This is the first study to provide an in vivo model for LCAL in SCID
mice. The B cell type grown here is quite rare and therefore most studies
performed on LCAL include only the T cell type. Therefore this should be a
particularly useful model to study the B cell LCAL. Many comparisons have
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been made between HD and LCAL and this animal model should provide an
insight into the biology of B cell LCAL for comparison with HD.
Case F -derived SCID tumours passaged very well and offer a model
to study tumour progression. Although a progression in oncogene
expression was not seen in this case (O'Grady et al 1993), perhaps 4
passages was not adequate to investigate tumour progression. However
most importantly, this SCID tumour was shown to survive liquid nitrogen and
grew again retaining the phenotype (genotype was not investigated) of the
previous Case F-derived SCID tumours. Therefore this SCID tumour can be
used as a continuous tumour model.
New therapeutic programs are being designed for NHL i.e.
monoclonal antibody therapy with attached radionucleotides or toxins or IL-2
with or without lymphokine activated killer (LAK) cells. These are being
tested - their role is yet to be established (Appelbaum 1991, Longo 1991,
Lim & Marcus 1992) and these SCID tumours offer a model to study this.
However, only 7/25 cases of NHL (28%) resulted in SCID tumour formation,
with only 5 representing the malignant clone of the original biopsies.
Therefore, technical improvements are needed before this model can be
used for individual NHL patients i.e. for selection of individual therapeutic
protocols.
This study has shown that the SCID mouse is not a satisfactory model
to study Hodgkin's disease. This was shown in this thesis by full
characterisation of these SCID tumours, this demonstrating the properties
exhibited by EBV-transformed normal B cells.
197
Transplantation of non-Hodgkin's lymphoma in SCID mice was
successsful in this thesis - this resulted in tumours which retained the
morphology, phenotype and genotype of the original biopsies, and as such
this study showed that the SCID mouse represents a satisfactory in vivo
model to study the cellular and molecular biology of NHL.
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Appendix B Alkaline Phosphatase Substrate for
Visualisation of in situ Hybridisation
0.1 M Tris Buffer pH9.5 for BCIP/NBT Substrate
0.1 M Tris 6.050g
0.01M NaCI 0.292g
0.005M MgCl2 (50mM) 0.238g
Dissolve in 450ml of distilled water,
distilled water.
Adjust pH to 9.5, make up to 500ml with
Substrate
To 50ml of 0.1M Tris pH9.5, add 1ml of 50mM levamisole.
NBT 75mg/ml in 70% dimethylformamide 198(il
BCIP 50mg/ml in 70% dimethylformamide 150pl
0.1M Tris pH9.5 + levamisole 45ml
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Appendix C Molecular Analyses
All the molecular analyses performed on the original lymphoma biopsies and
the SCID tumours were carried out by Alice Gallagher in the Department of
Veterinary Pathology in the University of Glasgow Veterinary School.
DNA was extracted from samples using a standard Proteinase K and
Sodium Dodecyl Sulfate digestion followed by phenol and chloroform
extractions to remove protein. Samples were resuspended in Tris EDTA.
PCR For IqH Gene Rearrangements
DNA samples from frozen biopsies and frozen SCID tumour blocks (Section
2.4) were examined for the presence of IgH gene rearrangements using a
PCR strategy. The primers used were common variable and joining region
primers homologous to the V and J regions of the IgH gene locus situated on
chromosome 14.
The following primer sequences were used : (bases in parentheses show
alternative bases at 2 positions)
primer 1(V) 5' CTG TCG ACA CGG TGT ATT ACT G 3'
primer 2(J1-J5) 5' CTC(T) ACC TGA G(A)GA GAC GGT GAC C 3'
primer 3(J6) 5' CAA AGG CCC TAG AGT GGC CAT T 3'
One microgram of DNA was amplified in a 50pil reaction volume using 1 unit
of Taq polymerase, 50 pmols of each primer, 200|^M/L of each
deoxynucleoside triphosphate and 1 x buffer containing 10mM Tris pH 8.2,
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50mM KCI, 1.5mM MgCl2 and 100pg/ml gelatin. A negative control of water
was included for every 2 samples analysed. A positive control sample from
a B cell Lymphoma was included in each assay.
40 cycles of amplification were performed in a programmable heat
block after initial denaturation for 7 minutes at 950c. Each cycle included
ramping to 94^c for 1 minute, at temperature for 10 seconds, 2 minutes to
reach 550c, at temperature for 10 seconds, and finally ramping to 72°c over
1 minute and at temperature for 30 seconds.
10pl of the products of the PCR experiments were run on a 8%
polyacrylamide gel and visualised on a UV transilluminator after staining in
500(ig/ml ethidium bromide for 10 minutes.
Southern Blot Analyses for Detection of EBV
Southern blot analysis was performed to investigate for the presence of the
Epstein Barr Virus. The BamW probe which detects the BamW repeats of
the virus was used to determine the EBV status. The EcoR1 D probe, which
detects the terminal repeats of the virus was used to determine clonality of
the samples containing EBV.
10pg of DNA were digested with BamH1 enzyme or BamH1 and
EcoR1 D double digest for hybridisation to the BamW and EcoR1 D probes
respectively. Digests were run on 0.8% agarose gels for 16-18 hours at 32
volts. DNA was transferred to nylon membrane after initial denaturation and
neutralisation of the gels using a standard capillary action southern blot
technique. Nylon filters were stratalinked to bind DNA to the membrane for
0.8 minutes at 1200 joules.
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50ng of BamW and EcoRID probes were labelled using the
Multiprime labelling system and 32P labelled alpha dCTP (3.0 MBq of 800
Ci/mMol).
Filters were pre-hybridised in 2.5 mis of 50% formamide southern
buffer for 4 hours and after addition of labelled probe (1 million counts/ml)
were hybridised for 16-20 hours. Washing to remove excess unbound probe
was carried out at room temperature for 10 minutes in
2x SSC/0.1% SDS, followed by 2x 1 hour washes in 0.5x SSC/0.1% SDS.
Excess moisture was removed from the filters which were then transferred to
an autoradiograph cassette with film and exposed for 1 day initially, followed
by a 7-10 day exposure.
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